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 C-MYC is a transcription factor and a potent driver of many human 
cancers. In addition to regulating transcription, C-MYC promotes formation of 
the mRNA cap which is important for transcript maturation and translation. 
However, the mechanistic details of C-MYC-dependent mRNA capping are not 
fully understood. Since anti-cancer strategies to directly target the C-MYC 
protein have had limited success, enzymatic co-factors or effectors of C-MYC 
present attractive alternatives for therapeutic intervention of C-MYC-driven 
cancers. mRNA capping enzyme (CE) initiates mRNA cap formation by 
catalysing the linkage of inverted guanosine via a triphosphate bridge to the first 
transcribed nucleotide. The involvement of CE in C-MYC-dependent mRNA 
capping and C-MYC function has not yet been explored. Therefore, I sought to 
determine whether C-MYC regulates CE, and whether CE is required for C-
MYC function. 
I found that C-MYC promotes CE recruitment to RNA polymerase II 
(RNA pol II) transcription complexes and to regions proximal to transcription 
start sites on chromatin. Consistently, C-MYC increases RNA pol II-associated 
CE activity. Interestingly, cells driven by C-MYC are highly dependent on CE for 
C-MYC-induced target gene expression and cell transformation, but only when 
C-MYC is overexpressed; C-MYC-independent cells or cells retaining normal 
control of C-MYC expression are insensitive to CE inhibition. C-MYC expression 
is also dependent on CE. Taken together, I present a bidirectional regulatory 
relationship between C-MYC and CE which is potentially therapeutically 
relevant. Studies here strongly suggest that inhibiting CE is an attractive 
xxiii 
 
strategy to selectively target cancer cells which have acquired deregulated C-
MYC.  
 
Chapter 1 : Introduction 
1.1 mRNA synthesis 
1.1.1 Transcription in gene expression 
Transcription is the first step in gene expression and is the process by 
which genetic information in nuclear DNA is utilised as a template to generate 
RNA molecules (Shandilya and Roberts, 2012). Messenger RNA molecules 
(mRNA), encoded by protein-coding genes, are processed during transcription 
and are then exported to the cytoplasm where they are translated (Hocine et al., 
2010). This permits synthesis of functional protein products (Jackson et al., 
2010). Transcription is a tightly controlled process and integrates extra- and 
intra- cellular stimuli to control appropriate cell behaviour (Barolo and Posakony, 
2002; Medzhitov and Horng, 2009; Ng and Surani, 2011). Dysregulation of 
transcription leads to perturbed expression of genes, which can result in the 
initiation and progression of cancer and other diseases (Lee and Young, 2013). 
It is therefore of great interest to understand more about how transcription and 
associated events are regulated. 
1.1.2 Promoter recognition and pre-initiation 
The enzyme that synthesises mRNA from a DNA template is termed 
RNA polymerase II (RNA pol II) (Jonkers and Lis, 2015). RNA pol II also 
synthesises a number of non-coding RNAs including micro RNAs (miRNA), long 
non-coding RNAs (lncRNA) and small nuclear RNAs (snRNA) (Lee et al., 2004; 
Matera et al., 2007; Wang and Chang, 2011). On the other hand, RNA pol I 
synthesises 45S precursor ribosomal RNA (rRNA) and RNA pol III primarily 
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synthesises 5S rRNA and transfer RNA (tRNA) (White, 2008). mRNA synthesis 
is preceded by sequential recruitment of multi-subunit complexes called general 
transcription factors (GTFs), mediator and RNA pol II to specific DNA 
sequences found close to the transcription start site (TSS) known as core 
promoters (Allen and Taatjes, 2015; Grunberg and Hahn, 2013). Following RNA 
pol II association, GTFs TFIIE and TFIIH associate to complete the pre-initiation 
complex (PIC) (Sainsbury et al., 2015). Promoters are often sufficient for PIC 
assembly and subsequent basal levels of transcription. However, up- or down- 
regulation of PIC assembly (and of other events in transcription) can be 
conferred by the binding of additional transcription factors to regions of DNA 
called enhancers (Kadonaga, 2004; Levine et al., 2014; Nikolov and Burley, 
1997). Transcription factors recruit additional co-activators such as chromatin 
remodelling enzymes to promote euchromatin formation. This aids PIC 
assembly, promoter opening and downstream transcriptional events (Voss and 
Hager, 2014). Enhancers can be close to transcription start sites or can regulate 
distal genes via DNA looping, and are bound by a plethora of different 
transcription factors in a sequence-, cell- and stimulus- dependent manner 
(Ernst et al., 2011; Levine et al., 2014; Spitz and Furlong, 2012). 
1.1.3 Initiation and pausing 
TFIIE is a heterodimer which bridges RNA pol II to TFIIH and 
stabilises/stimulates TFIIH (Maxon et al., 1994; Ohkuma and Roeder, 1994). 
TFIIH is composed of ten subunits including adenosine triphosphatases 
(ATPases), DNA helicases and the cyclin-dependent kinase activating kinase 
(CAK) complex (Compe and Egly, 2012). In the presence of nucleoside 
triphosphates, TFIIE and TFIIH recruitment stimulates DNA unwinding and 
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promoter opening together with RNA pol II phosphorylation and dissociation of 
several GTFs (while TFIIE and TFIIH remain associated). This allows 
transcription initiation to assume and RNA pol II begins to synthesise precursor-
mRNA (pre-mRNA). The TFIIH CAK consists of cyclin dependent kinase 7 
(CDK7), cyclin H and menage a trois 1 (MAT1), and mediates phosphorylation 
of RNA pol II on its C-terminal domain (CTD) concurrent with transcription 
initiation (Laybourn and Dahmus, 1990; Ohkuma and Roeder, 1994; Rossignol 
et al., 1997). This CTD structure lies within the largest subunit of RNA pol II 
(RPB1) and is unique throughout the polymerases; it is absent from RNA pol I 
and III. The CTD consists of tandem heptad repeats (52 in humans) with the 
canonical sequence Y1S2P3T4S5P6S7, and is subject to several modifications 
throughout transcription which govern the timely association of regulatory 
factors and pre-mRNA processing machinery (Hsin and Manley, 2012; 
Zaborowska et al., 2016). CDK7 specifically phosphorylates the RNA pol II CTD 
at Ser5 (S5p). This is generally required for global transcription, although CDK7 
recruitment can be stimulated to upregulate specific genes in certain conditions 
(Chipumuro et al., 2014; Christensen et al., 2014; Kwiatkowski et al., 2014; 
Wang et al., 2015). RNA pol II S5 phosphorylation initiates 5’ N7-
methylguanosine pre-mRNA capping (mRNA capping, Figure 1.1) (Ho and 
Shuman, 1999; Nilson et al., 2015; Trigon et al., 1998). The mRNA cap is 
important for transcript stability, further pre-mRNA processing, nuclear export 
and translation (discussed in section 1.2.4). RNA pol II typically synthesises 20-
60 nts before TFIIE is exchanged for 5,6-dichloro-1-beta-D-
ribofuranosylbenzimidazole sensitivity-inducing factor (DSIF, a heterodimer of 
suppressor of Ty 4 [SPT4] and SPT5) and negative elongation factor (NELF, a  
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Figure 1.1: Pre-mRNA processing. During transcription, pre-mRNA 
molecules undergo modification to achieve maturation. Firstly, pre-
mRNA molecules are capped with an N7-methylguanosine group at 
the 5’ end. Introns are then removed and exons are conjugated 
together in a process termed splicing. Finally, transcripts are 
modified at the 3’ end by addition of adenosines to form the poly(A) 
tail. Following processing, the mature mRNA is able to be exported 

















four-subunit complex) (Core et al., 2008; Larochelle et al., 2012; Muse et al., 
2007). DSIF and NELF cooperatively bind RNA pol II and nascent transcripts 
(Cheng and Price, 2008; Gebhardt et al., 2015; Missra and Gilmour, 2010). This 
occurs on around 30% of genes and induces a temporary arrest of transcription 
termed RNA pol II pausing (Figure 1.2) (Core et al., 2008; Wada et al., 1998a; 
Yamaguchi et al., 1999). Pausing permits pre-emptive assembly of the PIC 
such that transcription can be rapidly induced in response to signalling cues 
(Adelman and Lis, 2012; Bai et al., 2010; Wada et al., 1998b). It is also thought 
to serve as temporal window to allow the recruitment of mRNA capping 
machinery or for cap quality control (Mandal et al., 2004; Nechaev et al., 2010; 
Rasmussen and Lis, 1993). 
1.1.4 Pause release and elongation 
Pause release is stimulated and pre-mRNA synthesis is resumed upon 
recruitment of another kinase-containing complex – positive transcription 
elongation factor B (P-TEFb) – consisting of CDK9 and cyclin T (Marshall et al., 
1996; Marshall and Price, 1995; Wada et al., 1998b). P-TEFb is activated by 
CDK7 (in the context of the TFIIH CAK module) which phosphorylates the 
CDK9 subunit, ensuring sequential occurrence of the different kinase activities 
(Larochelle et al., 2012). Although P-TEFb is globally required for transcription 
(Jonkers et al., 2014; Laitem et al., 2015), P-TEFb recruitment can be 
upregulated to specific genes by a range of signal-responsive transcription 
factors (Barboric et al., 2001; Eberhardy and Farnham, 2002; Jang et al., 2005; 
Yang et al., 2005). Mechanistically, the CDK9 subunit of P-TEFb 
phosphorylates DSIF and NELF, causing NELF dissociation from RNA pol II 
while DSIF remains associated, and this stimulates productive transcription  
5






















































Figure 1.2: RNA pol II pausing. Legend overleaf.
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Figure 1.2 continued: RNA pol II pausing.
A simplified model of RNA pol II pausing is depicted; 
described in more detail within the text. Solid arrows denote 
factor recruitment, whereas dashed arrows denote regulatory 
influence.
(A) TFIIH recruitment completes PIC assembly which initiates
pre-mRNA synthesis. Pioneer transcription factors (PTF)
can enhance PIC assembly by recruiting DNA/histone
modifying enzymes.
(B) TFIIH (via its CDK7 catalytic subunit) phosphorylates the
RNA pol II CTD at Ser5 residues (orange phosphate
groups). After synthesis of 20-60nts, DSIF and NELF are
recruited which induces RNA pol II pausing. CE is
recruited to RNA pol II via phosphorylated Ser5 residues
and caps nascent pre-mRNA. TFIIH recruitment can be
enhanced by particular transcription factors (TFx).
(C)Transcription factors (TFy) can also enhance recruitment
of P-TEFb. P-TEFb (CDK9 catalytic subunit) is activated
by TFIIH and then phosphorylates the RNA pol II CTD at
Ser2 residues (blue phosphate groups) in addition to
NELF and DSIF. This causes dissociation of NELF and
RNA pol II pause release.
(D)Upon pause release, transcription resumes and RNA pol II
continues to synthesise pre-mRNA. As elongation
progresses, phosphorylation levels of RNA pol II CTD




elongation (Andrulis et al., 2000; Fujinaga et al., 2004; Ivanov et al., 2000; 
Marshall et al., 1996; Renner et al., 2001; Wu et al., 2005). The SPT5 subunit of 
DSIF possesses C-terminal repeats (CTRs) analogous to the RNA pol II CTD 
(Figure 1.3), which when phosphorylated by CDK9 recruits transcription 
activators (Chen et al., 2009; Ivanov et al., 2000; Wier et al., 2013; Yamada et 
al., 2006). Therefore, CDK9 converts DSIF from a negative regulator to a 
positive regulator of transcription elongation. CDK9 also phosphorylates RNA 
pol II on its CTD at Ser2 residues (S2p), which mediates the recruitment of 
diverse factors such as those involved in splicing, histone modification and 
polyadenylation; influencing pre-mRNA processing, elongation and termination 
(Hsin and Manley, 2012; Ramanathan et al., 2001). Splicing is the process by 
which non-coding sequences (introns) are removed and coding sequences 
(exons) are ligated (Figure 1.1). This is mediated by the spliceosome – a large 
ribonucleoprotein complex – and occurs co-transcriptionally during elongation 
(Merkhofer et al., 2014). As RNA pol II CTD S2 residues become 
phosphorylated during transcription elongation, S5p residues are 
dephosphorylated by phosphatases termed SSU72 and small CTD 
phosphatases (SCPs) 1-3 (Xiang et al., 2010; Yeo et al., 2003). 
1.1.5 Termination 
 As transcription approaches completion, amongst the last stretch of 
mRNA to be synthesised is a polyadenylation (poly(A)) signal (AAUAAA) 
followed by a G/U-rich sequence, which reduces RNA pol II processivity. 
Factors bind to the poly(A) signal and to S2p RNA pol II CTD which mediate 
sequential transcript cleavage, polyadenylation, and release of the mature 
mRNA from RNA pol II (Richard and Manley, 2009). The mRNA poly(A) tail is a  
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RNA pol II
Figure 1.3: RNA pol II CTD and SPT5 CTRs. The SPT5 subunit of 
DSIF contains C-terminal repeats (CTRs) analogous to that in the 
RNA pol II CTD. Canonical sequences of the CTD and different CTR 
subdomains (CTR1 and CTR2) are shown. Of note, 21 CTD repeats 
adhere to the consensus sequence and the remaining 31 repeats can 
vary; mostly at position 7 but also at positions 2, 4 and 5. The RNA 
pol II CTD can be phosphorylated by both CDK7 and CDK9 on S5 
and S2 residues, respectively. The T4 residues in the CTR1 domain 
of SPT5 are phosphorylated by CDK9 (Ivanov et al. 2000), whereas 
the CTR2 domain of SPT5 is phosphorylated by both CDK7 and 
CDK9 (Larochelle el al. 2006). Further studies are required to 
determine which residues in CTR2 are prefentially phosphorylated by 













stretch of typically 200-250 adenosines added to the 3’ of end of transcripts 
(Figure 1.1), which is not only important for termination, but also for mRNA 
stability by protecting transcripts from 3’-5’ exonucleases. Additionally, poly(A) 
tail-interacting proteins are important for promoting nuclear export and 
translation initiation (Goss and Kleiman, 2013). Before RNA pol II dissociation, 
S2p residues within the CTD are dephosphorylated by TFIIF-associating CTD 
phosphatase 1 (FCP1) in order for RNA pol II to be converted back to its 
unphosphorylated, pre-initiation-competent form (Chesnut et al., 1992; Cho et 
al., 1999; Ghosh et al., 2008). Although the precise mechanisms regarding RNA 
pol II disassembly remain incompletely understood, cleavage and termination 
factors induce RNA pol II pausing downstream of the poly(A) signal, which is 
thought to be key in this process (Proudfoot, 2016). This induces a 
conformational changes in the RNA pol II active site which likely destabilises the 










1.2 mRNA capping 
1.2.1 The N7-methylguanosine mRNA cap structure and catalysis 
N7-methylguanosine mRNA caps are found in eukaryotes and eukaryotic 
viruses, but not in bacteria or archaea. The eukaryotic N7-methylguanosine cap 
(also known as cap 0) is a guanosine moiety methylated on the N7 amine, 
conjugated to the 5’ end of RNA molecules in a unique inverted conformation 
via a 5’-5’ triphosphate linkage (Figure 1.4). mRNA molecules, as well as some 
non-coding RNAs including lncRNAs, primary miRNA transcripts and tRNAs, 
undergo N7-methylguanosine capping (Lee et al., 2004; Ohira and Suzuki, 
2016; Quinn and Chang, 2016). The addition of this structure involves a multi-
step process, which may be somewhat analogous between different RNA 
species but is best characterised in relation to mRNA. For the purpose of this 
thesis, N7-methylguanosine capping will be discussed in the context of mRNA 
and will be referred to as ‘mRNA capping’. mRNA capping is the first pre-mRNA 
processing event on RNA pol II transcripts, which occurs co-transcriptionally as 
they reach 18-35 nt in length (Moteki and Price, 2002; Nechaev et al., 2010; 
Nilson et al., 2015; Rasmussen and Lis, 1993). Historically, mRNA capping was 
thought be a constitutive process which proceeded to completion on all mRNA 
molecules. On the contrary, several lines of evidence have demonstrated that 
mRNA capping can be regulated at multiple levels in various biologically 
relevant contexts (discussed in subchapter 1.3). 
mRNA capping is the sum of three sequential enzymatic reactions – 
triphosphatase (TPase), guanylyltransferase (GTase) and methyltransferase 











Figure 1.4: The mammalian mRNA cap and capping enzymes.
The chemical structure of ‘cap2’ RNA is depicted together with the 
enzymes which catalyse mRNA capping. The frequency with which 
specific cap methylation events occur (i.e. the relative abundance 
of cap0, cap1 and cap2 mRNA) is still not clear. The catalytic 









































proteins (Figure 1.5). Firstly, the bifunctional protein capping enzyme/RNA 
GTase and 5'-phosphatase (CE/RNGTT) cleaves the terminal phosphate from 
the triphosphate group on the first transcribed nucleotide, yielding diphosphate 
RNA and inorganic phosphate (Pi). Secondly, CE acts via a two-step reversible 
ping-pong mechanism to catalyse cap guanylylation. CE hydrolyses guanosine 
triphosphate (GTP) to provide guanosine monophosphate (GMP) (with which it 
forms a covalent intermediate) and concurrently releases the inhibitory by-
product inorganic pyrophosphate (PPi). CE then transfers GMP to the 
diphosphate group on the 5’ end of mRNA. Thirdly, RNA guanine-7 
methyltransferase (RNMT) transfers a methyl group from S-adenosyl 
methionine (SAM) to the N7 position on the guanosine moiety to complete the 
mRNA cap (also termed cap0), meanwhile generating S-adenosyl-l-
homocysteine (SAH) as an inhibitory by-product. Complete (N7-
methylguanosine) and incomplete (guanosine) caps can be removed by 
decapping enzymes (discussed in section 1.3.4). It is worth noting that in lower 
eukaryotes (including yeast), the mRNA cap structure is conserved and cap 
catalysis is somewhat conserved, although the three activities contributing to 
cap formation are mediated by three distinct peptides.  
Methylation of the first and second transcribed nucleotides on the 2’-O-
ribose position (which occurs specifically in higher eukaryotes), is catalysed by 
cap methyltransferase 1 (CMTR1) and CMTR2, generating ‘cap1’ and ‘cap2’ 
structures (respectively) (Figure 1.4), both of which use SAM as a methyl donor 
(Belanger et al., 2010; Werner et al., 2011). Cap1 and cap2 structures are 




Figure 1.5: Mechanism of cap0 formation. The steps of mRNA 
capping (cap0 catalysis) by CE and RNMT are shown. CE cleaves 
the terminal phosphate from the triphosphate group on the first 
transcribed nucleotide, releasing Pi. In the presence of magnesium 
CE forms a covalent intermediate with GMP from GTP, releasing PPi. 
CE then transfers GMP to diphosphate RNA, yielding guanosine-
capped RNA. In the presence of SAM, RNMT-RAM then methylates
cap guanosine at the N7 position to complete the mRNA cap. As 
indicated, the two steps in the ‘ping-pong’ guanylyltransferase
reaction are reversible. the guanosine cap nucleotide is depicted in 




































innate immune response (Abbas et al., 2017; Daffis et al., 2010; Schuberth-
Wagner et al., 2015). Cap1 may also upregulate the translation of specific 
transcripts (Kuge et al., 1998; Kuge and Richter, 1995). Moreover, via an 
unidentified cytoplasmic methyltransferase, a reversible methylation event can 
occur on the first transcribed nucleotide at the N6 position of adenosine, which 
preferentially occurs on cap1 structures (Keith et al., 1978; Mauer et al., 2017). 
This promotes mRNA stability by preventing decapping (see section 1.3.4). 
1.2.2 mRNA capping enzyme (CE/RNGTT)  
 As mentioned above, CE is a bifunctional enzyme with both TPase and 
GTase activities that act together to initiate mRNA capping by addition of the 
inverted guanosine group on the 5’ end of nascent transcripts. CE belongs to a 
superfamily of covalent nucleotidyltransferases which include DNA/RNA 
ligases. The TPase domain resides at the N-terminal of CE and the GTase 
domain at the C-terminal. Within the GTase domain lies the active site (KxDG 
motif), in which the lysine contacts GMP, and also an oligonucleotide/ 
oligosaccharide binding (OB) domain which is involved in RNA-binding and 
protein-protein interactions. CE activity is coordinated with transcription (such 
that it caps nascent RNA as it emerges from RNA pol II) via interactions with 
S5p RNA pol II CTD and with 5’ triphosphate RNA; CE cannot interact with 
unphosphorylated RNA pol II CTD (Ho and Shuman, 1999; Martinez-Rucobo et 
al., 2015). Consistent with this, dephosphorylation of the CTD by FCP1 depletes 
capping of nascent RNA in vitro by 70% (Mandal et al., 2004). Through a 
different binding site, CE also interacts with S2p RNA pol II CTD in vitro (Ho and 
Shuman, 1999). Moreover, yeast CE can interact with both S7p and S5p RNA 




only S5p RNA pol II CTD peptides (and not S2p, S7p, nor other phospho-CTD 
peptides) were found to interact with CE in human cells (Pineda et al., 2015). 
Furthermore, when CE was co-crystallised with RNA pol II CTD peptides 
phosphorylated at both S2 and S5, CE only contacted S5p residues (Ghosh et 
al., 2011). In another study, inhibition of CDK7 (S5 kinase) but not CDK9 (S2 
kinase) reduced co-transcriptional mRNA capping in vitro (Moteki and Price, 
2002). Therefore, the predominant mode of contact between CE and the RNA 
pol II CTD is likely via S5p residues. In yeast, the lethal phenotype of Ser-Ala 
mutations at positions 5 (S5A) of the RNA pol II CTD can be rescued by 
tethering mammalian CE to S5A mutant RNA pol II (Schwer and Shuman, 
2011), highlighting the conservation of CE activity and the importance of the 
CE-S5p RNA pol II interaction. 
CE can also directly interact with the SPT5. Indeed, as previously 
mentioned SPT5 has a CTR with several Ser/Thr-Pro motifs analogous to that 
in the RNA pol II CTD (Figure 1.3) which are phosphorylated by CDK9 and 
CDK7 (Ivanov et al., 2000; Larochelle et al., 2006; Stachora et al., 1997). In 
yeast, CE interacts with the CTR domain of SPT5 (Pei and Shuman, 2002), 
although phosphorylation of yeast SPT5 CTR actually inhibits its interaction with 
the yeast capping enzymes (Doamekpor et al., 2014). Since the CTR and 
capping enzymes are substantially different to the mammalian homologues 
(Ghosh et al., 2011; Stachora et al., 1997), it is not clear if this mode of binding 
is conserved. Even though mammalian CE does not interact with yeast SPT5 
CTR, overexpression of mammalian CE in yeast somewhat alleviates the slow 
growth phenotype of CTR deletion in SPT5 (Schneider et al., 2010). This 




Interestingly, CE has roles in regulating RNA pol II transcription 
independent of its mRNA capping activity. The interaction of CE with SPT5 
relieved DSIF and NELF-mediated RNA pol II pausing in vitro, and this was also 
true of a CE mutant devoid of its guanylyltransferase activity (Mandal et al., 
2004). The variant of mouse CE (which is 95% similar to human CE) used in 
this study carries a substitution of the active site Lysine to Alanine (K294A), 
thereby CE guanylyltransferase activity is abolished while CE triphosphatase 
activity it retained (Yue et al., 1997). Consistent with CE recruitment regulating 
RNA pol II pausing/pause release, paused RNA pol II is phosphorylated at S5 
(Cheng and Sharp, 2003) and CE and RNA pol II co-localise at putative pause 
sites on chromatin in cells (Glover-Cutter et al., 2008). Moreover, CDK7 
inhibition caused a concurrent decrease in S5p RNA pol II phosphorylation, 
mRNA capping and RNA pol II pause efficiency in vitro (Nilson et al., 2015). 
Although pausing was not affected by inhibition of mRNA capping alone, the 
role of CE recruitment in pausing per se was not addressed (Nilson et al., 
2015). Additionally, CE can promote the formation of co-transcriptional pre-
mRNA:DNA hybrids termed R loops in vitro (Kaneko et al., 2007). Yet again, 
this was also true of the human K294A CE guanylyltransferase-dead variant 
(Kaneko et al., 2007), suggesting that CE recruitment rather than mRNA 
capping promotes R loop formation. R loops can promote transcriptional by 
protecting against DNA methylation at the TSS, amongst many other functions 
(Ginno et al., 2012; Santos-Pereira and Aguilera, 2015). In cells, the 




1.2.3 mRNA guanine-7 methyltransferase (RNMT) and RNMT-
activating miniprotein (RAM) 
 RNMT completes the final step in mRNA capping: methylation of the 
guanosine cap at the N7 position. N7 guanosine cap methylation is required for 
the interaction of cap-binding proteins with the cap (Izaurralde et al., 1994; Lee 
et al., 2016a; Lewis et al., 1996; Marcotrigiano et al., 1997). RNMT exists in a 
heterodimer with RNMT-activating miniprotein (RAM) which mediates RNA 
binding, structurally stabilises RNMT and enhances RNMT activity 
(Gonatopoulos-Pournatzis et al., 2011; Varshney et al., 2016). RNMT-RAM is 
recruited to transcription start sites in a CDK7-dependent manner (Aregger and 
Cowling, 2013; Posternak et al., 2017). However, an interaction between RNMT 
and RNA pol II is not readily observed (Aregger and Cowling, 2013; Pineda et 
al., 2015; Shatkin and Manley, 2000); only a weak ternary interaction between 
RNMT, CE and RNA pol II has been detected in vitro (Pillutla et al., 1998). 
Therefore the direct mechanism of RNMT-RAM recruitment is unknown.  
Interestingly, RNMT promotes cell transformation; on its own or in co-
operation with C-MYC and RAS oncogenes (Cowling, 2009). Additionally, 
RNMT regulates the expression of the cancer-associated genes cyclin D1 
(CCND1) and C-MYC (Cowling, 2009; Dunn et al., 2016). Efforts are currently 
underway in the Cowling laboratory to understand the global impact of RNMT-
RAM on gene expression in cancer cells.  
1.2.4 Function of the mRNA cap and cap interactors 
As previously alluded to, the mRNA cap is important for transcript 




(Figure 1.6). Firstly, the mRNA cap itself stabilises transcripts during synthesis 
by preventing degradation by 5’-3’ exonucleases (Furuichi et al., 1977; Murthy 
et al., 1991; Shimotohno et al., 1977). This is equally true of both the complete 
N7-methylguanosine cap and the incomplete guanosine cap. Other cap-
dependent functions are conferred by cap-binding proteins, including the cap 
binding complex (CBC). CBC consists of the essential nuclear cap binding 
protein 1 (NCBP1) with NCBP2 (canonical CBC) or NCBP3 (alternative CBC) 
(Gebhardt et al., 2015; Gonatopoulos-Pournatzis and Cowling, 2014). NCBP2 
or NCBP3 directly interacts with the mRNA cap, whereas NCBP1 stabilises 
NCBP2/3 and serves as an adaptor protein to recruit various factors. NCBP2 
and NCBP3 have somewhat redundant functions under normal conditions, yet 
NCBP3 is important for cellular response to viral infection (Gebhardt et al., 
2015). In vitro, CBC competes for cap binding with decapping enzymes (Jiao et 
al., 2013) and binds and inhibits poly(A)-specific ribonuclease (PARN) (Balatsos 
et al., 2006), which protects mRNA from both 5’-3’ and 3’-5’ exonuclease attack, 
respectively. CBC is an auxiliary factor for P-TEFb recruitment, and therefore 
promotes RNA pol II CTD S2 phosphorylation and efficient transcription 
elongation (Lenasi et al., 2011). CBC is resultantly important for S2p RNA pol II-
dependent recruitment of alternative splicing factor/splicing factor 2 (ASF/SF2) 
and thus modulates alternative splicing (Lenasi et al., 2011). CBC also directly 
interacts with the U4/U6.U5 triple small nuclear ribonucleoprotein and thereby 
promotes co-transcriptional spliceosome assembly and splicing (Pabis et al., 
2013). In addition, depletion of CBC causes defective 3’ end pre-mRNA 
cleavage at the poly(A) site (Flaherty et al., 1997) although the mechanisms 
involved are not clear. Within the transcription export complex (TREX) the 
Aly/REF subunit associates with CBC, thus facilitating mRNA nuclear export  
19
Figure 1.6: mRNA cap interactors and functions. The mRNA cap 
promotes many aspects of mRNA expression. 5’ mRNA guanylylation
is sufficient to confer resistance to 5’-3’ exonucleic degradation. N7 
methylation of guanosine is irreversible unlike 5’ mRNA 
guanylylation, therefore this might indirectly provide additional 
protection in some systems. Moreover, N7 methylation of the cap 
guanosine is required for the interaction of cap binding proteins 
which protect from both 5’-3’ and 3’-5’ degradation. Cap binding 
proteins confer a host of functions, described in detail within the text. 
The novel eIF3d cap-binding protein was shown to promote 
translation of specific mRNAs, which is likely to be via other 
components of the eIF3 complex recruiting ribosomes. How eIF3d 




































(Cheng et al., 2006). Finally, CBC is able to associate with eukaryotic initiation 
factors (eIFs) and related proteins (in arrangements distinct from the classical 
translation initiation complex, eIF4F) and is thus able to mediate ribosome 
recruitment in the cytoplasm (Choe et al., 2012; Kim et al., 2009; McKendrick et 
al., 2001). Rather than promoting productive mRNA translation into functional 
protein products, CBC primarily functions in the pioneer round of translation 
which is important for mRNA quality control (Choe et al., 2012; Lejeune et al., 
2004). 
Another well-characterised cap-binding protein is the eIF4E translation 
initiation factor, which is a subunit of the eIF4F complex. The eIF4F complex 
typically orchestrates the majority of mRNA translation in the cell, and consists 
of an RNA helicase (eIF4A), and a large scaffold protein (eIF4G) in addition to 
the eIF4E cap-binding component. eIF4A disrupts secondary structures in the 5’ 
untranslated region (UTR) of mRNAs whereas eIF4G makes supplementary 
contacts with mRNA and promotes mRNA looping in preparation for translation 
by bridging eIF4E and poly(A)-binding protein (PABP) (Kahvejian et al., 2005; 
Uchida et al., 2002; Yanagiya et al., 2009). Subsequently, eIF4G recruits the 
eIF3 complex which triggers ribosome assembly followed by translation of 
capped mRNA molecules (LeFebvre et al., 2006). eIF4E is also found in the 
nucleus, where it can directly mediate cap-dependent mRNA export (Cohen et 
al., 2001; Topisirovic et al., 2003a). Similar to the CBC, eIF4E competes with 
decapping enzymes for cap binding and thus stabilises transcripts (Grudzien et 
al., 2006). It is worth noting that the eIF4E is an oncoprotein which is regulated 
by oncogenic signalling pathways. Both eIF4E expression (for example via the 




phosphorylation of eIF4E negative regulators) are subject to upregulation during 
cell transformation (Avdulov et al., 2004; Schmidt, 2004). The cap-binding 
capacity of eIF4E is essential for its functions and tumourigenic properties 
(Cohen et al., 2001; Ruggero et al., 2004; Topisirovic et al., 2003a; Topisirovic 
et al., 2003b). 
An alternative cap-dependent translation pathway has recently been 
described. An eIF3 subunit (eIF3d) directly binds to the mRNA cap and 
mediates ribosome assembly and translation in an eIF4F-independent manner 
(Lee et al., 2016a). Interestingly, this upregulates the translation of a specific 
subset of mRNAs involved in cell proliferation such as C-JUN (Lee et al., 2016a; 
Lee et al., 2015). C-JUN possesses a stem-loop structure which prevents 
eIF4F-dependent translation and directs eIF3d recognition. Since eIF3d is 
structurally similar to a bifunctional decapping enzyme and exoribonuclease 
(decapping exoribonuclease, DXO) (Lee et al., 2016a) it is likely to promote 








1.3 Regulation of N7-methylguanosine mRNA capping  
1.3.1 CE recruitment and activity 
 As previously discussed, mammalian CE has been shown to interact with 
S5p RNA pol II, SPT5 and S2p RNA pol II. Interestingly, in vitro, S5p RNA pol II 
CTD and SPT5 (but not unphosphorylated or S2p RNA pol II CTD) can 
stimulate CE guanylylation and mRNA capping 2-5-fold relative to free CE 
(Ghosh et al., 2011; Ho and Shuman, 1999; Mandal et al., 2004; Moteki and 
Price, 2002; Nilson et al., 2015; Wen and Shatkin, 1999). In concurrence, CDK7 
inhibition, but not CDK9 inhibition, reduces mRNA capping (Moteki and Price, 
2002; Posternak et al., 2017). Since S5p RNA pol II CTD contacts regions in the 
CE nucleotide binding domain, this might stabilise an open conformation of CE 
more conducive to guanylylation (Chu et al., 2011; Ghosh et al., 2011). 
Reciprocally, CE self-guanylylation stimulates its binding to S5p RNA pol II 
CTD; i.e. CE primed for mRNA capping has a greater affinity for RNA pol II 
(Ghosh et al., 2011). Signal-responsive transcription factors can upregulate S5 
phosphorylation of RNA pol II (Aregger and Cowling, 2012; Cowling and Cole, 
2007b), therefore it is possible that CE recruitment and activity might be 
modulated in response to stimuli, rather than being a constitutive process.  
1.3.2 RNMT-RAM recruitment, activity and stability 
The oncogenic transcription factor C-MYC has been shown to regulate 
mRNA cap methylation of C-MYC target gene transcripts and some other 
mRNAs, thereby enhancing mRNA translation and protein synthesis (Figure 
1.7) (Cole and Cowling, 2009b; Cowling and Cole, 2007b; Fernandez-Sanchez 
et al., 2009; Posternak et al., 2017). C-MYC upregulates CDK7 expression and  
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Figure 1.7: C-MYC regulates mRNA capping via RNMT and SAHH.
C-MYC (and N-MYC) upregulate N7-methylguanosine mRNA capping. 
At least two mechanisms are thought to be involved. Firstly, C-MYC 
directly upregulates the SAHH gene, the protein product of which 
catalyses hydrolysis of SAH (the inhibitory by-product of cap 
methylation) into adenosine (A) and homocysteine (Hcy). Secondly, C-
MYC recruits TFIIH containing CDK7 which phosphorylates RNA pol II, 
and this activity is required for recruitment of CE and RNMT. Solid 




















recruitment (Bouchard et al., 2004; Cowling and Cole, 2007b) thereby 
increasing RNMT-RAM recruitment to chromatin and mRNA cap methylation 
(Aregger and Cowling, 2013; Posternak et al., 2017). A C-MYC mutant lacking 
the ability to interact with CDK7 had a somewhat diminished potential to 
increase mRNA capping on some – but not all – C-MYC target genes (Cole and 
Cowling, 2009b), hinting that C-MYC might also regulate mRNA capping 
through additional mechanisms. Indeed, C-MYC was subsequently shown to 
directly upregulate the expression of SAH hydrolase (SAHH) which catalyses 
removal of SAH (the inhibitory by-product of the cap methylation by RNMT-
RAM) (Fernandez-Sanchez et al., 2009). SAHH was shown to be required for 
C-MYC-dependent mRNA cap methylation and biological functions of C-MYC. 
Moreover, the SAHH inhibitor tubercidin (Radomski et al., 1999) reduced C-
MYC-dependent proliferation, but not basal proliferation (Fernandez-Sanchez et 
al., 2009). It is worth noting that that the ability of C-MYC to increase mRNA cap 
methylation of target transcripts in these studies was determined by isolation of 
mRNA molecules using an antibody or recombinant eIF4E, which specifically 
recognise the complete N7-methylguanosine mRNA cap (and not the 
unmethylated guanosine mRNA cap) (Cole and Cowling, 2009b; Posternak et 
al., 2017). Therefore, only the final step in mRNA capping (i.e. cap methylation 
catalysed by RNMT-RAM) has been investigated, and it is not known if prior 
steps in mRNA capping are also rate-limiting in C-MYC function. Since the 
different steps in co-transcriptional mRNA capping occur with different kinetics 
(Moteki and Price, 2002), it is feasible that they could be differentially regulated.  
RNMT-RAM is also regulated in a cell-cycle-dependent manner (Aregger 




C-MYC, the E2F1 transcription factor which is involved in cell cycle regulation 
upregulates mRNA capping (N7-methylguanosine mRNA cap addition) of its 
target gene transcripts, and this is dependent on its ability to stimulate RNA pol 
II phosphorylation (Aregger and Cowling, 2012; Cole and Cowling, 2009b). 
Moreover, RNMT is phosphorylated by CDK1 during the late S-phase and 
throughout G2/M-phases of the cell cycle, which coordinates RNMT-RAM 
activity with the peak of transcription at the beginning of the G1 phase (Aregger 
et al., 2016). RNMT phosphorylation both directly stimulates its catalytic activity 
and indirectly via relieving the inhibitory interaction of karyopherin alpha 2 
(KPNA2) with RNMT (Aregger et al., 2016). 
Furthermore, RNMT-RAM stability and activity are regulated during in 
vitro neural differentiation. High levels of RAM are required to maintain 
pluripotency in embryonic stem cells (ESCs), whereas during neural 
differentiation extracellular signal-related kinase (ERK) mediates phospho-
dependent ubiquitination and degradation of RAM (Grasso et al., 2016). This is 
associated with downregulation of pluripotency genes and upregulation of 
neural genes. 
1.3.3 CMTR1 expression  
 As previously mentioned, CMTR1 marks self-RNAs and therefore 
distinguishes them from viral RNAs during the innate immune response (Daffis 
et al., 2010). Consistently, expression of CMTR1 is stimulated by interferon in 
response to viral infection (Geiss et al., 2003; Guerra et al., 2003; Haline-Vaz et 




and CMTR2 as well as RNMT (Haline-Vaz et al., 2008), their activity also has 
the potential to be regulated by C-MYC. 
1.3.4 mRNA decapping and re-capping 
An emerging concept is that mRNA decapping is a regulated process. 
Decapping is the process by which the cap is removed and precedes transcript 
degradation by exonucleases, which recognise 5’-monophosphate RNA (the 
RNA product of most decapping enzymes). At least four mRNA decapping 
enzymes are functional in mammalian cells: decapping mRNA 2 (DCP2), 
nucleoside diphosphate-linked moiety X motif 16 (NUDT16), NUDT3 and DXO. 
DCP2, NUDT16 and NUDT3 recognise the complete N7-methylguanosine cap 
or incomplete guanosine cap, and cleave between the α- and β- phosphates of 
the triphosphate group (Figure 1.4) to generate N7-methyl-GDP and 5′-
monophosphate RNA (Song et al., 2013; Song et al., 2010; Wang et al., 2002). 
NUDT3 can also cleave between the β- and γ- phosphates of the cap, 
generating N7-methyl-GMP and 5′-diphosphate RNA (Song et al., 2013). The 
function of the latter is not clear, but it may be a substrate for re-capping (see 
below). DXO is a multifunctional enzyme which preferentially removes the 
incomplete mRNA cap (the unmethylated guanosine cap) in cells and removes 
the entire structure in conjunction with the first transcribed nucleotide (N), 
generating GTP-N and 5’ monophosphate RNA (Jiao et al., 2013). It also has 
two activities towards uncapped mRNA: it cleaves between the α- and β- 
phosphates of the triphosphate group on the 5’ end of RNA (generating N7-
methyl-GDP and 5′-monophosphate RNA) and possesses intrinsic 5’-3’ 
exonuclease activity (Jiao et al., 2013). Additionally, DXO was shown to act on 




present on mRNAs, snRNAs and small nucleolar RNAs (snoRNA) in human 
cells (Jiao et al., 2017). Although for the purpose of this thesis it will not be 
discussed at length, NAD+ caps – in contrast to m7G caps – destabilise RNA 
molecules and do not influence translation. NAD+ caps actively promote DXO 
recruitment to mediate degradation of the associated RNA (Jiao et al., 2017). 
DCP2 is the most studied decapping enzyme. It binds and decaps a 
subset of RNAs, which is achieved through recognition of specific RNA 
sequences containing a stem-loop structure within the first 10 transcribed 
nucleotides (Li et al., 2008; Piccirillo et al., 2003). DCP2 can bind mRNAs co-
transcriptionally in the nucleus but is thought to act primarily in the cytoplasm, 
and has a regulatory interacting partner DCP1 with which it forms a heterodimer 
(Brannan et al., 2012; Lykke-Andersen, 2002; van Dijk et al., 2002; Wang et al., 
2002). Various different factors regulate the DCP2-DCP1 interaction, DCP1 
recruitment, DCP2 catalytic activity, DCP2 expression and DCP2 stability 
(Castellanos-Rubio et al., 2016; Erickson et al., 2015; Fenger-Gron et al., 2005; 
Jia et al., 2012). DCP2-mediated decapping is involved in both nonsense-
mediated decay (NMD) and AU-rich element (ARE) mRNA decay pathways, 
and specific DCP2-interacting partners influence which of these pathways takes 
preference (Erickson et al., 2015; Fenger-Gron et al., 2005; Song and Kiledjian, 
2007). DCP2 can be phosphorylated by mammalian target of rapamycin 
(mTOR), triggering assembly of a decapping complex which promotes the 
degradation of autophagy-related mRNAs (Hu et al., 2015). Furthermore, 
nuclear factor-κB (NF-κB) can transcriptionally upregulate DCP2, which causes 
downregulation of a long-non-coding RNA associated with celiac disease 




PABP was shown to interact with the mRNA cap and thereby competes for 
DCP2 cap-binding in vitro (Khanna and Kiledjian, 2004) and reversible 
methylation of the first transcribed nucleotide at the N6 position of adenosine 
confers resistance to DCP2 (Mauer et al., 2017). 
NUDT16 and NUDT3 are cytoplasmic decapping enzymes which also 
regulate a small subset of mRNAs (Grudzien-Nogalska et al., 2016; Song et al., 
2010) although how they achieve specificity is not yet clear. Interestingly, 
through negatively regulating specific mRNAs, NUDT3 suppresses breast 
cancer cell migration (Grudzien-Nogalska et al., 2016). Although little is known 
about the biological role of DXO to date, it acts preferentially on nascent 
(unspliced) pre-mRNAs rather than mature (spliced) mRNAs and thus likely acts 
co-transcriptionally in the nucleus (Jiao et al., 2013). 
In a further layer of complexity, decapping may not always result in 
transcript degradation, and some transcripts were shown to be re-capped in the 
cytoplasm. These mRNAs are enriched for those involved in the cell cycle, 
nucleotide binding and RNA/protein localisation (Mukherjee et al., 2012). As 
previously mentioned, decapping usually generates 5’ monophosphate RNA 
which is not a substrate for capping. However, in the cytoplasm CE interacts 
with an adaptor protein non-catalytic region of tyrosine kinase 1 (NCK1) which 
bridges the interaction of an unknown 5’ kinase to yield a 5’-diphosphate RNA 
substrate for CE (Mukherjee et al., 2014). Although the guanosine cap is 
methylated during re-capping, RNMT is not detected in the cytoplasmic capping 
complex and therefore the cap methylation mechanism is not known (Otsuka et 
al., 2009). Re-capping of mRNAs promotes their stability and translation 




et al., 2013; Yiemwattana et al., 2012), it is possible that assembly of this 
complex is regulated. However, since CE is primarily nuclear, the biological 
significance of re-capping is not yet clear. 
In conclusion, recent evidence highlights that mRNA capping and cap 
homeostasis are regulated at multiple levels. The relative contribution of the 
above mechanisms to gene expression is not known, and their biological 














1.4 The MYC oncogenes 
1.4.1 C-MYC discovery 
The myelocytomatosis viral oncogene (v-Myc) was originally isolated 
from a chicken retrovirus (MC29) which caused solid, promyelocytic tumours 
(Ivanov et al., 1964). v-Myc in this viral strain was found fused to the viral gag 
(group-specific antigen) gene (Duesberg et al., 1977; Hu et al., 1979) and 
subsequently a homologous gene in vertebrates was identified (designated 
cellular Myc, or C-MYC) (Roussel et al., 1979; Sheiness and Bishop, 1979). v-
Myc was then identified in other oncogenic retroviruses (Graf and Beug, 1978), 
and insertion of other retroviral promoters from viruses other than MC29 greatly 
stimulated C-MYC expression and caused transformation (Hayward et al., 1981; 
Neel et al., 1981; Payne et al., 1981) adding to the notion that v-Myc is a 
retroviral oncogene and C-MYC its cellular homologue. This, together with the 
cloning of C-MYC in 1982 (Vennstrom et al., 1982) stimulated the wealth of 
further studies on the cellular oncogene.  
1.4.2 Structure and function of MYC proteins 
The MYC family of genes encode nuclear transcription factors which are 
conserved amongst metazoans and in premetazoans (Hartl et al., 2010; 
Simionato et al., 2007; Young et al., 2011). The normal function of MYC 
proteins is to control cell proliferation in response to extracellular growth cues 
via numerous signalling pathways. In humans there are three main family 
members designated C-MYC, N-MYC and L-MYC. They are of the basic helix-
loop-helix leucine zipper (bHLH-LZ) transcription factor family, and form 




factor X (MAX) to regulate gene expression. MYC-MAX not only binds to 
enhancer boxes (E-boxes) with specific sequences (Figure 1.8) proximal to 
transcription initiation sites, but also to enhancers and other genes without clear 
sequence specificity in particular circumstances (Figure 1.9) (Blackwood and 
Eisenman, 1991; Fernandez et al., 2003; Kress et al., 2015). All MYC proteins 
have an N-terminal transcription activation domain (TAD), which is able to 
recruit various factors to drive or repress the expression of target genes 
(discussed in sections 1.4.6 and 1.4.7, respectively), and a C-terminal DNA-
binding domain (DBD) (Figure 1.10). In contrast, MAX only has a DBD and does 
not possess a TAD (Kato et al., 1992). The LZ helix of the MYC DBD interacts 
with that of MAX, and the two basic helices bind the major groove of DNA (Nair 
and Burley, 2003). 
All MYC paralogues are bona fide oncogenes. When constitutively 
activated, they increase cell growth/proliferation and cause cell transformation 
(Birrer et al., 1988; Lee et al., 1985; Yancopoulos et al., 1985) and they have 
roles in both tumour initiation and progression (Gabay et al., 2014). MYC 
proteins are structurally and functionally similar, but differ in expression patterns 
and potencies. C-MYC is widely expressed during development and throughout 
adult tissues, often highly in proliferating tissues (Downs et al., 1989; Schmid et 
al., 1989; Zimmerman et al., 1986) including in stem cell compartments where it 
maintains cell pluripotency and self-renewal (Cartwright et al., 2005; Takahashi 
and Yamanaka, 2006; Varlakhanova et al., 2010). Conversely, C-MYC also 
promotes apoptosis. Different levels of C-MYC activity tend to govern whether a 
cell proliferates or undergoes cell death (specific examples discussed in section 
1.4.10) as an intrinsic tumour-suppressor mechanism (Murphy et al., 2008).  
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Figure 1.8: C-MYC sequence specificity. Relative affinities are 
shown for C-MYC-MAX dimers binding to the indicated 6mers in 
vitro. Shown are the top twelve 6mers in terms of C-MYC affinity 
of all possible 6mers, which includes the canonical E-box, non-
canonical E-boxes and variants, and other 6mers. Notably, 
sequence specificity does not always predict C-MYC genome 
binding and gene regulation in cells; chromatin, RNA pol II status 
and C-MYC expression level also play prominent roles. Affinity 
data from Guo et al. 2014. N denotes any nucleotide.




































Figure 1.9: Dosage model of C-MYC recruitment. (A) In the 
presence of low C-MYC levels, such as in most somatic cells, C-
MYC binds primarily to promoter proximal canonical E-boxes, 
promoting basal transcription. (B) In the presence of high C-MYC 
levels, such as in cancer cells, C-MYC also binds non-canonical 
(NC) E-boxes and non-specific (NS) DNA sequences in addition to 
distal regulatory elements and super-enhancers. This can cause 
elevated expression of C-MYC target genes and non-classical 
target genes. C-MYC recruitment is also influenced by chromatin 















Figure 1.10: C-MYC protein architecture. Depicted is a schematic 
of the C-MYC protein encompassing its transactivation domain 
(TAD) and DNA-binding domain (DBD) relative to the MYC box (MB) 
subdomains. The main known functions of MB domains and the 
bHLH-LZ domain are also shown. T58p and S62p represents 
phosphorylation of corresponding residues. Numbers correspond to 
amino acid position. N-MYC has an analogous arrangement, 
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C-MYC knockout mouse embryos die by day 10.5 with stunted growth 
and hypoplastic/aberrantly developed organs (Davis et al., 1993). Deregulation 
of C-MYC – caused by increased C-MYC gene expression, protein stability and 
activity – can contribute to the initiation and progression of many solid and 
blood-borne tumours including those of the breast, prostate, gastrointestinal 
tract and many haematopoietic cancers. C-MYC regulates RNA pol I, II and III 
transcriptional activity. The genes regulated by C-MYC vary between cell types 
with the exception of a core signature which essentially supports cell growth 
and proliferation (Brown et al., 2008; Kress et al., 2015; McMahon, 2010) (see 
sections 1.4.4 and 1.4.5). Ultimately, C-MYC deregulation directly up- and 
down-regulates a subset of genes and causes amplification of general 
transcription and translation, increasing the propensity of cells to undergo 
oncogenic transformation. 
Of note, most functional studies have focussed on C-MYC rather than 
the other MYC genes due to the overwhelming prevalence of C-MYC 
deregulation in cancers, although it is likely that at least some findings can be 
applied to all MYC members. N-MYC and L-MYC expression is subject to more 
spatial and temporal regulation than C-MYC, both during development and in 
adults. N-MYC is mostly expressed in neural tissue, kidney, heart and testes 
during development, where expression persists at low levels in adults 
(Jakobovits et al., 1985; Zimmerman et al., 1986). Amplification or 
overexpression of N-MYC is associated with the development of 
neuroendocrine cancers such as neuroblastomas, retinoblastomas, small cell 
lung cancers (SCLC) and prostate cancers (Lee et al., 2016b; Lee et al., 1984; 




lethal, at a slightly later stage than C-MYC knockouts (~day 11.5) and similar to 
C-MYC knockouts are small in size while exhibiting developmental defects in 
several organs (Charron et al., 1992; Sawai et al., 1991; Stanton et al., 1992). It 
is thought that C-MYC and N-MYC knockout embryos survive to the stage they 
do because they can functionally compensate for each other (perhaps in 
concert with L-MYC) until the point when their expression patterns start to 
diverge. Indeed, N-MYC can functionally compensate for C-MYC knockout 
when the N-MYC coding sequence is placed in the endogenous C-MYC locus 
(Malynn et al., 2000). Taken together, C-MYC and N-MYC have similar 
molecular functions, but their distinct regulation of expression is important. In 
contrast to the other MYC family members, L-MYC knockout mice are viable 
and develop healthily as in WT mice (Hatton et al., 1996). L-MYC is generally 
co-expressed with C-MYC or N-MYC during development (Zimmerman et al., 
1986), therefore it is thought that the other two MYC genes can functionally 
compensate for L-MYC loss. Additionally, L-MYC has a reduced capability to 
transactivate and induce cell transformation compared to C-MYC and N-MYC 
(Barrett et al., 1992; Birrer et al., 1988; Lee et al., 1985; Oster et al., 2003; 
Yancopoulos et al., 1985). During development, L-MYC expression is limited 
mainly to the central nervous system, kidneys and lungs with low level 
expression in other tissues (Hatton et al., 1996). L-MYC overexpression or 
amplification can also manifest in tumourigenesis, most commonly SCLC (Gu et 
al., 1988; Nau et al., 1985).  
There are other, less characterised C-MYC isoforms arising from 
alternative start codons (p64 and p67), internal translation start sites (S-MYC), 




Eisenman, 1984; Spotts et al., 1997; Stewart et al., 1984). For the most part, 
their functions are not clear, although more recent studies have shown that 
MYC-nick promotes cancer cell survival and invasion. MYC-nick lacks the DBD 
and nuclear localisation signal (NLS) and is thus located in the cytoplasm where 
it mediates cytoskeleton remodelling and promotes autophagy rather than 
apoptosis, lending to the above effects (Anderson et al., 2016; Conacci-Sorrell 
et al., 2010). 
1.4.3 C-MYC-MAX dynamics 
MAX is the primary partner of C-MYC in transcriptional regulation, and is 
required for both gene activation and repression by C-MYC (Amati et al., 1992; 
Cowling and Cole, 2007b; Mao et al., 2003). Moreover, the interaction is 
essential for many aspects of C-MYC biology and for its full transformative 
potential (Amati et al., 1993a; Amati et al., 1993b). C-MYC-MAX dimers can 
form tetramers which co-operatively bind chromatin and facilitate promoter DNA 
bending (Lebel et al., 2007; Nair and Burley, 2003), although its significance in 
vivo is yet to be explored. MAX knockout is lethal in mouse embryos at a 
significantly earlier stage (day 5.5-6.5) compared to C-MYC and N-MYC 
knockout mice (Shen-Li et al., 2000), which likely owes to lack of a 
compensatory factor unlike the three MYC genes. Endogenous MAX may be 
essential at even earlier stages of development (pre-implantation), since 
embryonic lethality coincides with loss of stable maternal MAX protein in the 
embryo (Shen-Li et al., 2000). C-MYC expression is highly dynamic (discussed 
in section 1.4.9), whereas MAX is constitutively expressed in stoichiometric 
excess to C-MYC with its mRNA and protein products being more stable and 




Wagner et al., 1992). However, a number of MAX binding partners exist other 
than C-MYC to antagonise C-MYC-MAX. MAX can form weak homodimers 
(when expressed highly enough relative to C-MYC), in addition to heterodimers 
with other bHLH-LZ transcription factors: MAX dimerization proteins (MXD) 1-4, 
MAX network transcriptional repressor (MNT) and MAX gene-associated (MGA) 
(Kretzner et al., 1992). All complexes have the same DNA binding specificity as 
C-MYC-MAX dimers, causing competition for promoter region binding. 
Alternative MAX complexes not only block C-MYC recruitment and C-MYC’s 
ability to activate transcription, but they can also recruit histone 
deacetylases/methyltransferases; passively or actively repressing genes, 
respectively (Hurlin et al., 1997; Laherty et al., 1997; Ogawa et al., 2002; Yin et 
al., 1998). Indeed, although moderate expression of MAX enhances C-MYC-
induced cell transformation, MAX overexpression actually antagonises C-MYC-
induced cell transformation in a dose-dependent manner (Amati et al., 1993a; 
Makela et al., 1992). In proliferating cells, MAX exhibits preference towards C-
MYC for dimerisation, whereas upon differentiation other interactions are 
favoured (Ayer and Eisenman, 1993; Blackwell et al., 1990; Prendergast and 
Ziff, 1991). MAX-interacting partners have opposite biological roles to that of C-
MYC with regard to target gene activation and cell transformation (Hurlin et al., 
1999; Kato et al., 1992; Nilsson et al., 2004; Schreiber-Agus et al., 1998). 
Taken together, when MAX is in a heterodimer with C-MYC it acts as a 
transcription co-factor of C-MYC, but when engaged in alternative complexes it 




1.4.4 C-MYC-dependent gene regulation: global or specific? 
C-MYC regulates thousands of genes (10-30% of the genome) which 
mostly vary depending on the cell type and conditions except a ‘core signature’ 
of genes involved in RNA processing, ribosome biogenesis and biomass 
accumulation (Fernandez et al., 2003; Ji et al., 2011; Li et al., 2003b; Zeller et 
al., 2006). Although C-MYC preferentially binds E-boxes in vitro and exhibits 
some preference of E-boxes in vivo, C-MYC genome binding in cells correlates 
more with RNA pol II location than E-boxes (Guccione et al., 2006; Guo et al., 
2014). It was proposed that C-MYC binds and regulates all transcriptionally 
active genes and enhancers, serving as an amplifier of transcriptional output 
and therefore upregulating the existing gene expression programme, rather 
than inducing a new set of genes (Lin et al., 2012b; Nie et al., 2012). This is 
consistent with the ‘core signature’ of C-MYC target genes being expressed in 
all cell types (Ji et al., 2011). More recently, it was shown that C-MYC 
transcriptional regulation and gene expression amplification can be separable 
events, indicating that C-MYC binds and regulates a distinct set of genes while 
indirectly amplifying gene expression through its target genes involved in global 
regulation of gene expression (Sabo et al., 2014; Walz et al., 2014). 
Mathematical modelling has postulated that genes with high affinity C-MYC 
binding sites (E-boxes) are upregulated even in the presence of low C-MYC 
levels, whereas those with low-affinity C-MYC binding sites (non-canonical E-
boxes or non-specific DNA sequences, i.e. global transcription amplification) are 
only upregulated upon C-MYC overexpression (Figure 1.9) (Benary et al., 2016; 
Lorenzin et al., 2016). Although a unified theory is yet to be solidified, it is 
evident that C-MYC target genes can vary between systems depending on C-




MYC interacting partners. A few genes which are ascribed as C-MYC targets in 
many systems will be described in the following section, and their expression 
will be analysed in particular parts of this thesis. These C-MYC target genes are 
involved in ribosome biogenesis, metabolism, chromatin modification, 
translation and the cell cycle. 
1.4.5 C-MYC target genes 
Nucleolin (NCL), nucleophosmin (NPM1) and fibrillarin (FBL) encode 
abundant nucleolar proteins which are transcriptionally regulated by C-MYC 
(Greasley et al., 2000; Ji et al., 2011; Zeller et al., 2001; Zeller et al., 2003). 
They have roles in promoting ribosome biogenesis at various stages, including 
RNA pol I transcription initiation and elongation (at ribosomal DNA, rDNA), 
processing of rRNA and assembly of rRNA with ribosomal proteins (Cong et al., 
2012; Ginisty et al., 1998; Murano et al., 2008; Rickards et al., 2007; Savkur 
and Olson, 1998; Tollervey et al., 1993). NCL, NPM1 and FBL are often 
upregulated in cancers, (Berger et al., 2015; Holmberg Olausson et al., 2015; 
Koh et al., 2011; Lim and Wang, 2006; Marcel et al., 2013; Su et al., 2014), 
likely supporting aberrant growth and proliferation of tumour cells. Intriguingly, 
when NCL is overexpressed it can also be found on the cell surface where it 
acts to transduce oncogenic and suppress anti-oncogenic signals (Reyes-
Reyes and Akiyama, 2008; Wise et al., 2013). 
Ornithine decarboxylase (ODC) is a C-MYC target gene encoding an 
enzyme rate-limiting in polyamine synthesis (Bello-Fernandez et al., 1993; 
Zeller et al., 2003). Polyamines can bind DNA, RNA and proteins, thereby 




and protein activity (Childs et al., 2003; Jänne et al., 2004). ODC and polyamine 
levels are important in the regulation of processes such as cell proliferation, 
cellular stress responses and apoptosis (Jänne et al., 2004; Miller-Fleming et 
al., 2015). ODC overexpression in itself is sufficient for cell transformation and 
occurs in various cancers (Auvinen et al., 1992; Deng et al., 2008; Hu et al., 
2005; Tamori et al., 1995). Another metabolism-associated C-MYC-target gene 
is nucleoside diphosphate kinase A/non-metastatic cells 1 (NME1), encoding an 
enzyme which utilises ATP to generate other nucleoside triphosphates. 
Additionally, NME1 phosphorylates and activates kinase suppressor of RAS 
(KSR), thereby down-modulating oncogenic RAS signalling (Hartsough et al., 
2002). NME1 also possesses exonuclease activity which is important for DNA 
replication and repair (Jarrett et al., 2012; Ma et al., 2004). Not surprisingly, 
NME1 is a suppressor of metastasis (Kaetzel et al., 2006; McCorkle et al., 
2014; Steeg et al., 1988). 
TIP49 (TATA box-binding protein-interacting protein 49kDa) is a DNA 
helicase and an essential subunit of the C-MYC co-activator tat-interactive 
protein 60kDa (TIP60) histone acetyltransferase (HAT) complex (discussed in 
section 1.4.6) (Jha et al., 2008). It is also transcriptionally induced by C-MYC 
(Cowling and Cole, 2007b; Westermann et al., 2008; Wood et al., 2000). The 
TIP60 complex is essential for C-MYC target gene expression and C-MYC-
mediated cell transformation (Wood et al., 2000). 
Components of the eIF4F complex (which mediates cap-dependent 
translation) are transcriptionally upregulated by C-MYC and contribute to C-
MYC-dependent translation and protein synthesis (Jones et al., 1996; Lin et al., 




whereby C-MYC increases eIF4F expression and in turn eIF4F upregulates C-
MYC expression and activity (Lin et al., 2008). The eIF4E cap-binding 
component in itself, or in cooperation with C-MYC, promotes cell transformation 
and oncogenesis (Avdulov et al., 2004; Li et al., 2003a; Polunovsky et al., 1996; 
Ruggero et al., 2004).  
The CCND1 gene, encoding cyclin D1, can be positively or negatively 
regulated by C-MYC depending on the system (Daksis et al., 1994; Huerta et 
al., 2007; Philipp et al., 1994; Rosenwald et al., 1993a), possibly through 
context-dependent positive or negative transactivators. For example, CCND1 is 
repressed by C-MYC and histone deacetylases (HDACs) in a complex involving 
zona occludens 2 (ZO-2) – a tight-junction protein with roles in intercellular 
communication, found in the cell membrane but also in the nucleus (Huerta et 
al., 2007). Cyclin D1 is the regulatory subunit of CDK4 and CDK6, and 
promotes the G1-S transition in the cell cycle (Resnitzky et al., 1994). 
Overexpression of cyclin D1 causes aberrant cell proliferation and often occurs 
in breast cancers amongst others (Musgrove et al., 2011; Wang et al., 1994). 
1.4.6 Transcription activation by C-MYC 
C-MYC activates transcription by recruiting HAT complexes and RNA pol 
II kinases, causing chromatin relaxation and influencing RNA pol II pausing, 
respectively. C-MYC directly associates with particular subunits of several HAT 
complexes through its TAD, which increases C-MYC target gene histone 
acetylation at histones 3 and 4 (H3/4) (Frank et al., 2001; Martinato et al., 
2008). Specifically, C-MYC interacts with transformation-TAD-associated 




acetyltransferases: general control of amino-acid synthesis 5 (GCN5) or TIP60 
(Frank et al., 2003; Liu et al., 2003; McMahon et al., 1998; McMahon et al., 
2000). TRRAP, GCN5 and TIP60 are required for C-MYC-dependent 
transcriptional activation and transformation (Flinn et al., 2002; Liu et al., 2003; 
McMahon et al., 2000; Wood et al., 2000). C-MYC also recruits the p300 and 
CBP HATs in a distinct complex which facilitates C-MYC-mediated transcription, 
with p300 binding the C-MYC TAD and CBP binding the DBD (Faiola et al., 
2005; Vervoorts et al., 2003). More recently, C-MYC was shown to bind to 
WD40-repeat protein 5 (WDR5) which is important for C-MYC DNA binding 
(Thomas et al., 2015b), and host cell factor 1 (HCF-1) scaffold protein which is 
known to recruit a range of different chromatin modifiers (Thomas et al., 2016). 
C-MYC recruits different chromatin modifier complexes in different studies, and 
to date there is no unifying model of recruitment specificity. It is thought that 
particular complexes might regulate specific genes depending on the 
circumstances.  
Additionally, C-MYC mediates transcription activation by increasing the 
expression and recruitment of TFIIH and P-TEFb complexes (which contain 
CDK7 and CDK9, respectively) to promoters, which is dependent on the C-MYC 
TAD domain but not the DBD (Bouchard et al., 2004; Cowling and Cole, 2007b; 
Kanazawa et al., 2003; Mateyak et al., 1999). As previously mentioned, CDK7 
and CDK9 phosphorylate S5 and S2 of the RNA pol II CTD, respectively, which 
in concert co-ordinate the recruitment of factors involved in RNA pol II pausing, 
pause release, elongation, mRNA processing and termination (Hsin and 
Manley, 2012). C-MYC (and N-MYC) modulation correlates with global cellular 




et al., 2012b). In most cases, C-MYC induces RNA pol II pause release without 
affecting RNA pol II initiation, in a P-TEFb-dependent manner (Eberhardy and 
Farnham, 2002; Lin et al., 2012b; Nie et al., 2012; Rahl et al., 2010). However, 
in a particular study C-MYC was shown to regulate transcription initiation as 
well as elongation (Walz et al., 2014), although the mechanisms governing this 
are not yet clear. It may be that C-MYC fulfils different roles in transcription 
depending on its abundance, the presence of different initiation/elongation 
factors, or on the chromatin environment. Moreover, as previously discussed, 
C-MYC upregulates mRNA capping in concurrence with increased RNA pol II 
phosphorylation (Cowling and Cole, 2007b; Posternak et al., 2017). Intriguingly, 
although the C-MYC DBD and C-MYC’s interaction with MAX were required for 
C-MYC target gene activation, they were not required for C-MYC-induced RNA 
pol II phosphorylation and mRNA capping, and C-MYC mutants lacking these 
regions were able to confer a partial C-MYC phenotype (Cowling and Cole, 
2007b). Perhaps when C-MYC is above a certain concentration in the nucleus it 
can reach RNA pol II complexes without direct DNA binding, although the DBD 
likely provides specificity in some contexts. It is not yet clear if C-MYC recruits 
HATs and CDKs to genes in a synergistic manner to drive transcriptional 
activation, whether CDK recruitment occurs as a consequence of C-MYC-
mediated histone acetylation, or if HAT and CDK recruitment are each 
preferentially recruited to specific genes. Further studies are required to dissect 
the relative importance and specificity of these C-MYC transactivation modules. 
In addition to regulating RNA pol II transcription, C-MYC also 
transactivates RNA pol I- and III- transcribed genes (Arabi et al., 2005; Gomez-




previously mentioned, RNA pol I synthesises 45S rRNA whereas RNA pol III 
synthesises 5S rRNA and transfer RNA (tRNA). These components are 
essential for ribosome biogenesis and mRNA translation. RNA pol I and III are 
required for cell growth, especially in cancer cells which exhibit aberrant 
proliferation and growth control mechanisms. C-MYC influences RNA pol I and 
III transcription in many ways. Firstly, C-MYC directly transactivates RNA pol II-
transcribed genes encoding RNA pol I and III subunits, transactivators and RNA 
processing factors (Gomez-Roman et al., 2003; Ji et al., 2011; Poortinga et al., 
2011; Schlosser et al., 2003). C-MYC also directly binds to RNA pol I- and III-
transcribed genes and influences their transcription. In the case of RNA pol I 
transcription, C-MYC increases the recruitment of selective factor 1 complex 
(SL1, important for pre-initiation complex recruitment) and increases RNA pol I 
loading (Arabi et al., 2005; Grandori et al., 2005). On RNA pol III-transcribed 
genes, C-MYC recruits TFIIB (transcription initiation factor) and increases RNA 
pol III loading (Koch et al., 2007; Steiger et al., 2008). Moreover, C-MYC 
recruits HATs via TRRAP to create a permissive chromatin environment for 
RNA pol III transcription as described for RNA pol II (Arabi et al., 2005; Grandori 
et al., 2005; Kenneth et al., 2007). On the RNA45S5 gene (encoding 45S 
precursor rRNA), C-MYC also influences rDNA looping to promote efficient RNA 
pol I transcription (Shiue et al., 2009). It is not known whether C-MYC also 
promotes higher order chromatin structures on RNA pol I-transcribed genes. Of 
note, RNA pol I and III do not possess a CTD ‘tail’ structure like that of RNA pol 
II, therefore it is thought that they are not amenable to C-MYC-dependent 
CDK7/9 activity. Ribosome biogenesis is critical to C-MYC function, since 




gene encoding L24 ribosomal protein for C-MYC’s full oncogenic potential 
(Barna et al., 2008). 
1.4.7 Transcription repression by C-MYC 
C-MYC is also able to directly repress the expression of particular genes. 
Although this is less well understood than C-MYC-induced transcription, it is 
thought to occur through displacement of transactivators and recruitment of 
transcriptional repressors. Notably, the first identified C-MYC-repressed gene 
was C-MYC itself, creating a negative feedback loop and tumour-suppressor 
mechanism when C-MYC expression reaches a critical threshold (Adams et al., 
1985; Murphy et al., 2008; Penn et al., 1990). One mechanism of C-MYC-
mediated gene repression is via MYC-interacting zinc finger protein (MIZ-1). 
MIZ-1 is a soluble protein able to activate the transcription of certain genes 
(including those which regulate the cell cycle, cell growth and apoptosis) in a C-
MYC-independent manner by recruiting HATs (Staller et al., 2001a; 
Varlakhanova et al., 2011; Ziegelbauer et al., 2004). However, when C-MYC 
interacts with MIZ-1, MIZ-1 becomes insoluble and instead recruits DNA 
methyltransferase 3 alpha (DNMT3A) to promoter regions, creating a restrictive 
chromatin environment, shutting down the expression of C-MYC-MIZ-1 target 
genes and thus alleviating cell cycle and growth restraints (Brenner et al., 2005; 
Peukert et al., 1997; Staller et al., 2001a; Varlakhanova et al., 2011). Of note, a 
single point mutation in C-MYC which disrupts its interaction with MIZ-1 
diminishes its oncogenic potential (Van Riggelen et al., 2010a), demonstrating 
the importance of this mechanism. C-MYC and N-MYC can also interact with 
specificity protein 1 (SP1) – a zinc finger transcription factor – thereby 




To achieve this, C-MYC sequesters SP1 from promoters or recruits HDACs 
(Gartel et al., 2001b; Liu et al., 2007). Interestingly, C-MYC can also negatively 
regulate genes in an E-box-dependent manner by recruiting HDACs, which for 
example occurs on the genes encoding CDK inhibitor p27 and cyclin D1 
(Amente et al., 2011; Chandramohan et al., 2008; Huerta et al., 2007; Kurland 
and Tansey, 2008). The mechanisms governing whether C-MYC activates or 
represses a given E-box-associated gene are not clear, although it may involve 
differential expression or availability of transcriptional co-factors.  
In addition to direct transcriptional repression, C-MYC can also achieve 
this via indirect mechanisms. C-MYC induces the expression of some miRNAs, 
thereby inhibiting translation of particular mRNAs or inducing their degradation. 
One such example is the C-MYC-induced miRNA cluster miR-17-92 (encoding 
six miRNAs) which cooperates with C-MYC in B cell lymphomagenesis (He et 
al., 2005; O'Donnell et al., 2005). In a further layer of complexity, C-MYC can 
directly repress other miRNA-encoding genes, which contributes to the 
oncogenic potential of lymphoma cells (Chang et al., 2008). Moreover, C-MYC 
indirectly causes activation and stabilisation of the methyltransferase enhancer 
of zeste 2 (EZH2) which trimethylates lysine 27 on H3 (H3K27me3) causing 
epigenetic silencing (Kaur and Cole, 2013). In at least certain systems this 
mediates widespread gene repression. 
1.4.8 Tumour-relevant functions of C-MYC 
C-MYC has been implicated in the control of essentially all cellular 
processes relevant to cancer initiation, development and maintenance in one 




clarification will be highlighted here (Figure 1.11). C-MYC drives DNA 
replication and the cell cycle, enforcing rapid cell division in the absence of 
appropriate mitogens (Bretones et al., 2015). Consequently, C-MYC causes 
replicative stress and DNA damage (Dominguez-Sola and Gautier, 2014). Cell 
growth and metabolism are regulated by C-MYC to provide sufficient nutrients, 
energy and proteins for the maintenance of tumour cell proliferation (Campbell 
and White, 2014; Schmidt et al., 2009; Stine et al., 2015). C-MYC can promote 
apoptosis as an intrinsic tumour suppressor mechanism (McMahon, 2014). 
Finally, C-MYC decreases cell adhesion, promotes cell motility and encourages 
tumour angiogenesis, thus supporting tumour maintenance and metastasis 
(Wolfer and Ramaswamy, 2011). It is not clear if all of these mechanisms in 
cohort are important for C-MYC oncogenic function, or whether dysregulation of 
particular processes are more important in different cancer types. 
1.4.9 Homeostatic regulation and tumourigenic deregulation of C-
MYC 
In non-oncogenic contexts, C-MYC is regulated at essentially every 
possible opportunity to maintain appropriate cell proliferation and prevent 
neoplasia (Figure 1.12). C-MYC is expressed at low levels in quiescent cells, 
but is rapidly induced in response to growth factor signalling (Dean et al., 1986). 
The C-MYC gene is influenced by regulation of both transcription initiation and 
elongation by a range of transcription factors (Bentley and Groudine, 1986; Eick 
and Bornkamm, 1986; Krystal et al., 1988). C-MYC mRNA nuclear export and 
translation initiation are positively regulated by eIF4E (Culjkovic et al., 2006; Lin 

















Figure 1.11: Cellular functions of C-MYC. Some main cellular 
functions controlled by C-MYC are shown here, and described in 
more detail within the text. C-MYC functions in normal conditions 
to control appropriate cell behaviour, but when deregulated has 
roles in tumour initiation, maintenance and development.
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Figure 1.12: Extensive C-MYC regulation. Mechanisms of C-MYC 
regulation are shown. At essentially every possible stage of C-MYC 
expression, it is subject to positive or negative regulation depending 
on cellular stimuli. These processes are utilised in normal cells to 
retain proper control of C-MYC, whereas in cancer cells they are 
often perturbed, resulting in increased C-MYC expression or activity. 






























specific RNA-binding proteins (Filipenko et al., 2004; Lemm and Ross, 2002; 
Mazan-Mamczarz et al., 2006). Furthermore, C-MYC mRNA is intrinsically 
unstable with a typical half-life of 10-30 minutes (Dani et al., 1984; Laird-
Offringa et al., 1991; Welcker et al., 2004), but it can be stabilised by RNA-
binding proteins (Lemm and Ross, 2002; Prokipcak et al., 1994). The C-MYC 
protein is also unstable (with a typical half-life of 20-30 minutes) (Hann and 
Eisenman, 1984; Ramsay et al., 1984), and is influenced by dynamic patterns of 
post-translational modifications including phosphorylation, ubiquitination, 
acetylation and glycosylation which control its stability and activity (Chou et al., 
1995; Liu et al., 2013; Noguchi et al., 1999; Patel et al., 2004; Popov et al., 
2007; Sears et al., 2000; Vervoorts et al., 2003; Welcker et al., 2004). 
Moreover, as previously discussed, C-MYC transcriptional activity is subject to 
regulation via its interacting partners and co-factors.  
C-MYC is overexpressed in approximately 50% of all cancers (Vita and 
Henriksson, 2006). C-MYC is most commonly upregulated or hyperactivated via 
altered upstream signal transduction. Many signalling pathways known to be 
deregulated in cancer culminate in C-MYC activation via upregulation of its 
expression or activity as described above. Oncogenic/tumour suppressive 
pathways that regulate C-MYC include adenomatous polyposis coli (APC) 
signalling, which suppresses C-MYC and is defective in colon cancers (He et 
al., 1998); NOTCH signalling which is upregulated in haematopoietic 
malignancies and activates C-MYC expression (Palomero et al., 2006; Weng et 
al., 2006); and the RAS- phosphoinositide 3-kinase (PI3K)/ERK pathways which 
promote phosphorylation of C-MYC at two sites; governing concomitant C-MYC 




phosphorylation by glycogen synthase kinase 3 (GSK-3) mediates its 
ubiquitination and proteasomal degradation, whereas C-MYC Serine 62 (S62) 
phosphorylation by ERK paradoxically stabilises the protein while priming it for 
phosphorylation at T58 (Sears et al., 2000). 
The C-MYC gene is amplified in a range of tumour types (Vita and 
Henriksson, 2006). Although less common, the C-MYC gene can also be 
upregulated by changes in its regulatory regions or coding sequence, which are 
more specifically associated with Burkitt’s lymphoma and AIDS-associated 
haematopoietic cancers (Bhatia et al., 1993; Bhatia et al., 1994; Hemann et al., 
2005). In B cells, C-MYC can be translocated to the immunoglobulin heavy 
chain locus, causing it to be constitutively active under control of an associated 
enhancer region (Adams et al., 1985). As previously mentioned, C-MYC can 
also be activated by retroviral insertion (Adey et al., 2013; Hayward et al., 
1981), leading to elevated C-MYC expression. An oncogenic mutation encoding 
a Threonine-Alanine alteration at position 58 (T58A) prevents phosphorylation 
of C-MYC at this residue, which as previously mentioned promotes wild-type C-
MYC degradation (Hemann et al., 2005). Consequently, the C-MYC T58A 
variant is substantially stabilised, leading to greater activity and oncogenic 
potential (Bahram et al., 2000; Wang et al., 2011). 
1.4.10 C-MYC response thresholds 
The phenomenon of distinct C-MYC expression thresholds governing 
different cellular responses has been documented in several studies, 
predominantly in cancer systems but also in development. Cells can be very 




C-MYC regulatory region (containing a common cancer-associated single 
nucleotide polymorphism) in mouse models only marginally lowered C-MYC 
mRNA levels and caused no obvious adverse effects on the animals, whilst 
conferring resistance to APC-induced intestinal polyps (Sur et al., 2012). In 
another study, mouse models overexpressing C-MYC in haematopoietic cells to 
different extents developed different tumour types depending on C-MYC levels: 
those expressing the highest levels of C-MYC developed aggressive T-cell 
lymphomas and those with lower levels developed late-onset monocytic 
tumours (Smith et al., 2006). Mice with intermediate C-MYC expression levels 
developed different proportions of these tumour types, corresponding to C-MYC 
levels. It is thought that increased C-MYC expression increases the propensity 
of cells to accrue gain-of-function mutations in anti-apoptotic genes which 
synergise with C-MYC in T-cell lymphomagenesis, which could account for the 
development of different tumour types. 
As previously discussed, C-MYC paradoxically promotes cell growth and 
proliferation, while also priming cells for apoptosis as an intrinsic tumour 
suppressor mechanism. The balance of these conflicting cellular processes is 
governed by distinct levels of C-MYC expression or activity. For example, a 
version of C-MYC which is unresponsive to growth signals (but expressed at a 
similar level to mitogen-stimulated endogenous C-MYC) was sufficient to confer 
an increase in proliferation of regularly cycling somatic cells. However, in the 
same system, gross C-MYC overexpression induced concomitant cell 
proliferation and apoptosis (Murphy et al., 2008). Conversely, in Drosophila 
wing development, cells engineered to express dMyc (Drosophila C-MYC 




expressing two-fold less than WT underwent apoptosis (Moreno and Basler, 
2004). The apoptotic response to C-MYC in some cases is likely influenced by 
the balance of pro-/anti-apoptotic proteins and survival factors (Askew et al., 
1991; Evan et al., 1992; Hoffman and Liebermann, 2008). Indeed, co-
deregulation of C-MYC with apoptosis-associated genes such as B-cell 
lymphoma 2 (BCL-2), BCL-2-like protein 11 (BIM), and p53 overrides C-MYC-
induced apoptosis and augments tumourigenesis (Hemann et al., 2005; Nesbit 
et al., 1998). 
Moreover, there are many genes and pathways which are not required 
for cell viability under normal conditions that become essential upon 
deregulation of C-MYC (examples discussed in section 1.5.6). The cause for 
particular thresholds of C-MYC expression/activity governing distinct cellular 
outcomes (rather than simply acting on an axis; enhancing or diminishing one 
outcome) could be due to C-MYC binding and regulating additional sets of 
genes when the concentration of C-MYC in the nucleus is above a certain level. 
The availability of specific co-factors involved in C-MYC-mediated transcription 






1.5 Therapeutic intervention of C-MYC in cancer 
1.5.1 Targeting C-MYC protein function 
With the overwhelming evidence of C-MYC’s involvement in cancer, 
much effort has been invested in trying to find and develop C-MYC inhibitors to 
use as chemotherapeutic agents. One route that has been explored is directly 
inhibiting the function of the C-MYC protein. To determine if this was a viable 
option, a peptide called Omomyc was developed, which forms homodimers and 
binds particular E-boxes with a greater affinity than C-MYC-MAX, thus blocking 
C-MYC-induced transactivation on those genes (Jung et al., 2016; Soucek et 
al., 2002) . Conditionally expressing Omomyc in mouse models of KRAS-
induced lung cancer caused tumour regression, while causing some adverse 
yet reversible side-affects in proliferating somatic tissues (Soucek et al., 2008). 
This is proof of concept that directly inhibiting C-MYC function could be an 
effective mode of action for anti-cancer therapies. However, the C-MYC protein 
lacks a defined active site, making it problematic to target using small molecule 
inhibitors. In addition, the structure of monomeric MYC is intrinsically disordered 
relative to when it is in a heterodimer (Fieber et al., 2001). As an alternative, 
inhibitors which disrupt the interaction of C-MYC with its binding partner MAX, 
and those which disrupt C-MYC-MAX DNA binding, have been discovered from 
chemical library screens with the intention of depleting C-MYC transcriptional 
activity (Berg et al., 2002; Kiessling et al., 2006; Wang et al., 2007; Yin et al., 
2003). However, relatively high concentrations were required to perturb the C-
MYC-MAX interaction and to inhibit cell growth. Inhibitors of C-MYC-MAX 
chromatin recruitment were tested in human xenograft mouse models, but were 




anti-tumour activity (Clausen et al., 2010; Guo et al., 2009). The development of 
more efficacious C-MYC-MAX dimerisation and DNA binding inhibitors is in 
progress (Jung et al., 2015; Wang et al., 2013a; Wanner et al., 2015). Taken 
together, inhibiting C-MYC protein function could be an effective mode of action 
for a chemotherapy, however more work is required to optimise drugs which 
can do so in vivo. 
1.5.2 Targeting C-MYC expression 
Since directly perturbing C-MYC function is problematic, alternative 
methods are being explored, including targeting the expression of C-MYC. 
Studies using mouse models of cancer conditionally expressing C-MYC provide 
rationale that inactivating C-MYC expression is an effective way to achieve 
sustained tumour regression (Jain et al., 2002; Shachaf et al., 2004). Inhibition 
of the BET family of proteins has been found to inhibit C-MYC expression 
(Dawson et al., 2011; Delmore et al., 2011; Zuber et al., 2011) and small 
molecule BET inhibitors are showing some positive therapeutic effects in clinical 
trials (Berthon et al., 2016; Stathis et al., 2016). However, BET inhibition 
interferes with the expression of many genes and does not always perturb C-
MYC expression (Baker et al., 2015; Fong et al., 2015), suggesting there could 
be tissue-specific regulation of C-MYC by BET proteins or compensatory 
mechanisms may occur to maintain C-MYC expression. In favour of the latter, 
studies in models of acute myeloid leukaemia demonstrated that C-MYC 
expression was either maintained or recovered after BET inhibition (Fong et al., 
2015; Rathert et al., 2015). Moreover, it was shown that interfering with C-MYC 
expression did not recapitulate the effect of BET inhibition on cell viability 




 Another potential therapeutic strategy for targeting C-MYC expression is 
stabilising G-quadruplexes in the C-MYC promoter, which negatively regulate 
transcription of the C-MYC gene. One small molecule compound which binds to 
the C-MYC G-quadruplex (Quarfloxin/CX-3543) was taken forward to phase II 
clinical trials, but its mechanism of action was actually shown to be through 
stabilising these structures on rRNA genes and had no effect on C-MYC 
expression (Drygin et al., 2009). 
Inhibition of CDK7 – which controls C-MYC expression and function – 
using an inhibitor called THZ1 specifically targeted small cell lung cancer, 
neuroblastoma and triple-negative breast cancer cells which harbour amplified 
or deregulated MYC family members (Chipumuro et al., 2014; Christensen et 
al., 2014; Kwiatkowski et al., 2014; Wang et al., 2015). Efficacy was likely due 
to THZ1 reducing super-enhancer-driven expression of MYC genes and other 
oncogenes exclusively in cancer cells but not normal cells (Figure 1.9). Super-
enhancers are clusters of enhancers bound by hubs of transcription apparatus 
and promote strong activation of effector genes, which was thought to render C-
MYC and other genes particularly sensitive to CDK7 inhibition. 
Similar to CDK7, CDK9 promotes C-MYC expression and activity. CDK9 
inhibition was shown to be effective in hepatocellular carcinoma models 
selectively in the presence of C-MYC overexpression (Huang et al., 2014). 
However, despite inducing global RNA pol II pausing defects, CDK9 inhibition 
induced compensatory C-MYC expression through increased BET-
bromodomain 4 (BRD4) -mediated CDK9 recruitment to the C-MYC gene (Lu et 




of C-MYC target genes in B cell cancer cells, but resistance was conferred in 
some cases by compensatory RNA pol II loading (Donato et al., 2016).  
A relatively novel strategy for oncogene inhibition is delivering specific 
siRNA molecules to tumours via nanoparticles, which is being tested in phase I 
clinical trials against various cancers (Young et al., 2016). Delivering C-MYC 
siRNA to tumours in via nanoparticles decreased, but did not halt, cancer 
progression in pre-clinical models (Chen et al., 2010a; Chen et al., 2010b) 
although co-delivery with the nucleoside analogue gemcitabine monophosphate 
(GMP, a currently available chemotherapy) improved the anti-tumour response 
(Zhang et al., 2013). 
In summary, there is some evidence that interfering with C-MYC 
expression could be an effective anti-cancer strategy, and there are drugs 
currently available which attenuate C-MYC expression in at least some 
circumstances. However, resistance to chemotherapy could be a problem since 
compensatory or redundant mechanisms are in place to control C-MYC 
expression. Perhaps combination therapies are required in order for this 
strategy to be successful. 
1.5.3 Targeting signalling upstream of C-MYC 
 As discussed in section 1.4.9, C-MYC is subject to extensive regulation 
by cellular signalling pathways on multiple levels. Targeting signalling upstream 
of C-MYC by has been explored as a potential route for tumour intervention. 
Interestingly, amplification or overexpression of C-MYC confers resistance to 
chemical inhibition of the PI3K pathway in breast and prostate cancer cells, 




heightened cellular protein translation, which may override decreased 
translation upon PI3K inhibition. Indeed, combined inhibition of BET proteins in 
combination with PI3K depleted N-MYC expression and showed promising 
results in N-MYC-driven models of neuroblastoma (Andrews et al., 2017). 
Moreover, dual inhibition of mTOR complex 1 (mTORC1) within the PI3K 
pathway and RNA pol I exerts anti-tumour effects in C-MYC-driven B cell 
lymphoma models (Devlin et al., 2016). Resistance to PI3K pathway inhibition in 
this case might be subverted by diminishing the ability of N-MYC to regulate 
ribosome biogenesis and therefore translation. Alternatively, directly 
antagonising NOTCH-mediated transcriptional activation perturbs C-MYC 
expression, decreases the expression of C-MYC target genes and perturbs 
tumour progression in mouse models of T-cell acute lymphoblastic leukaemia 
(Moellering et al., 2009). Understanding the interplay of signalling pathways with 
C-MYC and with each other in different cancer types will help elucidate which 
pathways to best target for suppression of C-MYC-mediated oncogenesis.  
1.5.4 Targeting C-MYC target genes 
 Since C-MYC functions through such diverse mechanisms, it is difficult to 
imagine how targeting individual or even combinations of C-MYC target genes 
could perturb C-MYC oncogenicity. There are however some C-MYC targets 
which have been considered as potential therapeutic targets; albeit not always 
in the context of C-MYC upregulation. One interesting example is targeting NCL 
on the surface cells via an immunoagent, which is co-internalised with NCL and 
prevents it from binding RNA substrates, thereby reducing the proliferation of 
some breast cancer cell lines (Palmieri et al., 2015). ODC inhibition has shown 




neuroblastomas (Funakoshi-Tago et al., 2013; Hogarty et al., 2008). However, 
as one might expect, ODC is not required for all C-MYC functions including C-
MYC-mediated differentiation blockade (Selvakumaran et al., 1996). In another 
study, knockdown of NPM1 in combination with RNA pol II inhibition (but not 
NPM1 knockdown alone) induced glioblastoma cell death (Holmberg Olausson 
et al., 2015). Components of the eIF4F complex, which are transcriptionally 
regulated by C-MYC, are also being considered as therapeutic targets in C-
MYC-driven cancer cells (see section 1.5.6). In conclusion, inhibiting C-MYC 
target genes in cancer cells could have limited or context-dependent efficacy, 
and may require the use of combination therapies. 
1.5.5 C-MYC co-factors and effectors as potential therapeutic targets 
Targeting enzymatic co-factors of C-MYC-mediated transcription might 
circumvent the need to directly perturb C-MYC activity. Of these co-activators, 
CDK7 and CDK9 (as previously discussed), which mediate C-MYC expression 
as well as transcriptional activity, are being considered as therapeutic targets. 
Interestingly, relieving N-MYC-mediated gene repression using an HDAC 
inhibitor significantly curbed tumour development in an N-MYC-driven 
neuroblastoma mouse model (Liu et al., 2007). HAT inhibitors are in 
development (Bowers et al., 2010; Zheng et al., 2005), although further studies 
are required to determine their efficacy in vivo and in the context of C-MYC-
deregulation. Moreover, as previously mentioned, inhibition of the C-MYC 
effector RNA pol I using a small molecule inhibitor specifically induced cell 
death in C-MYC-driven B cell lymphoma models (Bywater et al., 2012; Devlin et 
al., 2016). Knowing more about the relative importance of different co-activators 
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in C-MYC-mediated transcription will help elucidate which ones should be 
considered as potential therapeutic targets. 
1.5.6 Synthetic lethal approaches to target C-MYC-dependent cells 
Synthetic lethality, by definition, occurs when the perturbation of two 
particular genes or pathways manifests in cell death (or in the case of synthetic 
sickness – a less viable phenotype), whereas an individual one of said 
perturbations is tolerated by the cell. Identifying synthetic lethal interactions 
using knockout yeast strains has been a useful tool in identifying novel genetic 
pathways and novel genes within specific pathways (Forsburg, 2001). More 
recently, this approach has been utilised to identify synthetic lethal interactions 
with particular ‘undruggable’ oncogenes in human cells with a view to identifying 
novel targets for chemotherapies which would leave normal cells (without 
alteration of the particular oncogene) unscathed (Chan and Giaccia, 2011; 
Nijman, 2011). Logically, targeting these genes could be an effective, selective 
way to intervene with C-MYC driven cancers, particularly since targeting C-MYC 
directly and otherwise has yielded limited success thus far. High throughput 
screens and functional studies have identified synthetic lethal interactions with 
deregulated C-MYC in multiple pathways, interestingly some of which are not 
oncogenic drivers in themselves but are required for cell survival specifically 
upon C-MYC-mediated transformation. 
Genes synthetic lethal with deregulated C-MYC include those involved in 
transcription initiation and elongation, C-MYC co-factors, translation initiation, 
metabolism and those involved in ubiquitin- and SUMO- regulation of DNA 




(5' adenosine monophosphate-activated protein kinase-related kinase 5) (Liu et 
al., 2012). ARK5 optimises the expression of mitochondrial respiratory chain 
components, and is thus required to metabolise glutamine for a source of 
cellular ATP. Cells with upregulated C-MYC exhibit enhanced glutamine 
metabolism, which is consistent with cellular addiction to ARK5.  
Inhibition of the core spliceosome machinery also induces apoptosis 
specifically in C-MYC-driven-breast cancer cells (Hsu et al., 2015). Spliceosome 
perturbation caused intron retention to occur more frequently in cells with 
hyperactivated C-MYC compared to cells with basal C-MYC, likely because of 
the enhanced transcriptional load. The unspliced genes were shown to be 
involved in diverse essential cellular processes, explaining why cell viability was 
compromised. 
C-MYC also exhibits synthetic lethal interactions with components of the 
eIF4F complex, which are also C-MYC target genes. eIF4F inhibition reduced 
proliferation of and induced apoptosis in C-MYC-driven premalignant pre-B/B-
cells, while exhibiting minimal/reversible effects on normal cells (Lin et al., 
2012a). In the presence of overexpressed C-MYC, eIF4F component 
expression was induced, and eIF4F inhibition was shown to deplete the 
expression of specific growth-promoting and anti-apoptotic genes. Interestingly, 
the same genes in wild-type cells with basal C-MYC levels were not affected by 
eIF4F inhibition. 
It should be noted that a common method of C-MYC synthetic lethal 
interaction identification involves using RNA interference (RNAi) screens or 




libraries can cause variable protein depletion between genes, and small 
molecule libraries are limited to existing compounds. Therefore, there are likely 
unexplored synthetic lethal interactions with deregulated C-MYC which could be 















1.6 Summary and aims 
1.6.1 Summary 
 The transcription factor C-MYC is a potent oncogene frequently 
overexpressed or hyperactivated in cancers. Despite much effort to directly 
target C-MYC using small molecule compounds, no C-MYC inhibitors have 
been approved for cancer treatment. How C-MYC achieves its broad and varied 
effects on gene expression and cell physiology is still somewhat elusive, 
therefore understanding the intricacies of C-MYC function may illuminate a 
novel approach for cancer intervention. C-MYC regulates RNMT-RAM thus 
increasing mRNA cap methylation, which is important for C-MYC-driven protein 
synthesis. However, whether C-MYC also regulates formation of the guanosine 
mRNA cap is not known. Here, the mechanisms of C-MYC-mediated mRNA 
capping will be further investigated with an emphasis on the involvement of the 
enzyme which initiates mRNA cap formation - mRNA capping enzyme/CE. 
1.6.2 Aims 
 Determine if C-MYC regulates CE. 






Chapter 2 : Methods and materials 
2.1 Peptide pulldown     
The protocol was adapted from a previous study (Ho and Shuman, 
1999). Prior to incubation, magnetic streptavidin beads (Dynabeads M-280 
streptavidin, Thermo Fisher) were washed three times in phosphate buffered 
saline (PBS) pH 7.4. All wash steps were performed using a magnetic rack 
(Dynal). Biotinylated CTD3 and (S5pCTD)3 peptides (Pepceuticals) were pre-
bound to beads with rotation for 45 minutes at 4°C. 0.3-1nmol peptide and 15-
25μl bead suspension were used per pulldown in 300μl binding buffer (Table 
2.1) supplemented with 1mM dithiothreitol (DTT). Bead-peptide complexes were 
then washed three times with binding buffer. 1.2-4μg of recombinant protein 
was added to each pulldown in 50μl binding buffer and incubated with rotation 
at 4°C for 45 minutes. Supernatant was obtained (if analysing unbound fraction) 
and pulldowns were washed three times in binding buffer. Beads were eluted in 
F buffer with 1x Laemmli buffer and 0.1M DTT. 20% of eluate was analysed by 
SDS-PAGE and Western blotting. 
2.2 Cell culture  
All cells were maintained in 10cm plates at 37°C in a humidified 
incubator with 5% CO2. Appropriate cell medium is indicated in Table 2.2. When 
cells reached approximately 80% confluency, cells were washed in PBS before 
1ml of 0.05% trypsin-EDTA (Gibco) was added for 3-5 minutes. HeLa cells or 
PhoeNX cells were then resuspended in the appropriate culture medium before 






Binding buffer 25mM Tris/HCl pH 8, 50mM NaCl, 5% glycerol, 0.03% Triton X-100 
F buffer  
10mM Tris/HCl pH 7.05, 50mM NaCl, 30mM Na
4
 pyrophosphate, 
50mM NaF, 5μM ZnCl
2
, 10% glycerol, 0.5% Triton x-100 
Laemmli sample 
buffer (4x) 
240mM Tris/HCl pH 6.8, 8% SDS, 40% glycerol, 0.02% 
bromophenol blue 
Buffer A 10mM HEPES pH 7.9, 1.5mM MgCl2, 10mM KCl 
Stacking gel mix 400mM Tris pH 6.8, 0.1% SDS, 0.1% APS, 4-5% acrylamide 
Resolving gel mix 400mM Tris pH 8.8, 0.1% SDS, 0.1% APS, 5-12% acrylamide 
SDS running buffer 25mM Tris, 250mM glycine, 0.1% SDS 
Transfer buffer 25mM Tris, 192mM glycine, 20% methanol 
TBS-tween (pH 8.1) 25mM Tris, 155mM NaCl, 0.1% Tween-20 
Wash buffer 10mM Tris/HCl pH 7.5, 150mM NaCl, 0.5mM EDTA 
Reaction buffer 50mM Tris/HCl pH 7.8, 5mM MgCl2, 5mM DTT 
High salt buffer PBS, 0.5% NP-40, 1M NaCl 
Low salt buffer 10mM Tris/HCl pH 8.0, 1mM EDTA, 0.1M NaCl, 0.5% NP-40 
Sucrose cushion Low salt buffer/100mM sucrose 
NET buffer (11x) 550mM Tris/HCl pH 7.4, 1.56M NaCl, 5.5mM EDTA, 5.5% NP-40 
RIPA buffer 50mM Tris/HCl pH 8.0, 150mM NaCl, 0.1% SDS, 0.5% 
deoxycholate, 1% NP-40 
LiCl buffer 10mM Tris/HCl pH 8.0, 250mM LiCl, 1mM EDTA, 0.5% 
deoxycholate, 0.5% NP-40 
TE buffer 10mM Tris/HCl pH 8.0, 1mM EDTA 
Table 2.1: Buffers and solutions. 
The composition of buffers/solutions used in this thesis are 
indicated. Note that some of these require supplementation and this 





Cell line Medium 
HeLa 
DMEM + 10% FBS, 2mM L-glutamine, 50 units/ml 
penicillin, 50μg/ml streptomycin 
IMEC 
DMEM/F12 (1:1) + 2mM L-glutamine, 5mg/ml insulin, 
10ng/ml EGF, 0.5μg/ml hydrocortisone, 50 units/ml 
penicillin, 50μg/ml streptomycin, (±5% FBS) 
PhoeNX 
DMEM + 10% FBS, 1mM sodium pyruvate, 2mM L-
glutamine, 50 units/ml penicillin, 50μg/ml 
streptomycin 
All (freezing medium) 
70% FBS, 20% culture medium (see above), 20% 
DMSO 
Table 2.2: Cell culture media. 
Composition of culture medium is indicated. Note that for specific 
experiments, IMEC medium was supplemented with 5% FBS (see 
figure legends). DMEM/F12 medium was either obtained ready-
made (Sigma-Aldrich or Gibco) or made by mixing DMEM 1:1 with 
F12. DMEM (Gibco); F12, Ham's F12 nutrient mixture (Gibco); FBS 
(Gibco); L-glutamine (Gibco); penicillin/streptomycin mix (Gibco); 
insulin, recombinant human insulin (Sigma-Aldrich); EGF, 
recombinant human epidermal growth factor (Sigma-Aldrich); 





resuspended in DMEM/10% FBS medium to neutralise trypsin before being 
centrifuged at 1,600rpm for 3 minutes. The pellet was resuspended in the 
appropriate growth medium and a third (IMEC/vec) or a fifth (IMEC/C-MYC) of 
cell suspension was seeded on to a new plate. Approximately every two 
months, cells in passage were replaced with a new frozen vial of cells.  
2.3 Retroviral infection 
IMECs were stably transduced with recombinant DNA vectors by using 
retroviral infection. A 10cm plate of PhoeNX cells was transfected with 4ug of 
DNA by using 8ug of polyethylenimine. The media was changed after 24 hours 
and, after a further 24 hours, media was removed from cells before being 
passed through a 0.45μm filter. The filtered media/viral supernatant was mixed 
1:1 with recipient cell media and with 5μg/ml polybrene before being added to 
recipient cells. After 24-72 hours cells were selected with 150μg/ml hygromycin 
B (Sigma-Aldrich) for LxSH vectors (C-MYC constructs) or 500μg/ml G418 
(Formedium) (for pBMN-IRES-Neo vectors (CE-GFP/CE-GFP WBL constructs). 
2.4 Cell counting 
Cells were counted by mixing cell suspension in growth media 1:1 with 
trypan blue (0.4%, Gibco) and then using a Countess cell counter (Life 
technologies) according to the manufacturer’s instructions. 
2.5 Cell cryostorage 
Cells were trypsinised as before, except 0.5ml trypsin was used per 




freezing medium (Table 2.2) and each 2ml was transferred to a cryovial. For 
long term storage, cells were frozen gradually via propanol submersion in a Mr 
Frosty container. After 1-3 days, cells were transferred to liquid nitrogen 
storage. For short term storage (<1 year), cells were stored at -80°C. To thaw 
cells, cryovials were submerged in a 37°C water bath and washed in culture 
media before being seeded on a 10cm plate. 
2.6 Protein extraction 
The entire procedure was performed on ice/at 4°C. Immediately before 
starting, F buffer was further supplemented with 1mM DTT, 1μM pepstatin, 
10μM leupeptin, 0.1 trypsin inhibitor units aprotinin, 1% phosphatase inhibitor 
cocktail 2 and 1% phosphatase inhibitor cocktail 3 (all Sigma-Aldrich). Medium 
was removed from cells which were then washed twice in cold PBS. 
Supplemented F buffer was added to cells which were then removed from 
plates by scraping. The soluble fraction was collected from cell lysates after 
being centrifuged at 13,000rpm for 10 minutes. Protein concentration was 
determined by Bradford assay. 
2.7 Nuclear protein extraction 
The entire procedure was performed on ice/at 4°C. F buffer was 
supplemented, media was removed from cells and cells washed as above. 
Buffer A was added to cells which were then removed from plates by scraping. 
Cells were syringed 5 times with a 27G needle. Nuclei isolation was confirmed 




staining using a microscope. Nuclei were pelleted by centrifugation at 6000rpm 
for 10 minutes before being lysed in F buffer as above. 
2.8 Protein concentration determination 
Bradford assay was used to determine protein concentration. Serial 
dilutions of bovine serum albumin (BSA) standard (Thermo Fisher) in F buffer 
were performed from 0.4-1.5mg/ml in 0.1mg/ml increments, plus 0 (blank) and 
2mg/ml BSA, to generate a standard curve. 2μl of BSA dilutions were mixed 
with 200μl of 1x Bradford protein assay reagent (Bio-Rad) in a 96 well plate 
before absorbance was measured at 595nm using a plate reader. The blank 
reading was subtracted from BSA measurements. Absorbance was plotted 
against BSA concentration to derive a linear equation of y=0.196x, which was 
subsequently used to determine sample protein concentration. 1μl of each 
undiluted protein sample was first added to 1x Bradford reagent as above, and 
the colour shift was used as an approximation of how much each sample should 
be diluted. Samples were diluted in F buffer to similar protein concentrations 
within the linear range, before 2μl of diluted protein sample was added to 1x 
Bradford reagent and absorbance was measured as above. Each sample 
measurement was performed in triplicate wells.  
2.9 Sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE) 
Stacking and resolving gel mix composition is indicated in Table 2.1. 
Polyacrylamide gel polymerisation was initiated by addition of 0.01% 




PROTEAN tetra cells (Bio-Rad) in SDS running buffer according to the 
manufacturer’s instructions. RNA pol II and SPT5 were analysed on resolving 
gels containing 5% acrylamide (4% stacking gel); p21 and p27 were analysed 
on gels containing 12% acrylamide (5% stacking gel); and all other proteins 
were analysed on gels containing 8% acrylamide (5% stacking gel). In certain 
experiments (indicated in figure legends), samples were resolved using a pre-
cast NuPAGE 3-8% Tris-acetate gel (Thermo Fisher). In which case, gels were 
resolved using an X-cell SureLock mini-cell (Life Technologies) in 1x NuPAGE 
Tris-acetate SDS running buffer (Thermo Fisher) according to the 
manufacturer’s instructions. 
Samples were prepared for SDS-PAGE by using F buffer supplemented 
with Laemmli buffer and 0.1M DTT, diluting protein extracts to 1mg/ml. Samples 
were then boiled for 3-5 minutes before loading on a gel. Typically, 10-20μg of 
protein was loaded per well. 5μl of pre-stained protein ladder (PageRuler Plus, 
Thermo Fisher) was loaded for a molecular weight reference. 150-180V was 
applied until samples were resolved. 
2.10 Western blotting 
Following SDS-PAGE, proteins were transferred from the gel to a 
polyvinylidene fluoride (PVDF) membrane using the mini-trans-blot cell (Bio-
Rad) in transfer buffer, according to the manufacturer’s instructions. To prepare 
the ‘sandwich’, PVDF membranes were hydrated in methanol before being 
placed on the gel. This was placed between two 3mm Whattman filters followed 
by two Western blotting sponges; all pre-submerged in transfer buffer. 60-70V 




performed for 2.5-3.0 hours due to the large molecular weight (>250kDa). For 
analysis of other proteins, transfer was performed for 1.5-3.0 hours. Ice packs 
were placed in transfer tanks, or tanks were placed in an ice bucket, to prevent 
over-heating. 
Membranes were then blocked using TBS-tween supplemented with 5% milk 
(Marvel) or 3% BSA Fraction V (VWR). Primary antibodies are listed in Table 
2.3, and were diluted in the appropriate blocking solution. Generally, 
membranes were incubated with primary antibodies for 2-2.5 hours at room 
temperature, although for analysis of PARP an overnight incubation at 4°C was 
required. Membranes were washed three times in TBS-tween/5% milk for a total 
of 45-60 minutes before being incubated with the appropriate horse radish 
peroxidase (HRP) -conjugated secondary antibody diluted in TBS-tween/5% 
milk for a further 45-60 minutes. Membranes were washed three times in TBS-
tween for a total of 30-45 minutes before being incubated with SuperSignal 
West pico chemiluminescent substrate (Thermo Fisher) for 2 minutes according 
to manufacturer’s instructions. Finally, membranes were exposed to X-ray films 
for various lengths of time before being developed in a film processor. When 
appropriate, Western blots were quantified using ImageJ software as indicated 
in figure legends. 
2.11 Immunoprecipitation 
Immunoprecipitations (IPs) were performed at 4°C with rotation and in F buffer 
supplemented as above. CE-GFP co-IPs were performed for 2.5 hours using 
GFP-Trap_A (GFP antibody conjugated to agarose beads, Chromotek). Other 

























CE/RNGTT Sheep polyclonal DSTT n/a 1:750-
1000 BSA 
GST Sheep polyclonal DSTT n/a 1:1000 Milk 
S5p RNA pol II  Rat monoclonal Chromotek 3E8 1:20 BSA 
S2p RNA pol II  Rat monoclonal Chromotek 3E10 1:15-20 BSA 
RNA pol II pan 
(RPB1) Rabbit polyclonal Santa Cruz sc-899 
1:250-
750 BSA 
SPT5  Rabbit polyclonal Cell 
Signalling 9033 1:500 BSA 




PARP Rabbit polyclonal Cell 
Signalling 9542 1:1000 BSA 
p21 Rabbit polyclonal Santa Cruz sc-397 1:1000 BSA 
p27 Rabbit monoclonal Abcam ab32034 1:1000 BSA 
Actin Mouse monoclonal Abcam ab3280 1:2000 Milk 
Tubulin Rabbit polyclonal Santa Cruz sc-9104 1:2000 Milk 
SMC1 Rabbit polyclonal Bethyl 
laboratories A300-055A 1:2000 BSA 
Nucleolin/NCL Rabbit polyclonal Bethyl 
laboratories A300-711A 1:1000 BSA 
GFP Mouse, mix of two 
monoclonals Roche 11814460001 1:1000 BSA 
N-MYC Rabbit polyclonal Cell 
Signalling 9405 1:250 BSA 
HIF1α Rabbit polyclonal Santa Cruz sc-10790 n/a n/a 
FLAG (M2) Mouse monoclonal Sigma F1804 n/a n/a 
Table 2.3: Antibodies used for Western blotting and IP. 
The antibody species, type, provider and conditions for Western 
blotting are indicated. Amount of antibody used for IP is indicated 




 (Generon) for 1 hour before the antibody was added, and another 20ul of 
washed bead slurry added for 1 hour to bind the antibody. IPs were washed 
three times in wash buffer and then eluted in F buffer with 1x Laemmli buffer 
and 0.1M DTT. Samples were analysed by SDS-PAGE followed by either 
Western blotting or autoradiography. Amount of antibody and protein in IP, 
length of IP, and amount of eluate analysed is indicated in figure legends. 
Antibodies used for IP are included in Table 2.3. To perform co-IPs using HeLa 
cells, 1.5x106 cells were seeded on 10cm plates the day before lysis. To 
perform co-IPs using IMECs (including for guanylyltransferase assays), 2.3x106 
cells were seeded on 15cm plates 24 hours prior to lysis. To perform CE IPs for 
guanylyltransferase assays, 1x106 IMECs were seeded 24 hours prior to lysis 
on 10cm plates. 
2.12 Guanylyltransferase activity assay 
The guanylyltransferase activity assays were adapted from previous 
publications (Ho and Shuman, 1999; Ho et al., 1998). Cell lysis and IPs were 
performed as described above, except F buffer was supplemented with 5mM 
DTT. After IP, samples were washed in F buffer before being incubated with 
3.75U/ml RNase A and 150 U/ml RNase T1 (RNase cocktail enzyme mix, 
Thermo Fisher) in F buffer at room temperature for 15 minutes. IPs were then 
washed three times in reaction buffer before being incubated for 1 minute at 
37°C in reaction buffer/6.7μM [α-32P]GTP (BLU006H500UC, Perkin Elmer). IPs 
were eluted as above and analysed by SDS-PAGE. Gels were then dried and 
formation of CE-[α-32P]GMP covalent intermediate was quantified with a 




2.13 siRNA transfection 
Small interfering RNA (siRNA) transfections were performed using 
Lipofectamine RNAiMAX (Life Technologies) according to the manufacturer’s 
instructions. Immediately after seeding cells, transfection mix (containing 1:1:50 
volumetric ratio of transfection reagent, 50μM siRNA and DMEM) was added to 
culture medium to give a final siRNA concentration of 50nM for single target 
knockdowns or 75nM for double target knockdowns. Final concentration of 
siRNA and length of knockdown is specified in figure legends. siRNA target 
sequences are depicted in Table 2.4. For transfections prior to CE ChIP, 
1.5x106 cells were seeded on 10cm plates. For transfections prior to RNA pol II 
ChIP, 1.0x106 cells were seeded on 10cm plates. For transfections followed by 
qRT-PCR, Western blot analysis or cell counting (after 72 hours), 1.1x105 or 
2.3x105 cells. were seeded on 6 well plates or 6cm plates, respectively. For 
knockdowns longer than 24 hours, culture medium was changed at this time. 
2.14 RNA extraction 
RNA was extracted using TRIzol reagent (Life Technologies) according 
to the manufacturer’s instructions. RNA pellets were resuspended in 20-50μl of 
Milli-Q water and RNA concentration was measured with a NanoDrop 2000 
spectrophotometer. 
2.15 Complementary DNA (cDNA) synthesis 
cDNA synthesis reactions (20μl) containing 1μl reverse transcriptase 
(RT) and 200ng of RNA were prepared using iScript cDNA synthesis kit (Bio-





Table 2.4: siRNA oligos for cell culture transfection. 
Target Cat. no. Target sequence 
C-MYC D-003282-14-0050 AACGUUAGCUUCACCAACA 
CE (siRNA #1) D-009782-01-0050 CAAAAGAGCUGAAACAGUA 
CE (siRNA #2) D-009782-02-0050 CUAAAGAGCCUAAAGGUUA 
Non-targeting control D-001210-03-50 - 
The corresponding mRNA target sequence for each siRNA used in 
this thesis is indicated. siRNAs were purchased from Dharmacon 
as lyophilised powder and were resuspended in sterile PBS to a 




2.16 Quantitative polymerase chain reaction (qPCR) 
qPCRs were performed with SsoFast EvaGreen supermix (Bio-Rad) 
according to manufacturer’s instructions. Primers for qRT-PCR and ChIP qPCR 
are indicated in Tables 2.5 and 2.6, respectively. 5μl reactions were performed 
using 1μl cDNA, and 10μl reactions were performed using 1μl ChIP DNA; both 
in 384 well plates. 
2.17 Chromatin immunoprecipitation (ChIP) 
The protocol was adapted from a previous study (Varshney et al., 2015). 
One or two plates of HeLa cells were used for each RNA pol II ChIP or CE 
ChIP, respectively. siRNA transfection conditions prior to ChIP are specified in  
section 2.13 and in figure legends. Protein–DNA complexes were cross-linked 
using 1% formaldehyde (Thermo Fisher) in growth media for 10 minutes (RNA 
pol II ChIP) or 15 minutes (CE ChIP) with gentle agitation at room temperature. 
The reaction was quenched by adding 0.125M glycine and incubating with 
gentle agitation at room temperature for 5 minutes. The rest of the protocol was 
performed on ice/at 4°C unless otherwise stated. Cells were removed from 
plates by scraping and washed twice in PBS then twice in PBS/0.5% NP-40. 
Nuclei were isolated by incubation in high salt buffer for 30 minutes followed by 
low salt buffer for 30 minutes before being cleaned by centrifugation through 
two sucrose cushions. The chromatin was then sheared by water bath 
sonication using a Bioruptor (Diagenode) at high intensity for 30 minutes of 30 
second on/off cycles, yielding fragment sizes of 200-500bp. Samples were pre-
cleared for 1 hour with 20μl slurry of washed Protein A agarose beads blocked 





   
Table 2.5: RT-PCR primers. 
Target 
(cDNA) Forward primer Reverse primer 
C-MYC 5'-TCTGAGGAGGAACAAGAA-3' 5'-GAAGGTGATCCAGACTCT-3' 
FLAG-MYC 
(mouse) 5'-CACGGAGGAAAACGACAAGA-3' 5'-GAATGGACAGGATGTAGGCG-3' 
NCL  5'-TGCCAGAAGCCAGCCATCCAAA-3' 5'-GCCCGAACGGAGCCGTCAAAT-3' 
ODC 5'-CGCTGTGACCTGCCTGAAATG-3' 5'-TGCATGAGTTGCCACGCAGGC-3' 
FBL 5'-AAGAATGTGATGGTGGAGCC-3' 5'-GTGACCAGTGCATCTTCCTT-3' 
NME1 5'-TCATGCAAGCTTCCGAAGATC-3' 5'-GCCCTGAGTGCATGTATTTCAC-3' 
NPM  5'-GAAGAGGAGGAGGATGTG-3' 5'-TTCTGTGGAACCTTGCTA-3' 
TIP49 5'-CATTGGGCTGCGAATAAA-3' 5'-TCTGTCTCACACGGAGTT-3' 
UBF 5'-CTGAGATGAGCAACCTGGAC-3' 5'-ACCTTCTTCTCGTGGGTGTA-3' 
CCND1 5'-CATTGAACACTTCCTCTCC-3' 5'-ATGAACTTCACATCTGTGG-3' 
GAPDH 5'-GGAGTCAACGGATTTGG-3' 5'-GTAGTTGAGGTCAATGAAGGG-3' 
CE 5'-ATTGGAGTATCGAAGCAG-3' 5'-GGTGCTTCCTCTATGTCACC-3' 
eIF4E 5'-AACGAATGACCACCAGCATT-3' 5'-GATGCAGAGTCGTTTAGGCA-3' 
CRD-BP 5'-GTACCAAGAGACCAGACCCC-3' 5'-GATCTTCCGTTGAGCCATCT-3' 
The corresponding cDNA target sequence for each RT-PCR primer 





   
Table 2.6: ChIP primers. 
Target 
(gDNA) Forward primer Reverse primer 
NCL -2500 5'-GTTTGTAATGG 
CCAAACATAGCA-3' 5'-GGCATTCCTTGTGTGGAAGG-3' 
NCL TSS 5'-TTTCCACAGGCGATTACTGG-3' 5'-GAGCACGTACACCCGAAG-3' 
NCL 500 5'-TTTTGCGACGCGTACGAG-3' 5'-ACTAGGGCCGATACCGCC-3' 
NCL 1000 5'-CGGTTGAGAGTAGTCCCTCT-3' 5'-TCATCTCCGTCCTCAGATCC-3' 
FBL -200 5'-GGGAAGCCTTTTTGGGTGTA-3' 5'-CACCCCAATAATCAGGGCTC-3' 
FBL TSS 5'-GAGAATCCAGGCTCACTGC-3' 5'-GTTCACAACTCCACGAGTCC-3' 
FBL 300 5'-GCCATGAAGCCAGGTCAG-3' 5'-CTTCCCACAGGAGACTGGAA-3' 
NME1 TSS 5'-GAATGACTGCC 
TACTCCCAAGAG-3' 5'-CACGCACGGAACGCTTCT-3' 
NME1 500 5'-CCTTTCTCGTCAGGCCG-3' 5'-CTTACAGAGCGCCAACTCC-3' 
GAPDH TSS 5'-TACTAGCGGTTTTACGGGC-3' 5'-GCTGCGGGCTCAATTTATAG-3' 
C-MYC -2000 5'-AAGACGCTTTGCAGCAAAATC-3' 5'-AGGCCTTTGCCGCAAAC-3' 
C-MYC TSS 5'-GGAGGGATCGCGCTGAGT-3' 5'-TATTCGCTCCGGATCTCCCT-3' 
C-MYC 450 5′-GCACTGGAACTTACAACACC-3′ 5′-ATCCAGCGTCTAAGCAGC-3′ 




TIP49 300 5′-TGTGGCCAGTGGACC-3′ 5′-ACTTCCCTGAGGAAATAATGG-3′ 
CCND1 250 5′-AGCTGCCCAGGAAGAGC-3′ 5′-CCGCCTTCAGCATGG-3′ 
RNMT 100 5′-TGAGTGTGACGGCTGGAACTC-3′ 5′-CACGCGTTGGGTAGTGAAG-3′ 
The corresponding genomic DNA (gDNA) target sequence for each 
ChIP primer set used in this thesis is indicated. Oligos were 




material to include in final qPCR analysis and ensure equal loading of chromatin 
into IPs. Immunoprecipitation was performed overnight in 1x NET buffer using 
1μg of RNA pol II or CE antibody. 20μl bead slurry was then added to each 
sample for 1 hour. Immunoprecipitates were washed twice in RIPA buffer, twice 
in LiCl buffer and twice in TE buffer before being eluted in TE/1% SDS for 30 
minutes with rotation at room temperature. 125μg/ml proteinase K was added to 
samples and incubated overnight at 42°C. DNA was purified with QIAquick PCR 
purification kit (Qiagen) according to the manufacturer’s instructions. DNA was 
eluted in 50μl Milli-Q water and analysed by qPCR. Input samples were diluted 
10-fold for PCR reactions. 
2.18 Anchorage-independent cell growth assay 
0.75x105 IMECs (maintained in 5% FBS growth media for at least a week 
beforehand) were plated in 6 well plates and transfected with siRNA as above. 
After 72 hours, 0.8x104 cells were plated in 2ml of growth medium/5% FBS 
containing 0.33% noble agar in a 6 well plate on top of a 0.6% noble agar base 
layer (2ml). Technical triplicates were performed for each condition within each 
biological replicate. Cells were fed with 500μl of growth media/5% FBS every 
second day. After 9-15 days, colonies were scored using a graticule. Total 
number of cells (undivided and divided), colonies >20µm and colonies >50µm 
were counted in five randomly selected fields of each well. Micrographs were 
taken after one month. Note that noble agar stock solutions (3.3% and 6%) 




2.19 Cell viability assay 
CellTiter-Blue viability assays were performed according to 
manufacturer’s instructions (Promega). Media was removed from cells growing 
in 96 well plates. 120µl of pre-warmed 1x CellTiter-Blue reagent in the 
appropriate medium was added to cells (or empty wells as blank 
measurements). Cells were incubated at 37°C for 2 hours before fluorescence 
was measured at 590nm using a Gemini XPS microplate reader. Cell number 
per well was optimised (Figure 5.7) and for each experiment cell number is 
indicated in figure legends. 
2.20 Inhibitor treatment 
Inhibitors used in this thesis – MG132 (Merck) and THZ1 (see below) – 
were dissolved in DMSO, therefore as a negative control cells were treated with 
an equal volume of DMSO alone. If two inhibitor concentrations were used, the 
DMSO control corresponded to the higher inhibitor concentration. In 96 well 
THZ1 titration assays, DMSO controls were performed for each THZ1 
concentration, and each condition was performed in triplicate wells. Since THZ1 
is a covalent CDK7 inhibitor, THZ1 and control treatment were washed out (i.e. 
media changed) after 4 hours to minimise off-target effects (Kwiatkowski et al., 
2014). Treatments were performed the day after cell seeding (unless siRNA 
was also used; indicated in figure legends). Inhibitor concentration and length of 
treatments are specified in figure legends. THZ1 was a gift from Dr. Nathanael 
Gray (Dana Farber Cancer Institute, Boston) to Dr. Francisco Inesta-Vaquera in 




2.21 Statistical analysis 
Statistical significance was calculated by two-tailed Student’s t-test 
(assuming equal variance) throughout this thesis. Paired t-tests were performed 
between conditions (for example CE siRNA versus non-targeting control) and 
unpaired t-tests were performed between stable cells lines (i.e. IMEC/vec and 
IMEC/C-MYC). Data from at least three independent experiments was used for 
statistical tests (n≥3). Sample size for each experiment is indicated in figure 
legends. For Kaplan-Meier curves, statistical significance was calculated using 





Chapter 3 : C-MYC regulates mRNA capping 
enzyme 
3.1 Introduction 
C-MYC increases the expression and recruitment of CDK7 and CDK9, 
leading to a global increase in S5 and S2 RNA pol II CTD phosphorylation 
(Cowling and Cole, 2007b). These modifications are essential for the 
association of a range of factors involved in transcription initiation, elongation, 
mRNA capping, splicing and transcription termination (Heidemann et al., 2013). 
C-MYC depends on the recruitment of these factors for driving expression of its 
target genes. Since attempts at therapeutically targeting C-MYC directly have 
been largely unfruitful, these components could provide an alternative route to 
block C-MYC function. 
C-MYC regulates RNMT to catalyse formation of the 7-methylguanosine 
cap structure linked to the first transcribed nucleotide on its target transcripts, 
which contributes to C-MYC-dependent gene expression and cell proliferation 
(Cowling and Cole, 2007b; Fernandez-Sanchez et al., 2009). The mRNA cap 
protects transcripts from degradation, promotes splicing and 3’ end processing, 
facilitates nuclear export of mRNA, and facilitates translation initiation. It has not 
yet been determined whether C-MYC also regulates other stages of mRNA cap 
formation. 
The enzyme which initiates cap formation, mRNA capping enzyme/RNA 
guanylyltransferase and 5’ triphosphatase (CE/RNGTT), specifically binds to the 
RNA pol II CTD when phosphorylated at S5, spatially and temporally localising 
the enzyme to cap nascent mRNA as it emerges from RNA pol II (Ghosh et al., 




vitro, CE also interacts with S2p RNA pol II CTD and a mediator of RNA pol II 
elongation – the SPT5 subunit of DSIF – but the mechanism of binding and 
biological significance of these interactions are not well understood (Ho and 
Shuman, 1999; Mandal et al., 2004; Wen and Shatkin, 1999). CE has 
triphosphatase and guanylyltransferase activities which act sequentially to 
catalyse addition of the basic guanosine cap structure. S5p RNA pol II CTD and 
SPT5 per se stimulate CE guanylyltransferase activity in vitro (in contrast to S2p 
RNA pol II CTD which binds CE but does not alter activity) (Ho and Shuman, 
1999; Mandal et al., 2004; Wen and Shatkin, 1999). RNMT methylates the 
guanosine cap moiety in complex with its activating subunit RAM to complete 
the mRNA cap structure. Although C-MYC regulates RNMT-RAM, whether CE 
is also regulated to achieve C-MYC-dependent mRNA capping is not clear. 
In this chapter, it was investigated whether C-MYC modulates 






3.2.1 C-MYC increases the interaction of CE with RNA pol II and 
SPT5 
To investigate the interaction of capping enzymes with the RNA pol II 
CTD in vitro, GST-tagged recombinant CE and RNMT were incubated with RNA 
pol II CTD peptides. Biotinylated peptides were used which consisted of three 
unphosphorylated heptad repeats – (YSPTSPS)3 / CTD3 – or three repeats 
phosphorylated at S5 residues – (YSPTSpPS)3 / (S5pCTD)3. As previously 
observed, CE bound specifically to (S5pCTD)3 peptides and not to CTD3 
peptides (Figure 3.1 A) (Ho and Shuman, 1999). In a preliminary experiment, 
RNMT and RAM did not interact with the (S5pCTD)3 or CTD3  peptides (Figure 
3.1 B), consistent with previous observations. Since CE specifically binds 
phosphorylated RNA pol II, its recruitment and activity has the potential to be 
regulated by C-MYC. 
To further investigate the interaction of CE and RNA pol II, co-
immunoprecipitations were performed with HeLa cell protein extracts (Figure 
3.2). Interestingly, only a small proportion of total S5p RNA pol II co-purified 
with CE. The interaction of CE with SPT5 was also investigated, and an even 
smaller proportion of SPT5 co-purified with CE relative to S5p RNA pol II. 
However, RNA pol II interacts with SPT5 and therefore it is not clear whether 
the interaction between CE and SPT5 is direct. RNA pol II is one of the top 
interactors of CE as demonstrated by CE-GFP immunoprecipitation and mass 
spectrometry (unpublished data, Dr D. Varshney/Cowling lab), indicating that 







































Figure 3.1: CE binds S5p RNA pol II CTD in vitro. (A) Recombinant 
GST-tagged CE was incubated with streptavidin beads alone or with 
immobilised biotinylated peptides; either three tandem 
unphosphorylated CTD repeats - CTD3 - or three tandem S5 
phosphorylated CTD repeats - (S5pCTD)3.Bound (B) and unbound (U) 
fractions were analysed by SDS-PAGE and Western blotting using a 
CE antibody. *potential breakdown products. Representative of two 
independent experiments. (B) Recombinant GST-tagged CE, RNMT 
and RAM were incubated with beads alone or with immobilised 
peptides on beads as above. Bound fractions were analysed by SDS-

















mg of protein in IP: 5.6 11.2 16.8
*
Figure 3.2: A small fraction of total cellular CE co-purifies with 
RNA pol II and SPT5. CE was immunoprecipitated from HeLa cell 
protein extracts. Three distinct IPs were performed overnight with 
5.6mg, 11.2mg or 16.8mg of protein and 1μg, 2μg or 3μg of CE 
antibody, respectively. Samples were analysed by SDS-PAGE and 
Western blotting. 80% of IP eluate was loaded for S5p pol II and 
SPT5 Western blots (same gel) and 3% of IP eluate was loaded for 
the CE Western blot. 20μg of input material was loaded for 





performed for the above experiment to ensure the co-purification of RNA pol II 
with CE is not due to non-specific binding to the antibody/beads. 
In order to determine if the interaction of CE and RNA pol II was 
modulated by C-MYC, retroviral infection was used to stably overexpress C-
MYC (Figure 3.3). Expressing wild type (WT) C-MYC did not increase total C-
MYC protein levels compared to the empty vector (vec). This could be because 
C-MYC represses its own expression at a critical threshold as a negative-
feedback mechanism (Cleveland et al., 1988; Penn et al., 1990). 
Overexpressing a mutant version of C-MYC (C-MYC T58A), which as 
previously discussed encodes a substantially more stable version of the protein 
(Sears et al., 2000), only slightly increased net C-MYC protein levels. The C-
MYC gene in HeLa cells exhibits strong transcriptional activation due to viral 
insertion, thus these cell already have high levels of endogenous C-MYC (Adey 
et al., 2013). Although C-MYC T58A increased S5p RNA pol II levels (Figure 
3.3), cells proliferated slower than cells expressing the empty vector control 
(data not shown). Perhaps ectopic C-MYC T58A in HeLa cells is toxic, since it is 
known that gross C-MYC activity in some systems can induce apoptosis as a 
tumour suppressor mechanism (Murphy et al., 2008). Therefore, this system 
was not optimal and a different system was adopted to overexpress C-MYC. 
IMECs are a non-transformed human cell line which are immortalised by 
overexpression of the catalytic subunit of telomerase (hTERT) (DiRenzo et al., 
2002). They exhibit growth control mechanisms such as cell cycle checkpoints, 
contact inhibition and anchorage dependency, and display genome integrity in 
cell culture (Cowling et al., 2007; Toouli et al., 2002). C-MYC is endogenously 
expressed in IMECs, but at low basal levels. Retroviral infection was used to 
89
Figure 3.3: C-MYC overexpression in HeLa cells. HeLa cells 
were stably transduced with empty vector (vec), FLAG-tagged wild-
type C-MYC vector (C-MYC WT) or a FLAG-tagged mutant C-MYC
vector which encodes a stabilised version of the protein (C-MYC 
T58A). Protein extracts were analysed by SDS-PAGE and Western 
































 stably express empty vector or WT C-MYC, establishing IMEC/vec and 
IMEC/C-MYC cell lines, respectively. A second round of infection stably 
expressed CE-GFP or control (INI). Equivalent levels of CE-GFP were 
expressed in IMEC/vec and IMEC/C-MYC, and CE-GFP expression did not 
alter C-MYC expression (Figure 3.4 A). To determine if the interaction of CE-
GFP with RNA pol II was C-MYC-responsive, CE-GFP was immunoprecipitated 
from IMEC/vec and IMEC/C-MYC protein extracts via the GFP tag (Figure 3.4 
B). C-MYC increased the interaction of CE-GFP with RNA pol II. The vast 
majority of the co-purified RNA pol II was of a higher molecular weight 
compared to that in the input, indicating phosphorylated RNA pol II is interacting 
with CE-GFP in cells. However, IPs should be treated with phosphatase to 
confirm the phosphorylated status of RNA pol II. To observe this interaction with 
endogenous protein, CE was immunoprecipitated from IMEC/vec and IMEC/C-
MYC protein extracts (Figure 3.5 A and B). As previously observed (Cowling 
and Cole, 2007b), C-MYC increased S5p RNA pol II levels. Overexpressing C-
MYC increased co-purification of phosphorylated RNA pol II with endogenous 
CE. This was observed using both a phospho-specific antibody recognising S5p 
RNA pol II CTD and a pan RNA pol II antibody. Elevated C-MYC expression 
also increased the co-purification of SPT5 with CE. As previously mentioned, 
this could represent a direct interaction between CE and SPT5, or an indirect 
association via RNA pol II. Previous screens for C-MYC interacting partners 
(Agrawal et al., 2010; Dingar et al., 2015) and CE interacting partners 
(unpublished data, Dr D. Varshney/Cowling lab) have not identified CE and C-
MYC in a complex, thus C-MYC-induced CE recruitment is likely not via a direct 
interaction between the two proteins. In summary, C-MYC promotes the 







































































Figure 3.4: C-MYC overexpression in IMECs increases the 
interaction of CE-GFP with RNA pol II. (A) Protein extracts of 
IMEC/vec and IMEC/C-MYC stably transduced with CE-GFP or 
empty vector (INI) were analysed by Western blotting. Individual 
experiment. This was performed in collaboration with Dr. Dhaval
Varshney in the Cowling lab. (B) CE-GFP was immunoprecipitated
from protein extracts of IMEC/vec and IMEC/C-MYC expressing CE-
GFP or empty vector for 2.5 hours using GFP antibody-conjugated 
beads. 9mg of protein was used in each IP. 80% of eluate was 
loaded for RNA pol II Western blots and 10% for CE Western blots. 











Figure 3.5: C-MYC overexpression increases the interaction of 
endogenous CE with S5p RNA pol II and SPT5. (A) CE 
immunoprecipitation was performed for 2.5 hours from IMEC/vec
and IMEC/C-MYC protein extracts. IPs using a FLAG tag antibody 
were performed as a control (ctrl IP). 4.7mg protein and 2μg 
antibody was used in each IP. 40% of eluate was loaded for S5p 
RNA pol II, SPT5 and RNA pol II Western blots (the former two from 
the same gel) and 4% loaded for the CE Western blot. Input and IP 
panels are from the same Western blots but are different 
exposures. Representative of four (S5p RNA pol II) or two (RNA pol 
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Figure 3.5 continued: C-MYC overexpression increases the 
interaction of endogenous CE with S5p RNA pol II and SPT5. 
(B) Densitometry was performed using ImageJ software to 
quantify the Western blot signal of S5p RNA pol II, RNA pol II pan 
and SPT5 following CE immunoprecipitation, normalised to the 
CE IP Western blot signal. Both bands in the RNA pol II pan WB 
are included in the quantification. Error bars represent standard 
error of the mean, n=4; RNA pol II pan and SPT5 WB signals are 
averaged from two independent experiments. Significance was 

























































To confirm the relationship between C-MYC expression and CE 
recruitment, RNA pol II and SPT5 were immunoprecipitated from IMEC/vec and 
IMEC/C-MYC protein extracts to observe the reciprocal interaction (Figure 3.6 A 
and B). However, CE could not be detected in RNA pol II nor SPT5 IPs. This 
could be due to poor immunoprecipitation efficiency (as suggested by the 
amount of RNA pol II in the flow-through), or the fact that the RNA pol II 
antibody IPs the non-phosphorylated form of the protein more efficiently than 
the higher molecular weight RNA pol II (compare relative amounts in the IP with 
that in the input). 
To further investigate C-MYC-dependent CE recruitment, an additional 
set of IMEC stable cell lines was made expressing C-MYC mutants (Figure 3.7 
A). C-MYC ΔMBII and C-MYC T58A were expressed in addition to C-MYC WT. 
C-MYC ΔMBII lacks the MBII component of the TAD which is required for the 
interaction of C-MYC with TFIIH/CDK7 (and other transactivators) and is 
defective in stimulating RNA pol II S5 phosphorylation (Cowling and Cole, 
2007b). As previously mentioned, C-MYC T58A is more stable and its 
expression results in elevated steady-state C-MYC levels (Figure 3.7 A). As 
expected, C-MYC ΔMBII did not increase S5p RNA pol II levels and C-MYC 
T58A caused a greater increase in S5p RNA pol II levels than C-MYC WT 
(Figure 3.7 A). Preliminary experiments showed that C-MYC ΔMBII was not 
able to increase the interaction of CE with RNA pol II (Figure 3.7 A and B), 
indicating that C-MYC-mediated CE recruitment is dependent on its ability to 
stimulate RNA pol II S5 phosphorylation. Moreover, C-MYC T58A had a 
heightened capability to induce the interaction of CE with S5p RNA pol II 









































Figure 3.6: The reciprocal immunoprecipitation of CE with RNA 
pol II and SPT5 if not detectable. (A) RNA pol II was 
immunoprecipitated from 2.9mg IMEC/vec and IMEC/C-MYC protein 
extracts for 2.5 hours with 1μg antibody. IPs with a GST antibody were 
performed as a control (ctrl IP). 30% of eluate was loaded for CE and 
RNA pol II Western blots. ~5% of the unbound flow-through (FT) was 
loaded to examine RNA pol II IP efficiency. 20μg of input material was 
loaded for comparison. Samples are from the same Western blots and 
same exposures (indicated by dashed lines). Representative of three 
independent experiments. (B) SPT5 was immunoprecipitated from 
8.9mg IMEC/vec and IMEC/C-MYC protein extracts for 2.5 hours with 
5μl antibody. HIF1α IPs were performed as a control (ctrl IP). 80% of 
eluate was loaded for the CE Western blot and 10% for the SPT5 
Western blot. 20μg of input material was loaded for comparison. *non-







































































































































































Figure 3.7: Probing C-MYC-dependent CE recruitment using C-
MYC mutants. IMECs were stably transduced with empty vector 
(vec), C-MYC WT, C-MYC ΔMBII or C-MYC T58A constructs. CE IPs 
were performed for 2 hours from protein extracts. IPs using a GST 
tag antibody were performed as a control (ctrl IP). 19mg protein and 
2μg antibody was used in each IP. 80% of eluate was loaded for S5p 
RNA pol II and CE Western blots (same gel). IP eluates were 
analysed on a 3-8% pre-cast gel. *non-specific/likely heavy chain. 
Individual experiment. (B) Densitometry was performed using ImageJ 
software to quantify the Western blot signal of S5p RNA pol II 
following CE immunoprecipitation, normalised to the CE IP Western 
blot signal. GST (control) IP signal was subtracted. All bands in the 





relationship between C-MYC activity and CE recruitment. To verify that this 
relationship is S5p RNA pol II-dependent, the effect of CDK7 inhibition on C-
MYC-dependent CE recruitment should be analysed. 
3.2.2 Investigating whether C-MYC regulates SPT5 modification 
As previously mentioned, SPT5 possesses a CTR domain which is 
analogous to the RNA pol II CTD, and can be phosphorylated by TFIIH/CDK7 
and P-TEFb/CDK9 (Figure 1.3) (Kim and Sharp, 2001; Larochelle et al., 2006). 
Since C-MYC increases the expression and recruitment of these kinases, it is 
possible that C-MYC could regulate SPT5 phosphorylation, which in turn may 
mediate its interaction with CE. In IMECs, C-MYC overexpression increased the 
abundance of a higher molecular weight form of SPT5 (Figure 3.8 A). Knocking 
down C-MYC by siRNA in HeLa cells diminished RNA pol II S5 and S2 
phosphorylation, as expected, and decreased the presence of higher molecular 
weight SPT5 (Figure 3.8 B). This preliminary data indicates that C-MYC 
regulates SPT5 phosphorylation, although further studies are required to verify 
this result. Extracts could be treated with phosphatase to confirm that the higher 
molecular weight band is phosphorylated SPT5, and samples could be labelled 
with Phos-tag (Alpha Laboratories) to better resolve and analyse 
phosphorylated SPT5 on a gel. 
3.2.3 C-MYC increases the CE guanylyltransferase activity 
associated with RNA pol II 
Since binding of RNA pol II S5pCTD peptides allosterically stimulates CE 
guanylyltransferase activity in vitro and C-MYC increases S5 RNA pol II 


























Figure 3.8: Investigating how C-MYC influences SPT5 
modification. (A) IMEC/vec and IMEC/C-MYC protein extracts were 
analysed by SDS-PAGE and Western blotting. Indicated is the 
amount of protein loaded on the gel. Individual experiment. (B) HeLa 
cells were transfected with 50nM C-MYC siRNA or a non-targeting 
control (-). After 24 hours, protein was extracted and analysed as 
above. Individual experiment. *slower migrating SPT5. 
250
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CE guanylyltransferase activity. RNA 5’ guanylylation is thought to be the rate-
limiting step in basic guanosine cap synthesis since the specific activity of the 
CE triphosphatase is much greater than that for the guanylyltransferase 
(Shuman, 1995). GMP-binding assays were performed which have previously 
been used to analyse guanylyltransferase activity of recombinant CE in vitro 
(Ho and Shuman, 1999). Using GTP labelled on the alpha phosphate ([α-
32P]GTP) as a substrate for CE results in formation of a covalent CE-[32P]GMP 
intermediate, which can be quantified and used as an approximation of CE 
guanylyltransferase activity (Figure 3.9 A). In previous studies, RNA pol II S5p-
CTD stimulated the guanylyltransferase activity of CE by 1.5-, 2.8- or 4-fold 
when 2, 4 or 6 tandem S5pCTD repeats were used, respectively (relative to 
reactions with no CTD peptides) (Ho and Shuman, 1999). No stimulation was 
observed with non-phosphorylated CTD or S2pCTD repeats. Two tandem CTD 
repeats are necessary for the CE-RNA pol II interaction, which is likely because 
an additional contact is made between CE and Y1 of the following CTD heptad 
(Ghosh et al., 2011). Here, CE was immunoprecipitated from IMEC/vec and 
IMEC/C-MYC nuclear protein extracts. Nuclear fractionation was performed to 
exclude the activity of cytoplasmic re-capping by CE (Otsuka et al., 2009). After 
being incubated with [α-32P]GTP for one minute, IPs were resolved by SDS-
PAGE and [32P]GMP incorporation quantified by phosphorimager. CE-GMP 
could be specifically immunoprecipitated and CE was the only detectable GMP-
binding protein in CE IPs (Figure 3.9 B). Incubating reactions with [α-32P]GTP 
for longer than 2.5 minutes decreased the CE-GMP signal, indicating that 
substrate turnover may be occurring (Figure 3.9 C). Therefore, IPs were treated 
with RNase prior to incubation with [α-32P]GTP to prevent substrate turnover 





















































































Figure 3.9: CE guanylyltransferase assays using cell extracts.
(A) CE reacts with [α-32P]GTP, yielding a 32P-labelled CE-GMP 
intermediate which is used as an approximation of CE 
guanylyltransferase activity. (B) CE was immunoprecipitated from 
IMEC/vec and IMEC/C-MYC nuclear protein extracts. IPs using GST 
tag antibody were performed as a control (ctrl IP). Each IP contained 
100μg protein and 0.5μg antibody. IPs immobilised on beads were 
incubated with [α-32P]GTP reaction mix. Eluates were run on a gel 
which was then dried and analysed by phosphorimager for 
incorporation of 32P. ar, autoradiograph. (C) CE IPs were incubated 
with [α-32P]GTP reaction mix for the indicated times. Average values 
from two experiments (except 2.5 min time-point – individual 
experiment). (D) 12.5% or 25% of CE IP eluate from four independent 
samples were loaded to test the linearity of the assay. (E) As in (D) 
except expressed as average increase in signal. Error bars represent 












amounts of CE IPs demonstrated that this method is semi-quantitative (Figure 
3.9 D and E). C-MYC did not alter nuclear CE guanylyltransferase activity 
(Figure 3.10 A and B). However, only a fraction of CE co-purifies RNA pol II and 
SPT5 in IMECs (Figure 3.5), consistent with the majority of CE not being 
associated with RNA pol II chromatin complexes in the cell. CE catalyses co-
transcriptional mRNA capping when engaged with transcription complexes, and 
therefore RNA pol II- and SPT5- bound protein fractions were analysed for 
guanylyltransferase activity. RNA pol II and SPT5 were immunoprecipitated 
from IMEC protein extracts and the co-purifying CE-GMP complexes were 
analysed (Figure 3.11). Consistent with CE co-immunoprecipitations, a 
relatively small amount of CE-GMP was co-purified with RNA pol II and SPT5 
compared to with CE. There was more CE-GMP associated with RNA pol II 
than SPT5, illustrating that RNA pol II-bound CE is more abundant or 
catalytically active than that associated with SPT5. However, this does not 
exclude the possibility that the IP efficiencies were different, and as before the 
SPT5-bound CE-GMP could be indirectly interacting via RNA pol II. It was then 
investigated if C-MYC increased guanylyltransferase activity of RNA pol II-
bound CE. RNA pol II was immunoprecipitated from IMEC/vec and IMEC/C-
MYC protein extracts and the co-purified CE-GMP was the only GMP-binding 
protein detected (Figure 3.12 A). Interestingly, there was consistently less RNA 
pol II purified from IMEC/C-MYC extracts by immunoprecipitation compared to 
IMEC/vec under these experimental conditions. Since C-MYC does not typically 
cause a reduction in RNA pol II expression levels (Figures 3.4 B, 3.5 A and 3.6 
A), RNA pol II may be more unstable when immunoprecipitated from IMEC/C-
MYC extracts. This is likely a result of the long  
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Figure 3.10: C-MYC does not alter total nuclear CE 
guanylyltransferase activity. (A) CE was immunoprecipitated from 
IMEC/vec and IMEC/C-MYC nuclear protein extracts for 2.5 hours. 
Technical duplicates were performed for each condition. Each IP 
contained 100μg protein and 0.5μg antibody. After being incubated 
with reaction mix, eluates were run on a gel which was then dried and 
analysed by phosphorimager for incorporation of 32P. CE Western 
blots (wb) were performed as a loading control. ar, autoradiograph. 
(B) The signal obtained by phosphorimager was quantified using 2D 
densitometry in AIDA image analyser. Error bars represent standard 
























Figure 3.11: Comparison of total CE guanylyltransferase activity 
to that associated with RNA pol II and SPT5. CE, RNA pol II and 
SPT5 were immunoprecipitated from IMEC/vec protein extracts for 
2.5 hours using 1μg, 2μg and 10μl of antibody, respectively. The CE 
IP contained 0.6mg of protein and the RNA pol II and SPT5 IPs 
contained 15.8mg. After IPs were incubated with reaction mix and 
eluted, 80% of eluates were run on a gel which was then dried and 
analysed by phosphorimager for incorporation of 32P. 5% of eluates 
were run on a gel for analysis by Western blot to confirm that the 
proteins of interest were immunoprecipitated. ar, autoradiograph. 
Individual experiment.





























Figure 3.12: C-MYC overexpression increases RNA pol II-
associated CE guanylyltransferase activity. (A) RNA pol II was 
immunoprecipitated from IMEC/vec and IMEC/C-MYC protein 
extracts overnight. IPs using HIF-1α antibody were performed as a 
control (ctrl IP). IPs contained 26.5mg protein and 4μg antibody. A CE 
IP was performed as a positive control with 100μg protein. IPs were 
incubated in reaction mix before being eluted. Samples were run on a 
gel which was then dried and analysed by phosphorimager for 
incorporation of 32P (phos). RNA pol II Western blots (wb) were 
performed as a loading control. ar, autoradiograph. (B) The signal 
obtained by phosphorimager was quantified using 2D densitometry in 
AIDA image analyser. The CE-GMP signal was normalised to the 
RNA pol II Western blot signal, quantified by densitometry using 
ImageJ. Error bars represent standard error of the mean, n=4. 


















































































































immunoprecipitation time, as shorter RNA pol II immunoprecipitations from 
IMEC/vec and IMEC/C-MYC protein extracts purify equal amounts of RNA pol II 
(Figure 3.6 A), but these shorter immunoprecipitations were not sufficient to 
detect CE-GMP (data not shown). To interpret the CE-GMP signal relative to 
RNA pol II, the CE-GMP signal was normalised to the RNA pol II IP Western 
blot signal (Figure 3.12 B). C-MYC increased relative RNA pol II-bound CE 
guanylyltransferase activity. Although this increase is not additive to the 
increased interaction of CE with RNA pol II (Figure 3.5 B), both this assay and 
IP-Western blots are only semi-quantitative which makes it difficult to compare 
the CE-RNA pol II interaction with RNA pol II-associated CE activity. 
Nonetheless, C-MYC increases RNA pol II-associated CE guanylyltransferase 
activity, whether that is solely due to increased CE recruitment or also allosteric 
stimulation of CE. 
3.2.4 C-MYC regulates CE recruitment to C-MYC target genes 
Since C-MYC increased the interaction of CE with RNA pol II and SPT5, 
it was investigated whether C-MYC overexpression in IMECs increased the 
recruitment of CE to C-MYC target genes. Although CE does not directly 
interact with DNA, RNA pol II and SPT5 do and thus it has the potential to be 
crosslinked to chromatin. Therefore, CE chromatin immunoprecipitation (ChIP) 
was performed in IMECs, but no binding above background levels could be 
detected (data not shown). As an alternative, HeLa cells were used which are 
routinely used for ChIP assays and express endogenously deregulated C-MYC. 
C-MYC siRNA was optimised, and an associated decrease in S5p RNA pol II 
levels was observed after 24 hours at higher siRNA concentrations (Figure 3.13 














Figure 3.13: Optimisation of siRNA-mediated C-MYC depletion in 
HeLa cells. (A) HeLa cells were transfected with 50nM C-MYC siRNA 
or a non-targeting control (-). 24, 48 or 72 hours later, protein was 
extracted and analysed by SDS-PAGE and Western blotting. Individual 
experiment. (B) HeLa cells were transfected with 12.5-50nM C-MYC 
siRNA or a non-targeting control (-) as indicated. After 24 hours, 
protein was extracted and analysed as above. Individual experiment.
































 of C-MYC target genes was analysed by RT-qPCR to identify those which were 
most responsive to C-MYC knockdown (Figure 3.14 A and B). Only NCL and 
NME1 expression was substantially depleted after 24 hours (Figure 3.14 A), but 
most of the target genes were diminished after 48-72 hours (Figure 3.14 B), 
which probably reflects the stability of the C-MYC target gene mRNAs. NCL, 
FBL and NME1 transcripts were the most significantly reduced in response to 
C-MYC suppression and thus the recruitment of CE to these genes was 
analysed by ChIP. Sonication of samples was optimised to yield chromatin 
fragment sizes suitable for ChIP (200-500 bp - 30 minutes sonication selected) 
(Figure 3.15 A) CE binding to regions surrounding the TSS and C-MYC-binding 
sites was analysed by qPCR (Figure 3.15 B and C). As previously observed, it 
is not uncommon for C-MYC binding sites to occur within the first intron (Dang, 
2012). The binding of CE to the TSS of the constitutively expressed gene 
GAPDH was also analysed. A low, yet above background, signal could be 
detected for CE binding to the analysed regions in control treated cells (<0.2% 
of input DNA recovered bound to CE, data not shown). CE was most abundant 
at the TSS of C-MYC target genes or proximally upstream, and there was a 
reproducible trend towards less CE recruitment upon C-MYC depletion, 
although this did not achieve statistical significance. C-MYC knockdown 
resulted in a significant decrease in CE binding to NCL and FBL genes 
downstream of their transcription start sites. Additionally, the recruitment of CE 
to the TSS of NME1 and GAPDH was reproducibly diminished by C-MYC 
knockdown, but this again is not statistically significant. Although GAPDH 
transcript levels were not affected by C-MYC knockdown in HeLa cells (data not 
shown), the GAPDH gene contains a non-canonical E-box (CGCGTG) ~300 





























Figure 3.14: Verification of C-MYC target genes in HeLa cells.
(A) HeLa cells were transfected with 50nM C-MYC siRNA or a non-
targeting control (ctrl). After 24 hours, RNA was extracted and 
analysed by qRT-PCR. Transcript expression is normalised to that 
of GAPDH. Error bars represent standard error of the mean, n=3 
(technical replicates). (B) As in (A) but analysed after 48-72 hours. 
Error bars represent standard error of the mean, n≥3. Significance 





























Figure 3.15: C-MYC depletion diminishes CE recruitment 
to C-MYC target genes. (A) HeLa cells were cross-linked for 
15 minutes before being lysed and treated with and without 
RNase prior to sonication to ensure the nucleic acid 
visualised was DNA. RNA was used as a positive control for 
RNase treatment. Lysates were then subject to 30 seconds 
on/off cycles of sonication for the indicated times. Samples 
are from the same gel and same exposure, indicated by the 



















Figure 3.15 continued: C-MYC depletion diminishes CE 
recruitment to C-MYC target genes. (B) Schematics depicting 
regions of primer amplification used for analysis for CE ChIP
DNA, relative to the TSS (arrow) and E-box sequence(s) (pink 
band). (C) HeLa cells were transfected with 50nM C-MYC
siRNA or non-targeting control (ctrl) and were cross-linked after 
24 hours. Lysates were sonicated to shear chromatin before 
performing CE immunoprecipitation. IPs with no antibody were 
included as a control. DNA was purified from eluates and then 
analysed by qPCR for C-MYC target gene or GAPDH DNA. CE 
ChIP signal is expressed as fold enrichment over no antibody 
ChIP signal. Error bars represent standard error of the mean, 



















































































downstream of the TSS (Figure 1.6), which might explain why CE recruitment to 
GAPDH is C-MYC-responsive. CE binding to the furthermost downstream 
regions analysed of NCL and NME1 was low (only ~2-fold over background) 
and was not C-MYC-responsive. Of note, although in most studies C-MYC is 
reported to increase RNA pol II elongation and not RNA pol II recruitment, the 
latter has been reported (Walz et al., 2014). Therefore, it would be favourable to 
analyse RNA pol II occupancy on these genes upon C-MYC knockdown to 
determine if this contributes to reduced CE recruitment. In summary, C-MYC 
promotes the recruitment of CE to classical C-MYC target genes and probably 







 In this chapter, it was demonstrated that C-MYC deregulation increased 
the recruitment of CE to RNA pol II and SPT5. This was associated with 
stimulation of RNA pol II-bound CE guanylyltransferase activity. Inhibiting C-
MYC expression abolished CE recruitment to C-MYC target genes proximal to 
the TSS. In summary, C-MYC regulates the recruitment of CE to transcription 
complexes near the 5’ end of genes, which could be used to drive or enhance 
C-MYC target gene expression. 
3.3.2 Potentially distinct mechanisms for CE and RNMT recruitment 
  RNA pol II CTD phosphorylation is thought to mediate the timely 
recruitment of various factors during transcription. RNA pol II S5 
phosphorylation occurs after RNA pol II has associated with transcription start 
sites during initiation. S5p RNA pol II recruits CE to nascent pre-mRNA which 
are capped as they emerge from RNA pol II at 18-25 nucleotides in length 
(Coppola et al., 1983; Martinez-Rucobo et al., 2015; Moteki and Price, 2002). In 
vitro and in cells, an interaction between RNMT and RNA pol II CTD cannot be 
detected (Figure 3.1; Aregger and Cowling, 2013; Pineda et al., 2015; Shatkin 
and Manley, 2000). Logically, the recruitment of RNMT via a different 
mechanism could allow for it be recruited after CE in transcription, since basic 
guanosine cap addition is a prerequisite for cap methylation. Indeed, in vitro, 
RNMT methylates nascent pre-mRNAs which are at least 35 nucleotides long, 
and the time taken for cap methylation to occur is six-fold longer than for 




showed that the spatial occupancy of CE and RNMT across several genes was 
much the same, although temporal information concerning recruitment may be 
lost since binding correlates with RNA pol II pausing (Glover-Cutter et al., 
2008). Alternatively, perhaps both are recruited within a similar timeframe to 
ensure seamless catalysis of the capping reactions, but via different proteins to 
prevent competition for binding. 
3.3.3 The CE and RNA pol II interaction 
 Results presented here showed that a very small proportion of CE 
purified with RNA pol II and transcription complexes from cells. This is observed 
by CE-RNA pol II co-IPs, RNA pol II-bound CE guanylyltransferase assays and 
CE ChIPs. There are several possible interpretations of this observation. It 
could reflect a transient interaction. In favour of this, CE is thought to dissociate 
from RNA pol II once capping occurs (Martinez-Rucobo et al., 2015). On the 
other hand, it might indicate that there is a great excess of CE relative to RNA 
pol II in the cell, such that CE abundance is not limiting. This could potentially 
allow for rapid tuning of CE recruitment via modulation of RNA pol II CTD S5 
phosphorylation.  
3.3.4 C-MYC increases CE recruitment 
The finding that C-MYC regulates CE recruitment is an exciting 
observation which demonstrates that C-MYC regulates mRNA capping at 
multiple levels. As previously discussed, C-MYC-mediated RNA pol II 
phosphorylation upregulates RNMT recruitment (Aregger and Cowling, 2013; 
Cowling and Cole, 2007b; Posternak et al., 2017). Moreover, the C-MYC-target 




(SAH) (Fernandez-Sanchez et al., 2009). However, whether C-MYC regulated 
the prior steps in cap catalysis was not clear. Observations in this chapter show 
that C-MYC co-ordinates both CE and RNMT to drive effective mRNA capping. 
C-MYC increasing 5’ mRNA guanylylation – which is critical for transcript 
stability – via CE recruitment is consistent with C-MYC activation globally 
enhancing mRNA stability in other studies (Dang et al., 2017; Hsu et al., 2015). 
Since C-MYC deregulation causes broad changes in cellular metabolism, 
including increased nucleotide biosynthesis (Barfeld et al., 2015; Liu et al., 
2008), it may be that C-MYC also regulates CE via additional routes such as 
modulating GTP availability or upregulating removal of the inhibitory by-product 
of RNA guanylylation (PPi). Notably, C-MYC is likely not the only transcription 
factor that upregulates mRNA capping, but since C-MYC globally enhances 
transcription it may be particularly reliant on CE recruitment to enhance target 
gene expression.  
3.3.5 C-MYC increases CE activity 
Although C-MYC increased CE guanylylation associated with cellular 
RNA pol II, it is not clear if this is solely indicative of more CE recruitment or if 
C-MYC-dependent RNA pol II phosphorylation also allosterically activates CE. 
By removing RNA in IPs prior to the CE guanylylation assay it was hoped this 
would prevent substrate turnover, thereby preserving the CE-GMP interaction, 
but it is possible that substrate RNA bound to RNA pol II and CE was masked 
from RNase degradation. Furthermore, CE guanylylation is a reversible 
reaction, and the kinetics of the forward and back reactions in this experiment 
are not clear. Perhaps using more limiting concentrations of GTP would have 




GMP to RNA is slower than GTP hydrolysis by CE (Shuman, 1995), it may be a 
more limiting step in RNA 5’ guanylylation. It would therefore be interesting to 
analyse how C-MYC deregulation affects the ratio of guanosine-capped to 
uncapped mRNA in the cell. However, this could prove difficult to analyse in 
cells since uncapped mRNAs are unstable.  
3.3.6 Specificity of C-MYC dependent CE recruitment 
As determined by co-IPs, the C-MYC-mediated increase in CE 
recruitment occurs on a global scale. This is consistent with C-MYC globally 
increasing RNA pol II phosphorylation, globally enhancing mRNA stability, and 
the observation that C-MYC binds to the promoters of all actively expressed 
genes in certain systems (Cowling and Cole, 2007b; Hsu et al., 2015; Lin et al., 
2012b; Nie et al., 2012; Sabo et al., 2014). It would be of interest to conduct 
ChIP-sequencing (ChIP-seq) analysis of CE, C-MYC and RNA pol II to 
determine if CE is preferentially recruited to C-MYC target genes and/or highly 
transcribed genes. Furthermore, it would be interesting to modulate other 
transcription factors which activate genes via similar mechanisms to C-MYC 
(i.e. influence RNA pol II pause release rather than recruitment) such as NF-κB 
and HIF1α to determine whether they also regulate CE recruitment to their 
target genes (Liu et al., 2015). Analysis of a select number of genes in this 
study indicated that CE recruitment is influenced by C-MYC. In yeast, TFIIH 
(containing a CDK7 homologue) is recruited to subsets of genes which 
mediates transcript-specific capping, and there is some evidence that this is 
governed by specific transcription factors (Viladevall et al., 2009). This indicates 
that CE may exhibit a degree of specificity. However, it should be noted that 




expression, as can be observed for changes in C-MYC recruitment for example 
(Kress et al., 2015). To this end, in the following chapter it will be investigated if 





Chapter 4 : mRNA capping enzyme regulates C-
MYC and C-MYC target genes 
4.1 Introduction 
 C-MYC induces expression of its protein-coding target genes by binding 
promoter regions and enhancing RNA polymerase II transcription. C-MYC 
mediates these changes through several mechanisms, including increasing the 
recruitment of histone acetyltransferases (HATs), which promote histone 
acetylation and thus create a permissive chromatin environment (Frank et al., 
2003; McMahon et al., 2000; Thomas et al., 2015a). In addition, C-MYC 
increases recruitment of RNA pol II CTD kinases, increasing S5 and S2 
phosphorylation thereby enhancing the transition of paused RNA pol II 
molecules into processive elongation (Cowling and Cole, 2007b; Lin et al., 
2012b; Rahl et al., 2010). RNA pol II pausing is controlled by DSIF and NELF, 
and release of RNA pol II from the pause site is a rate-limiting step in 
transcription (Adelman and Lis, 2012; Henriques et al., 2013; Liu et al., 2015; 
Min et al., 2011; Smith and Shilatifard, 2013). It is thought that pausing might 
function as temporal window for the recruitment of mRNA capping machinery 
and/or a checkpoint to ensure nascent RNA molecules are properly capped 
before transcription resumes. In addition, CE recruitment has a putative role in 
alleviating the RNA pol II pause (Mandal et al., 2004). Taken together with the 
role of C-MYC in RNA pol II pausing and with findings in the previous chapter, it 
is possible that C-MYC drives recruitment of CE to its target genes in order to 




mRNA capping of C-MYC target gene transcripts and enhance transcriptional 
pause release. 
 In this chapter, it was investigated whether CE influenced the expression 

















4.2.1 CE is required for C-MYC expression 
 In order to study how CE affected C-MYC target genes, CE was depleted 
using siRNA. The siRNA oligo, siRNA concentration and length of knockdown 
was optimised in IMEC/vec and IMEC/C-MYC; a higher concentration of CE 
siRNA 2 was used since it does not work as well as CE siRNA 1 (Cowling lab, 
personal communication) (Figure 4.1 A-C). Using the selected conditions (72 
hour knockdown using 50nM CE siRNA 1), CE was equivalently depleted in 
both cell lines at the mRNA and protein level (Figures 4.1 C and 4.2 A). 
Unexpectedly, CE knockdown resulted in a substantial (~40%) reduction in C-
MYC protein levels, which occurred to an equal extent with endogenous C-MYC 
in IMEC/vec and exogenous C-MYC in IMEC/C-MYC (Figure 4.2 A-C). Note 
that the variation in this trend (Figure 4.2 B) lies mostly in the fluctuation of 
ectopic C-MYC levels, since the change in C-MYC expression upon CE 
knockdown is consistent (Figure 4.2 C). To confirm that this was a specific 
effect of CE knockdown, a second round of retroviral infection was used to 
stably express constructs encoding siRNA-resistant CE-GFP (CE-GFP WBL), 
regular CE-GFP or GFP alone. The CE-GFP WBL construct contains wobble 
codons/silent mutations, such that the mRNA sequence is not complementary 
to the siRNA but the protein sequence is the same as the wild-type. CE-GFP 
WBL mRNA was not significantly affected by CE siRNA (Figure 4.3 A). CE-GFP 
WBL protein was not affected by CE depletion, whereas endogenous CE and 
regular CE-GFP were depleted (Figure 4.3 B). CE-GFP WBL expression 
rescued the C-MYC expression defect in response to CE knockdown in  
120
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Figure 4.1: Optimisation of CE siRNA-mediated knockdown in 
IMECs. (A) IMEC/vec (IMEC/v) and IMEC/C-MYC (IMEC/M) were 
transfected with 25-80nM of non-targeting control (-), CE siRNA 1 or 
CE siRNA 2 as indicated. Higher concentrations of CE siRNA 2 were 
used following personal communication that it is not as efficient as CE
siRNA 1 (Cowling lab). 48 hours later, protein was extracted and 
analysed by SDS-PAGE and Western blotting. Individual experiment. 
(B) As in (A) but cells transfected with 12.5-40nM siRNA and analysed 
after 72 hours. (C) IMEC/vec and IMEC/C-MYC were transfected with 
50nM CE siRNA 1 or non-targeting control siRNA (ctrl). After 72 hours, 
RNA was extracted and analysed by qRT-PCR. Transcript level is 
normalised to that of GAPDH. Error bars represent standard error of 










































Figure 4.2: CE is required for C-MYC protein expression. (A) 
IMEC/vec (IMEC/v) and IMEC/C-MYC (IMEC/M) were transfected 
with 50nM CE siRNA 1 or non-targeting control siRNA (-). Protein 
was extracted from cells after 72 hours and analysed by Western 
blotting. (B) Densitometry was performed using ImageJ software to 
quantify the C-MYC Western blot signal (normalised to actin) 
following transfection of CE siRNA 1 or non-targeting control (ctrl) as 
above. Error bars represent standard error of the mean, n≥6. (C) As 
in (B) but expressed as change (Δ) in expression following CE 
depletion relative to that in non-targeting control. Error bars 
represent standard error of the mean, n≥6. Significance was 





































































































































Figure 4.3: Generation of siRNA-resistant CE-GFP cell lines. 
(A) IMEC/vec (IMEC/v) and IMEC/C-MYC (IMEC/M) stably 
transduced with GFP or siRNA-resistant CE-GFP (CE-GFP WBL) 
were transfected with 50nM CE siRNA 1 or non-targeting control 
siRNA (-). RNA was extracted from cells after 72 hours and 
analysed by RT-qPCR. Transcript level is normalised to that of 
GAPDH. Error bars represent standard error of the mean, n=3. 
Significance was calculated by Student’s t-test; *p≤0.05, **p≤0.01.
(B) IMEC/vec and IMEC/C-MYC stably transduced with GFP, CE-
GFP or CE-GFP WBL were transfected with 50nM CE siRNA 1 or 
non-targeting control siRNA (-). Protein was extracted from cells 
after 72 hours and analysed by Western blotting. 
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IMEC/C-MYC (Figure 4.4), indicating that the effect of CE siRNA on C-MYC 
expression is specific. 
Since mRNA capping can regulate several steps in gene expression, C-
MYC mRNA levels were investigated to gain insight into how CE regulates C-
MYC (Figure 4.5). Consistent with C-MYC undergoing autorepression above a 
certain expression threshold (Cleveland et al., 1988; Penn et al., 1990), 
endogenous C-MYC mRNA is repressed in IMEC/C-MYC. Both endogenous C-
MYC in IMEC/vec and exogenous FLAG-C-MYC in IMEC/C-MYC were 
depleted in response to CE siRNA. However, despite endogenous and 
exogenous C-MYC protein levels being equivalently depleted, exogenous C-
MYC mRNA is more sensitive to CE depletion. C-MYC mRNA in HeLa cells – 
which is highly expressed (Adey et al., 2013) – was also substantially reduced 
by CE siRNA. This is indicative of a transcriptional, stability or processing defect 
of C-MYC mRNA. Exogenous C-MYC is sensitive to CE depletion despite it 
lacking its endogenous promoter and introns, suggesting a decrease in mRNA 
stability is most likely.  
 Since C-MYC regulates RNA pol II phosphorylation, it was investigated 
whether the reduction in C-MYC expression as a result of CE depletion caused 
reduced S5 and S2 RNA pol II phosphorylation in IMECs (Figure 4.6 A and B). 
C-MYC increased S5 and S2 phosphorylation (Figure 4.6 B), as in previous 
studies. CE depletion caused fluctuations in both S5 and S2 phosphorylation, 
but no consistent trends were observed. This could be due to conflicting 
mechanisms, for example RNA pol II phosphorylation may be downregulated as 
a result of lower C-MYC levels, but upregulated via a distinct mechanism to 













Figure 4.4: siRNA-resistant CE-GFP rescues the C-MYC 
expression defect upon CE knockdown in IMECs. IMEC/vec
(IMEC/v) and IMEC/C-MYC (IMEC/M) stably expressing siRNA-
resistant CE-GFP (CE-GFP WBL) or GFP alone were transfected 
with 50nM CE siRNA 1 or non-targeting control siRNA (-). Protein 
was extracted from cells after 72 hours and analysed by Western 
blotting. Representative of two independent experiments.













































Figure 4.5: C-MYC mRNA levels are reduced upon CE knockdown. 
IMEC/vec (IMEC/v), IMEC/C-MYC (IMEC/M) and HeLa cells were 
transfected with 50nM CE siRNA 1 or non-targeting control (ctrl) 
siRNA. RNA was extracted from cells after 72 hours and analysed by 
RT-qPCR. Transcript level is normalised to that of GAPDH. Error bars 
represent standard error of the mean, n≥4. Significance was calculated 






























Figure 4.6: CE knockdown does not significantly affect RNA 
pol II S5 and S2 phosphorylation in IMECs. (A) IMEC/vec
(IMEC/v) and IMEC/C-MYC (IMEC/M) were transfected with 50nM 
CE siRNA 1 or non-targeting control siRNA (-). Protein was 
extracted from cells after 72 hours and analysed by Western 
blotting. Two biological replicates are shown. (B) Densitometry was 
performed using ImageJ software to quantify the S5p or S2p RNA 
pol II Western blot signal (normalised to pan RNA pol II) following 
transfection of CE siRNA 1 or non targeting control (ctrl). Error bars 
represent standard error of the mean, n≥4. Significance calculated 












































S5p RNA pol II
S2p RNA pol II
RNA pol II




IMEC/v IMEC/M IMEC/v IMEC/M




CE inhibition on RNA pol II phosphorylation, the endogenous CE locus could be 
replaced by CE fused to an auxin-inducible degron tag or GFP tag using the 
clustered regularly interspaced short palindromic repeats (CRISPR) system. By 
addition of auxin, or stable transfection of inducible von Hippel-Lindau E3 
ubiquitin ligase fused to a GFP nanobody (respectively), this could induce 
targeted proteolysis of endogenous CE-GFP in a rapid manner, thus minimising 
secondary effects of CE inhibition (Fulcher et al., 2016; Natsume et al., 2016).  
 To further examine the relationship between CE and C-MYC expression, 
CE was overexpressed to determine if this increased C-MYC levels. In IMECs, 
stably expressing CE-GFP did not elevate C-MYC expression (Figures 3.4 A 
and 4.4). Similarly, inducing FLAG-CE overexpression in HeLa cells expressing 
FLAG-CE under control of an inducible promoter did not increase C-MYC 
expression or RNA pol II phosphorylation (Figure 4.7). In the previous chapter, it 
was shown that a small fraction of RNA pol II co-purified with CE from cells, 
consistent with CE being present in excess. This would explain why increasing 
CE expression had no effect on C-MYC levels. 
 It was then investigated whether CE knockdown affected C-MYC protein 
levels in HeLa cells. Consistent with C-MYC mRNA levels (Figure 4.5), CE 
depletion caused reduced C-MYC protein expression, and a concurrent 
reduction in RNA pol II phosphorylation (Figure 4.8). During the time-course of 
CE knockdown using two independent siRNAs, CE levels correlate with that of 
C-MYC, suggesting that CE directly regulates C-MYC expression. Although 
RNA pol II phosphorylation defects might occur due to reduced C-MYC 
expression, it is possible that CE influences RNA pol II phosphorylation in other 
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Figure 4.7: Overexpressing CE does not increase C-MYC 
expression in HeLa cells. HeLa cells stably expressing FLAG-CE
under control of a tetracycline-inducible promoter were treated with 
1μg/ml doxycycline (dox) or DMSO as a control (-). After 48 hours, 
protein was extracted and analysed by Western blotting. Technical 
duplicates for this experiment are shown. The cell line was made by Dr. 
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Figure 4.8: Temporal dynamics of CE knockdown, C-MYC levels 
and RNA pol II phosphorylation. HeLa cells were transfected with 
50nM of non-targeting control (ctrl), CE siRNA 1 or CE siRNA 2. 24, 48 
or 72 hours later, protein was extracted and analysed by SDS-PAGE 
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C-MYC expression and S5p RNA pol II phosphorylation in response to CE 
depletion, confirming these effects are specific (Figure 4.9 A and B). 
In summary, CE is required for optimal C-MYC expression in IMECs and 
HeLa cells. It would be interesting to determine whether this is also true in other 
cell types. 
4.2.2 CE knockdown increases RNA pol II occupancy at the C-MYC 
pause site 
To determine if CE depletion in HeLa cells impacted transcription, RNA 
pol II ChIP was performed. CE has the potential to impact RNA pol II 
transcription directly, or indirectly via influencing C-MYC expression and RNA 
pol II phosphorylation. The C-MYC gene itself is regulated by RNA pol II 
pausing, thus primers were designed spanning the C-MYC gene to analyse 
RNA pol II distribution (Figure 4.10 A). This could also indicate whether CE 
influences C-MYC expression via a transcriptional mechanism. RNA pol II 
pausing on the C-MYC gene occurs near the first exon-intron boundary (Bentley 
and Groudine, 1988; Keene et al., 1999; Krumm et al., 1992; Spencer and 
Kilvert, 1993; Strobl and Eick, 1992). Interestingly, CE depletion increased RNA 
pol II occupancy at the pause site (Figure 4.10 B). This indicates that CE may 
have a role in RNA pol II pause release. However, there was also a 
reproducible – although not significant – increase in RNA pol II occupancy at 
the mid-gene region (+3600) which could indicate a general RNA pol II 
processivity impairment. To determine is CE knockdown caused a similar effect 
on other genes, promoter proximal regions of CCND1 (a C-MYC-repressed 









Figure 4.9: siRNA-resistant CE-GFP rescues the C-MYC 
expression defect upon CE knockdown in HeLa cells. (A) 
HeLa cells were stably transduced with a construct encoding 
siRNA-resistant CE-GFP (CE-GFP WBL) or GFP as a control. 
Cells were transfected with 50nM CE siRNA 1 or non-targeting 
control siRNA (-). After 72 hours, RNA was extracted from cells 
and analysed by RT-qPCR. Average of two independent 
experiments. (B) As in (A) except protein was extracted from cells 
after 72 hours and analysed by Western blotting. Representative 
of two independent experiments.
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Figure 4.10: CE knockdown increases RNA pol II occupancy on 
the C-MYC gene. (A) Schematic depicting regions of primer 
amplification used for analysis of RNA pol II ChIP DNA relative to the 
TSS (arrow) on the C-MYC gene. Note that only half of the gene is 
shown. *RNA pol II pause site. (B) HeLa cells were transfected with 
50nM CE siRNA 1 or non-targeting control siRNA (ctrl). After 48 
hours, RNA pol II was immunoprecipitated and the co-purified DNA 
analysed by qPCR. Signal is expressed as the RNA pol II-bound DNA 
relative to DNA in the input. The background signal (in the control 
ChIP with no antibody) was subtracted. Values indicate position 
relative to the TSS. Error bars represent standard error of the mean, 
n=3 for C-MYC gene regions. RNA pol II ChIP signal values for other 
genes is averaged from two independent experiments. Significance 








































were analysed (Figure 4.10 B). These preliminary results indicate that CE may 
also influence RNA pol II transcription on other genes, although further 
verification is required. Analysing RNA pol II distribution across these genes (or 
performing ChIP sequencing) would clarify these observations. Additionally, 
comparing levels of nascent (unspliced) C-MYC mRNA relative to mature 
(spliced) C-MYC mRNA would confirm whether CE influences C-MYC 
transcription. C-MYC mRNA synthesis could also be measured using nuclear 
run-on, during which nascent RNA is synthesised in cells whilst being labelled 
with bromouridine and then purified for RT-qPCR analysis (or sequencing for 
global analysis). 
4.2.3 Investigating whether CE regulates C-MYC expression via the 
coding region determinant of stability 
 As previously mentioned, exogenous FLAG-C-MYC in IMEC/C-MYC (not 
expressed from the endogenous C-MYC promoter) is sensitive to CE depletion 
in addition to endogenous C-MYC in IMEC/vec and HeLa cells. This indicates 
that CE mayo regulate C-MYC mRNA stability rather than C-MYC transcription 
in IMECs. C-MYC mRNA degradation is mediated by two sequences: a region 
in the 3’ UTR and a region at the 3’ end of the coding sequence within the third 
exon called the coding region determinant (CRD) (Brewer and Ross, 1988; 
Herrick and Ross, 1994; Wisdom and Lee, 1991). The 3’ UTR is not present in 
exogenously expressed FLAG-C-MYC, therefore mechanisms involving the 
CRD may render C-MYC mRNA sensitive to CE depletion. The CRD mediates 
co-translational degradation of C-MYC mRNA. A series of rare codons precede 
the CRD, causing translation to slow down (when availability of the 




by polysome-associated endonuclease(s) (Lee et al., 1998; Lemm and Ross, 
2002). A CRD-binding protein (CRD-BP) stabilises C-MYC mRNA by protecting 
it from endonucleolytic attack (Bernstein et al., 1992; Sparanese and Lee, 
2007). It is possible that CE could regulate CRD-BP expression, thus indirectly 
regulating C-MYC mRNA stability. CE was depleted by siRNA in HeLa cells to 
test this (Figure 4.11). Preliminary data indicates that CRD-BP expression is 
modestly impacted by CE depletion. However, this is obscured by the fact that 
CRD-BP is itself a C-MYC target gene (Noubissi et al., 2010), as confirmed by 
C-MYC knockdown in this system (Figure 4.11). Therefore CE may regulate 
CRD-BP directly or through C-MYC. Further studies are required to determine if 
the CRD has a role in CE-dependent C-MYC stability. For example, CRD-BP 
exists in a multimeric complex with four obligate binding partners 
(Weidensdorfer et al., 2009), any of which might be regulated by CE. 
Alternatively, perhaps 5’-3’ looping of mRNA allows the cap or cap-binding 
proteins to interact with the CRD or CRD-BP, which could mask the CRD or 
stabilise CRD-BP binding. It would be interesting to express a mutant C-MYC 
lacking the CRD sequence in cells to determine if this renders C-MYC resistant 
to CE depletion. Importantly, to truly determine if CE influences C-MYC mRNA 
stability, a transcription inhibitor should be used in cells and C-MYC transcript 
decay tracked in the presence and absence of CE knockdown. It would also be 
interesting to determine whether the C-MYC transcript exhibits reduced 7-
methylguanosine capping upon CE knockdown using an antibody which 





























Figure 4.11: Investigating if CE regulates CRD-BP expression. 
HeLa cells were transfected with 50nM CE siRNA 1, C-MYC siRNA 
or non-targeting control siRNA (ctrl). After 72 hours, RNA was 
extracted and analysed by qRT-PCR. Transcript level is normalised 
to that of GAPDH. Individual experiment. This experiment was 





4.2.4 Investigating if CE influences C-MYC protein stability 
Since CE depletion affects C-MYC transcript levels, it was suspected that 
CE primarily influences C-MYC mRNA synthesis or stability. However, it is 
possible that multiple mechanisms are involved, for example CE influencing C-
MYC translation or indirectly impacting C-MYC protein stability. To test the latter 
possibility, HeLa cells were treated with the proteasome inhibitor carbobenzoxy-
Leu-Leu-leucinal (MG132) to prevent proteasomal degradation of C-MYC. As 
expected, since C-MYC has a high turnover rate, C-MYC protein generally 
accumulated in a dose- and time- dependent manner in response to MG132 
treatment (Figure 4.12 A). Preliminary experiments showed that when C-MYC 
degradation was inhibited, there was still a relative decrease in C-MYC protein 
levels in response to CE knockdown (Figure 4.12 B), indicating that CE does 
not significantly affect C-MYC protein stability in HeLa cells. 
4.2.5 C-MYC overexpression sensitises C-MYC target genes to CE 
depletion 
 It was then investigated whether CE regulates C-MYC target genes. CE 
was knocked down in IMEC/vec and IMEC/C-MYC before analysing C-MYC 
target gene mRNA levels. This experiment probes the net effect of CE on C-
MYC target genes which encompasses several potential mechanisms: 1) CE 
directly regulating C-MYC target genes; 2) CE controlling C-MYC expression; 
and 3) other secondary effects of CE knockdown. NCL, ODC, NME1, NPM, FBL 
and TIP49 were verified as C-MYC-induced genes in IMECs (Figure 4.13 A). 
CE depletion reversed the induction of these target genes in IMEC/C-MYC 
(Figure 4.13 A). Notably, C-MYC-induced genes were unaffected by CE  
137
Figure 4.12: Investigating if CE influences C-MYC protein 
stability. (A) HeLa cells were treated with DMSO (-) or MG132 
(5μM or 10μM) for the indicated times before protein was extracted 
from cells and analysed by Western blotting. Individual experiment. 
(B) HeLa cells were transfected with 50nM CE siRNA 1 (+) or non-
targeting control siRNA (-). After 72 hours, cells were treated with 
DMSO or 5μM MG132 for the indicated times before protein was 
extracted from cells and analysed by Western blotting. Individual 
experiment. These experiments were performed in collaboration with 
Olga Suska and Maria Pisliakova in the Cowling lab.







































































































































Figure 4.13: C-MYC overexpression sensitises C-MYC target 
genes to CE depletion. (A) IMEC/vec (IMEC/v) and IMEC/C-MYC 
(IMEC/M) were transfected with CE siRNA 1 or a non-targeting 
control (ctrl) siRNA. RNA was extracted after 72 hours and analysed 
by RT-qPCR. qPCR data was not normalised since the reference 
gene (GAPDH) was significantly changing. Error bars represent 
standard error of the mean, n≥3. Significance was calculated by 












































































Figure 4.13 continued: C-MYC overexpression 
sensitises C-MYC target genes to CE depletion. (B) 
For each gene analysed in part (A), the fold-change in 
mRNA level upon CE knockdown (ctrl siRNA / CE siRNA, 
i.e. CE dependency) is plotted against the fold-change in
mRNA level upon C-MYC overexpression (IMEC vec / 












































depletion in IMEC/vec, which only express endogenous C-MYC (Figure 4.13 A). 
This was surprising given that endogenous C-MYC expression is impaired by 
CE knockdown. GAPDH was modestly induced by C-MYC and modestly 
depleted by CE knockdown (Figure 4.13 A). This indicates that the CE and C-
MYC interplay may act globally, albeit to a lesser extent than with canonical C-
MYC target genes. More comprehensive studies are required to confirm this. As 
previously mentioned, canonical and non-canonical E-boxes reside 300-800 
bases from the GAPDH TSS which might explain why it is C-MYC-responsive. 
UBF (upstream binding factor), a C-MYC target gene in some systems 
(Poortinga et al., 2004a; Wall et al., 2008), was unresponsive to both C-MYC 
and CE knockdown in IMECs. Transcript levels of CCND1 – a C-MYC-
repressed gene in IMECs (Cowling, 2009; Philipp et al., 1994) (Figure 4.16 C) – 
slightly increased when CE was depleted in IMEC/vec (Figure 4.13), correlating 
with reduced C-MYC expression. However, when CCND1 was repressed by 
elevated C-MYC expression, it was unresponsive to CE depletion. This could be 
because C-MYC levels in IMEC/C-MYC/CE siRNA cells were generally 4-fold 
higher than in IMEC/vec/control siRNA cells (Figure 4.2 B), indicating that 
sufficient C-MYC remained to maintain CCND1 repression. Taken together, 
there is a good correlation between gene dependency on CE and gene 
dependency on C-MYC, but only in the presence of C-MYC deregulation 
(Figure 4.13 B). This suggests that CE may preferentially regulate genes 
targeted by overexpressed C-MYC rather than endogenous C-MYC, and that 
CE inhibition may have a biased effect on these genes in cells with deregulated 
C-MYC. Expression of siRNA-resistant CE-GFP rescued the defect in C-MYC 
target gene expression in IMEC/C-MYC in response to CE suppression (Figure 











































































GAPDH Figure 4.14: siRNA-resistant CE-
GFP rescues C-MYC target gene 
expression upon CE depletion. (A) 
IMEC/vec (IMEC/v) and IMEC/C-
MYC (IMEC/M) expressing GFP or 
CE-GFP resistant to siRNA (CE-GFP 
WBL) were transfected with CE 
siRNA 1 or a non-targeting control 
(ctrl) siRNA. RNA was extracted 
after 72 hours and analysed by RT-
qPCR. GAPDH was used as a 
reference gene but qPCR data is not 
normalised. Error bars represent 
standard error of the mean, n=3. 
Significance was calculated by 
Student’s t-test; *p≤0.05, **p≤0.01, 












































































































































Figure 4.14 continued: siRNA-resistant CE-GFP 
rescues C-MYC target gene expression upon CE 
depletion. (B) Average change (Δ) in mRNA levels 
of C-MYC target genes (NCL, ODC, FBL, NME1, 
NPM and TIP49) upon CE depletion relative to 
control transfections. Error bars represent standard 
error of the mean, n=6. Significance was calculated 
























indicating that the effect of CE knockdown on C-MYC target genes is specific. 
To confirm that these trends are reflected at the protein level, NCL protein 
expression was analysed in IMECs upon CE knockdown (Figure 4.15 A and B). 
Consistent with mRNA levels, NCL protein was diminished by CE depletion in 
IMEC/C-MYC, but was not affected in IMEC/vec. In summary, IMECs with 
overexpressed C-MYC are dependent on CE for inducing C-MYC target genes 
above the basal level, whereas their expression in IMECs with normal, 
endogenous C-MYC levels is not CE-dependent. 
4.2.6 Investigating the relationship between low C-MYC levels and 
resistance of C-MYC target genes to CE depletion 
 The observation that C-MYC target gene expression was unaffected by 
CE depletion in IMEC/vec, despite endogenous C-MYC levels being reduced, 
was unexpected. With the premise that C-MYC and N-MYC share a substantial 
proportion of target genes and are partially functionally redundant, in addition to 
the fact that N-MYC is a C-MYC-repressed gene (Breit and Schwab, 1989; 
Malynn et al., 2000; Westermann et al., 2008), it was tested if N-MYC 
compensated for C-MYC loss in IMEC/vec (Figure 4.16 A). N-MYC was 
undetectable in IMEC/vec, and only trace amounts were detected in IMEC/C-
MYC. Alternatively, it was possible that the genes analysed are only regulated 
by C-MYC when C-MYC is expressed above a certain threshold. To investigate 
this, IMEC/vec were transfected with C-MYC siRNA. Endogenous C-MYC levels 
were diminished to a very low level (Figure 4.16 B). RNA pol II S5 
phosphorylation decreased in response to C-MYC suppression, indicating that 
endogenous C-MYC is functional in IMEC/vec (Figure 4.16 B). NCL, ODC and 




































CE siRNA: - + - +
Figure 4.15: The sensitivity of C-MYC target genes to CE 
depletion is reflected at the protein level. (A) IMEC/vec (IMEC/v) 
and IMEC/C-MYC (IMEC/M) were transfected with CE siRNA 1 or a 
non-targeting control siRNA (-). Protein was extracted after 72 hours 
and analysed by Western blotting. (B) Densitometry was performed 
using ImageJ software to quantify the nucleolin Western blot signal 
(normalised to actin) following transfection of CE siRNA or non-
targeting control (ctrl) as above. Error bars represent standard error 


































































Figure 4.16: Investigating the resistance of C-MYC target genes in 
IMECs to CE depletion. (A) IMEC/vec (IMEC/v) and IMEC/C-MYC 
(IMEC/M) were transfected with 50nM CE siRNA 1 or a non-targeting 
control (-). After 72 hours, protein was extracted and analysed by 
Western blotting. Tet21-N cell protein was used as a positive control for 
N-MYC expression. Individual experiment. (B) IMEC/vec were 
transfected with C-MYC siRNA or non-targeting control (-). After 72 
hours, protein was extracted and analysed by Western blotting. 
Representative of three independent experiments. (C) As in (B) but 
RNA was extracted and analysed by RT-qPCR. Transcript levels are 
expressed relative to that of GAPDH. Error bars represent standard 
error of the mean, n=6. Significance calculated by Student’s t-test, 
**p≤0.01; *p≤0.05. (D) IMEC/vec were transfected with C-MYC siRNA, 
CE siRNA 1 or non-targeting control (-). After 72 hours, protein was 























and FBL transcript levels were sensitive (Figure 4.16 C). It should be noted that 
C-MYC siRNA caused a greater decrease in C-MYC expression than CE siRNA 
(Figure 4.16 D). Therefore, NCL, ODC and TIP49 are not regulated by 
endogenous C-MYC in IMEC/vec, which could explain why they are resistant to 
the effects of CE depletion. On the other hand, NME1, NPM and FBL are target 
genes of low level endogenous C-MYC, but are resistant to the intermediate 
level of C-MYC depletion observed upon CE knockdown. 
4.2.7 Exploring a method to functionally uncouple CE regulating C-
MYC and C-MYC target genes 
 As stated above, overexpressed C-MYC requires CE for inducing 
expression of its target genes. However, it is not clear whether this dependency 
is due to the requirement of CE to maintain C-MYC expression, if C-MYC 
requires CE as a transcriptional co-factor to directly regulate its target genes, or 
if overexpressed C-MYC induces CE dependency through other means. In an 
attempt to functionally uncouple CE regulating C-MYC expression and function, 
it was investigated if there was a temporal window during the process of CE 
knockdown when CE was depleted before C-MYC protein levels were affected. 
Since C-MYC mRNA and protein are both unstable, and C-MYC is very 
responsive to changes in CE expression (Figure 4.8), IMECs expressing C-
MYC T58A (designated IMEC/T58A) were used in order to maximise the time 
after CE knockdown before C-MYC was affected. This mutation typically 
stabilises the protein by 2-5-fold, as it impairs C-MYC phospho-dependent 
ubiquitination and degradation (Gregory and Hann, 2000; Salghetti et al., 1999; 
Sears et al., 2000). As previously observed, C-MYC T58A protein levels are 
higher than C-MYC WT (Figure 4.17), consistent with it being stabilised. The  
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Figure 4.17: Investigating C-MYC T58A stability in response to 
CE depletion. IMECs stably transduced with the wild-type C-MYC 
vector (IMEC/M) or a C-MYC vector carrying the T58A mutation 
(IMEC/T58A) were transfected with CE siRNA 1 or a non-targeting 
control (-). After 36 or 48 hours, protein was extracted and analysed 
by Western blotting. Individual experiment.
CE siRNA:
IMEC/M IMEC/T58A











effect of CE knockdown on C-MYC expression in IMEC/C-MYC and IMEC/T58A 
was compared after 36-48 hours (Figure 4.17). After 36 hours, CE was at least 
partially depleted whereas neither C-MYC WT nor C-MYC T58A were affected. 
However, both C-MYC variants were substantially diminished after 48 hours. 
Following the observation that many C-MYC target genes take over 24 hours to 
be affected by C-MYC depletion (Figure 3.14 A and B), it seems it would be 
challenging to dissect how CE regulates C-MYC target genes using this 
method.  
4.2.8 C-MYC suppression in cancer cells desensitises C-MYC target 
genes to CE depletion  
 The role of CE in regulating C-MYC target genes was next investigated 
in cancer cells with deregulated C-MYC. HeLa cells overexpress C-MYC as a 
result of viral insertion at the C-MYC gene, causing strong transcriptional 
activation (Adey et al., 2013). C-MYC siRNA was used to modulate endogenous 
C-MYC expression in addition to CE siRNA. Cells were simultaneously 
transfected with combinations of the two targeting siRNAs and/or non-targeting 
control and conditions were optimised (Figure 4.18 A and B; Figure 3.13 A and 
B). The experiment was designed based upon whether effective knockdown 
was achieved, if this was equivalent in the presence and absence of the other 
siRNA, whether C-MYC knockdown was sufficient to reduce S5p RNA pol II 
levels and whether there would be sufficient time following knockdown to impact 
C-MYC target gene expression (72 hour knockdown using 25nM C-MYC siRNA 
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Figure 4.18: Optimisation of C-MYC and CE double knockdown 
in HeLa cells. (A) HeLa cells were transfected with combinations of 
CE siRNA 1, C-MYC siRNA and non-targeting control siRNA (-). 50nM 
of CE siRNA was used and either 10nM or 5nM of C-MYC siRNA. 
After 72 hours, protein was extracted and analysed by Western 
blotting. Individual experiment. (B) As in (A) except 25nM of CE siRNA 
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and 50nM CE siRNA selected, Figure 4.20 A). It should be noted that C-MYC 
knockdown occurs in less than 24 hours following C-MYC-siRNA transfection 
(Figure 3.13 B) whereas CE depletion was not detected until 48 hours after CE 
siRNA transfection in HeLa cells (Figure 4.8). Therefore, in this experimental 
arrangement, CE is depleted following changes in C-MYC protein level. CE 
siRNA caused equivalent depletion of CE mRNA (Figure 4.19 A) and protein 
(Figure 4.20 A) in the presence and absence of C-MYC siRNA. Strangely, C-
MYC siRNA was not particularly effective in depleting C-MYC mRNA levels 
(Figure 4.19 A), but was efficient in suppressing C-MYC protein levels (Figures 
4.20 A and B); to a similar extent in the presence and absence of CE siRNA 
(Figure 4.20 C). The primary mechanism of silencing by this C-MYC siRNA 
oligo is likely translation repression rather than mRNA degradation. As in 
IMECs, C-MYC expression was dependent on CE; both C-MYC mRNA (Figures 
4.19 A and B) and C-MYC protein (Figures 4.20 A and B) were sensitive to CE 
knockdown, in the presence and absence of C-MYC siRNA. Interestingly, CE 
siRNA caused a greater relative reduction in C-MYC levels when C-MYC was 
knocked down by siRNA (Figure 4.20 D). 
CE depletion in HeLa cells resulted in a substantial repression of C-MYC 
target genes (Figure 4.21 A). On the other hand, when C-MYC was repressed 
by siRNA, CE depletion had a dampened effect on C-MYC target genes 
compared to that in HeLa cells with high C-MYC levels (Figure 4.21 A). On 
average, C-MYC target genes in HeLa cells were significantly (1.5-fold) more 
sensitive to CE depletion in the presence of deregulated C-MYC (Figure 4.21 







































C-MYC siRNA:   +       -
** **
Figure 4.19: Analysis of CE and C-MYC mRNA levels in 
single- and double-target knockdowns. (A) HeLa cells were 
transfected with combinations of CE siRNA 1, C-MYC siRNA 
and non-targeting control siRNA (-). 50nM CE siRNA and 25nM 
C-MYC siRNA was used. After 72 hours, RNA was extracted 
and analysed by RT-qPCR. Error bars represent standard error 
of the mean, n=4. (B) As in (A) but expressed as change (Δ) in 
C-MYC mRNA level following CE depletion in the presence (+) 
or absence (-) of C-MYC siRNA (relative to control 
transfections). Error bars represent standard error of the mean, 
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Figure 4.20: Analysis of C-MYC protein expression upon CE 
and C-MYC double knockdown. (A) HeLa cells were 
transfected with combinations of C-MYC siRNA, CE siRNA 1 
and non-targeting control siRNA (-). 50nM CE siRNA and 25nM 
C-MYC siRNA was used. After 72 hours, protein was extracted 
and analysed by Western blotting. (B) Densitometry was 
performed using ImageJ software to quantify the C-MYC 
Western blot signal (normalised to actin) following transfection of 
siRNA as above. Error bars represent standard error of the 
mean, n≥5. (C) As in (B) but expressed as change (Δ) in 
expression following C-MYC depletion in the presence (+) or 
absence (-) of CE siRNA relative to control transfections. Error 
bars represent standard error of the mean, n≥5. (D) As in (B) but 
expressed as change in expression following CE depletion in the 
presence or absence of C-MYC siRNA relative to control 
transfections. Error bars represent standard error of the mean, 




























































































































Figure 4.21: C-MYC depletion desensitises C-MYC target genes to 
CE knockdown. (A) HeLa cells were transfected with combinations of 
C-MYC siRNA, CE siRNA 1 and non-targeting control siRNA (-). 50nM 
CE siRNA and 25nM C-MYC siRNA was used. After 72 hours, RNA 
was extracted and analysed by RT-qPCR. Error bars represent 
standard error of the mean, n=4. (B) Average change (Δ) in mRNA 
levels of C-MYC target genes (NCL, NME1, ODC, FBL, and NPM) 
upon CE depletion relative to control transfections in the presence (+) 
and absence (-) of C-MYC siRNA. Error bars represent standard error 
of the mean, n=5. Significance calculated by Student’s t-test, *p≤0.05; 
**p≤0.01; ***≤0.001. Figure continued overleaf.
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Figure 4.21 continued: C-MYC depletion desensitises C-MYC 
target genes to CE knockdown. (C) For each gene, fold-change 
in mRNA level upon CE knockdown (CE dependency) is plotted 





genes on CE. As in IMECs, the C-MYC-repressed gene CCND1 was unaffected 
by CE depletion in cells expressing high levels of C-MYC (Figure 4.21 A), 
perhaps because sufficient C-MYC remains to maintain CCND1 suppression 
(Figure 4.20 B). However, unlike IMECs, no significant changes in GAPDH 
levels were observed upon CE and/or C-MYC knockdown (data not shown). In 
conclusion, suppression of endogenously overexpressed C-MYC desensitises 
its target genes to CE depletion. Interestingly, there was a correlation between 
gene dependency on CE and gene dependency on C-MYC selectively in the 
presence of C-MYC overexpression (Figure 4.21.C), which is complementary to 
the above observations in IMECs. This indicates that genes regulated by 
overexpressed C-MYC may have a heightened dependency on CE for their 
expression. 
4.2.9 CE regulates C-MYC target genes partially independently of 
regulating C-MYC expression 
The above data provide insight into whether CE knockdown only 
influences C-MYC target gene expression by regulating C-MYC, or whether it 
directly (or indirectly by other means) regulates C-MYC target genes. C-MYC 
knockdown in HeLa cells causes a 3-fold greater decrease in C-MYC levels 
than CE knockdown (Figure 4.22 A). However, CE knockdown diminishes C-
MYC target gene expression to the same extent as C-MYC knockdown (Figure 
4.22 B, average change in expression of five genes). This indicates that CE 
does not control C-MYC target genes simply by regulating C-MYC expression. 
A similar observation can be drawn from IMECs: CE knockdown in IMEC/C-
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Figure 4.22: CE regulation of C-MYC target genes is partially 
independent of C-MYC expression. (A) Densitometry was 
performed using ImageJ software to quantify change (Δ) in C-MYC 
Western blot signal (normalised to actin) relative to control 
transfections following C-MYC knockdown, CE knockdown or both. An 
exemplar Western blot is depicted in Figure 4.21-A. Error bars 
represent standard error of the mean, n≥5. (B) Average change (Δ) in 
mRNA levels of C-MYC target genes (NCL, NME1, ODC, FBL, and 
NPM) upon CE depletion relative to control transfections. Error bars 
represent standard error of the mean, n=5. Significance calculated by 




IMEC/vec/control (Figure 4.2 B) and yet C-MYC target gene expression in 
IMEC/C-MYC is abolished to that in IMEC/vec (Figure 4.13 A). Of note, in 
IMECs certain C-MYC target genes are insensitive to changes in C-MYC below 
a certain threshold of C-MYC expression (Figure 4.16 B), which might partially 
account for this phenomenon. C-MYC siRNA could be titrated in HeLa cells to 
test whether C-MYC target genes also become desensitised to changes in low 
C-MYC levels in this system. In HeLa cells, the expression of C-MYC target 
genes upon double knockdown of CE and C-MYC correlates with C-MYC 
protein levels, unlike when CE alone is depleted (Figure 4.22 A and B). A 
possible interpretation of this is that CE has a minor role in regulating C-MYC 
target genes via regulating C-MYC expression, but in cells with overexpressed 
C-MYC it has additional influences on C-MYC target genes. In conclusion, C-
MYC deregulation sensitises C-MYC target genes to CE depletion, and this is 













In this chapter it was demonstrated that CE regulates C-MYC 
expression, potentially via a transcriptional mechanism or regulation of C-MYC 
mRNA stability. CE was shown to regulate C-MYC target genes, and this was 
partially independent of CE regulating C-MYC expression. Importantly, C-MYC 
deregulation sensitised C-MYC target genes to CE depletion; target gene 
expression in normal cells with basal C-MYC levels, or cancer cells with 
suppressed C-MYC levels, was less affected or unaffected by CE depletion. 
Since C-MYC is deregulated in a large proportion of cancers, the relationship 
between CE and C-MYC could be therapeutically relevant. 
4.3.2 CE influences RNA pol II on the C-MYC gene 
CE depletion in HeLa cells resulted in greater RNA pol II occupancy at 
the pause site on the C-MYC gene. A possible interpretation of this result is that 
CE knockdown causes a defect in pause release, which would support studies 
showing that CE releases RNA pol II from the pause in vitro (Mandal et al., 
2004) and is consistent with the notion that the RNA pol II pausing serves as a 
‘capping checkpoint’. Indeed, in a previous study, CDK7 inhibition caused a 
similar change in RNA pol II occupancy on the C-MYC gene (Larochelle et al., 
2012). Alternatively, since there is also more RNA pol II present at a mid-gene 
region of C-MYC upon CE knockdown, this might indicate a general 
transcription defect. This could be attributed to CE’s ability to induce R-loop 
formation (Kaneko et al., 2007). Furthermore, lack of the mRNA cap would 




thus a splicing impairment could cause slower processivity of RNA pol II 
(increasing RNA pol II occupancy). Consistent with this, knockdown of the CBC 
caused a decrease in S2p RNA pol II and elevated RNA pol II occupancy 
across gene bodies (Lenasi et al., 2011) similar to that observed upon CE 
knockdown in HeLa cells. More studies are required to determine the reasons 
for, and consequences of, CE-mediated changes in RNA pol II transcription. It 
would be interesting to determine if CE influences RNA pol II occupancy 
globally or if there is a preference for certain genes, for example C-MYC or C-
MYC target genes. Global nuclear run-on followed by sequencing (GRO-seq) 
could also be performed to analyse how CE knockdown influences C-MYC 
mRNA and global mRNA synthesis. A guanylyltransferase dead mutant of CE 
(K294A) was shown to retain the ability to alleviate RNA pol II pausing and 
induce R-loop formation in vitro (Kaneko et al., 2007; Mandal et al., 2004), 
therefore it would be of interest to asses if expressing this mutant could reverse 
changes in RNA pol II occupancy upon CE depletion. This could help 
distinguish the effects of CE recruitment and mRNA capping on RNA pol II 
transcription. 
4.3.3 C-MYC target genes are differentially sensitive to CE depletion 
In this study, cells carrying deregulated C-MYC were significantly more 
dependent on CE for C-MYC target gene expression than cells with low C-MYC 
expression. IMECs which express low endogenous C-MYC levels or HeLa cells 
in which C-MYC expression was supressed by siRNA were largely unaffected 
by CE knockdown. This was somewhat surprising given that both endogenous 
and ectopic C-MYC expression are dependent on CE for their expression. In 




effects on gene expression. However, as estimated by transcript and protein 
levels, there is 20% of CE remaining in cells after knockdown. Therefore, in 
cells with low C-MYC expression, perhaps sufficient amounts of CE remain to 
maintain transcript capping. Indeed, since studies in this thesis indicate that CE 
is in excess, the amount of CE remaining after knockdown may suffice for 
efficient gene expression in these circumstances. To explore this possibility, the 
cap status of C-MYC target genes could be tested in the presence of CE 
depletion, for example by immunoprecipitating target gene transcripts using an 
antibody which specifically recognises the 7-methyl-guanosine cap (Cole and 
Cowling, 2009a). Notably, CE has been described as an essential gene via 
genome-wide knockout screens using the CRISPR system in seven human cell 
lines (including HeLa cells), supporting the above hypothesis (Hart et al., 2015; 
Wang et al., 2014). However, it would be intriguing to attempt CRISPR knockout 
of CE in IMECs to determine whether CE is truly essential for mRNA synthesis 
and deregulated C-MYC-driven gene expression in this system. 
C-MYC overexpression causes a substantial increase in transcriptional 
load which may render CE availability more limiting. This might be the case for 
genes expressed above a particular level, or there could be a degree of 
specificity towards C-MYC target genes, for example if CE is preferentially 
recruited to C-MYC target genes. In favour of the latter, the effect of C-MYC 
deregulation on the specific genes analysed is inversely proportional to the 
effect of CE depletion. Importantly, the global impact of CE knockdown on 
transcripts in these cells should be investigated by RNA sequencing to 
determine whether this observation is true on a genome-wide scale. It is also 




regulating C-MYC expression. However, as shown above, the defect in C-MYC 
target gene expression in response to CE depletion is greater than that on C-
MYC protein expression, demonstrating that CE regulates C-MYC target genes 
somewhat independently of regulating C-MYC expression. In favour of this, at 
least in IMECs, CE does not significantly impact global levels of RNA pol II 
phosphorylation unlike C-MYC, consistent with CE impacting C-MYC target 
genes in other ways. In light of findings in this thesis, this could be due to CE 
being a co-factor in C-MYC-driven gene expression. However, the possibility 
remains that secondary effects of CE knockdown alter the expression of C-MYC 
target genes. To determine if CE is truly a transcriptional co-factor of C-MYC, 
CE could be fused to the C-MYC DBD (which alone is insufficient for C-MYC-
driven transcription) via a flexible linker region and its ability to transactivate C-
MYC target genes tested. This would determine whether localising CE in 
proximity of C-MYC target genes and paused RNA pol II was sufficient to 
induce partial activation of gene expression.  
It is worth noting that during the preparation of this thesis, the 
mechanism of C-MYC-mediated mRNA capping was investigated in an 
independent study, with a focus on specific C-MYC target genes involved in 
WNT signalling (Posternak et al., 2017). RNMT depletion but not CE depletion 
significantly reduced capping of these transcripts (as determined by N7-
methylguanosine cap precipitation) relative to total mRNA levels. From this the 
authors concluded that RNMT but not CE was rate-limiting in C-MYC-driven 
mRNA capping. However, mRNA levels were not reported; only capped mRNA 
relative to total mRNA levels. Therefore any alterations resulting from 




the relative contribution of CE and RNMT to net C-MYC target gene expression 
is still not known. 
Regardless of whether CE directly or indirectly regulates C-MYC target 
genes, the differential sensitivity of target genes depending on C-MYC levels 
means these observations are exciting from a therapeutic point of view, since 
an ideal chemotherapy for C-MYC-driven cancers should impact cancer cells 
with deregulated C-MYC but not healthy cells with basal C-MYC activity. 
Therefore, in the following chapter the effect of CE inhibition on cell 
transformation will be tested to determine whether CE should be considered as 





Chapter 5 : Deregulated C-MYC induces mRNA 
capping enzyme dependency 
5.1 Introduction 
 C-MYC overexpression or hyperactivation increases cell proliferation and 
invasiveness, and contributes to cell transformation. Deregulation of C-MYC 
occurs in many cancer types and in over 50% of all cancer cases. Despite 
extensive efforts to target C-MYC via a plethora of avenues, there are still no 
therapies available which do so. This is partially because C-MYC, being a 
transcription factor, has no active site which can be readily inhibited by small-
molecule compounds. Therefore, interest has been maintained in targeting 
enzymatic co-factors of C-MYC. Moreover, compensatory mechanisms upon 
inhibiting C-MYC have been reported (Donato et al., 2016; Fong et al., 2015; Lu 
et al., 2015; Rathert et al., 2015), suggesting that combination therapies may be 
required to treat C-MYC-dependent cancers. 
 In previous chapters it was shown that C-MYC promoted CE recruitment 
to transcription complexes. Moreover, C-MYC target genes were highly 
sensitive to CE depletion in the presence of supraphysiological C-MYC, but less 
so in the presence of basal C-MYC levels, indicating that cells with 
overexpressed C-MYC are particularly sensitive to CE inhibition. CE was also 
shown to regulate the expression of C-MYC itself. Therefore, inhibiting CE has 
the potential to diminish both C-MYC expression and C-MYC function. In this 




properties conferred by overexpressed C-MYC to determine if CE should be 






5.2.1 CE knockdown specifically reduces IMEC/C-MYC cell number 
 As previously mentioned, C-MYC increases cell proliferation. CE is 
required for C-MYC target gene expression in cells with overexpressed C-MYC 
but not in those retaining normal control of C-MYC. Therefore, it was tested if 
CE inhibition affected IMEC/vec and IMEC/C-MYC cell number over time, which 
is an indication of their proliferative potential. Cells were transfected with CE 
siRNA and counted after 72 hours (Figure 5.1 A). Consistent with previous 
studies, overexpression of C-MYC in IMECs increases cell number (Cowling et 
al., 2007), indicating that C-MYC increased proliferation in these cells. There 
was a 20% reduction in IMEC/C-MYC cell number in response to CE inhibition, 
but IMEC/vec cell number was unaffected. This suggests that CE is required for 
C-MYC-induced proliferation, but not basal IMEC proliferation, and 
demonstrates that C-MYC overexpression sensitises IMECs to CE depletion. In 
order to truly determine if proliferation is affected, cell doubling time should be 
measured. Note that although there is some variation in IMEC/C-MYC cell 
number after three days, the trend upon CE knockdown remains much the 
same between biological replicates (Figure 5.1 B). The variation may be due to 
cell passage number or a counting error when first seeding cells. 
 The standard IMEC culture medium is serum-free and is instead 
supplemented with specific growth factors (Table 2.2). However anchorage-
independent growth assays (see below) require further supplementation with 
5% fetal bovine serum (FBS). C-MYC increases IMEC cell number to a similar 



























Figure 5.1: CE depletion affects IMEC/C-MYC cell number. (A) 
1.1x105 IMEC/vec or IMEC/C-MYC were transfected with CE siRNA or 
a non-targeting control (ctrl) siRNA and counted after 72 hours. Error 
bars represent standard error of the mean, n=3. (B) As in (A) except 
cell number after 72 hours is depicted for three biological replicates 
(1-3). (C) as in (A) except cells were maintained in media containing 
FBS. Error bars represent standard error of the mean, n=3. (D) 
Change (Δ) in IMEC/vec and IMEC/C-MYC cell number following CE 
depletion (relative to ctrl siRNA) in the presence or absence of FBS. 
Error bars represent standard error of the mean, n=3. Significance 

































































































still induces IMEC proliferation in these culture conditions. The cell number of 
IMEC/vec maintained in FBS was not significantly affected by CE depletion, 
whereas IMEC/C-MYC cell number was reduced by 40%. This suggests that 
CE is required for C-MYC-induced proliferation, even more so when cells are 
cultured in FBS (Figure 5.1 D). C-MYC expression was not noticeably altered by 
culturing cells in FBS (Figure 5.2 B) although FBS noticeably increased IMEC 
proliferation (data not shown). It is likely that FBS stimulates growth factor 
signalling and IMEC proliferation, which could be coupled with increased global 
gene expression, and this may increase cellular dependency on CE. 
5.2.2 CE depletion upregulates CDK inhibitors 
 A possible explanation for the above observations is that CE depletion 
induces apoptosis in IMEC/C-MYC. However, there were no obvious 
morphological changes that would indicate this (Figure 5.2 A) and no floating 
cells were observed in petri dishes. Consistent with this, poly ADP ribose 
polymerase (PARP) cleavage, a common indicator of apoptosis, was not 
detected in cells cultured with or without FBS (Figure 5.2 B). Alternatively, cell 
cycle progression could be inhibited by CE depletion. The CDK inhibitors p21 
and p27 negatively regulate the G1-S transition in the cell cycle and are 
repressed by C-MYC (Gartel et al., 2001a; Seoane et al., 2002; Yang et al., 
2001). Therefore it was tested whether CE depletion altered p21 and p27 
expression. Although only p21 was reproducibly suppressed by C-MYC in 
IMECs, CE depletion in IMEC/C-MYC upregulated both p21 and p27 
expression, whereas that in IMEC/vec was unaffected (Figure 5.3 A and B). 
Accordingly, C-MYC does not always impact p27 expression (Vlach et al., 
1996). Regardless, this indicates that CE knockdown restrains C-MYC-driven  
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Figure 5.2: Apoptosis is not detected upon CE depletion. 
(A) Bright-field images of IMEC/vec and IMEC/C-MYC (maintained in 
media supplemented with FBS) transfected with CE siRNA or a non-
targeting control siRNA (ctrl). Micrographs were taken after 72 hours. 
Scale bar represents 100µm. (B) IMEC/vec and IMEC/C-MYC 
maintained with or without FBS were transfected with CE siRNA or a 
non-targeting control siRNA (-). Protein was extracted from cells after 
72 hours and analysed by Western blotting. # IMEC/C-MYC treated 
with 10μM MG132 for 24 hours as a positive control for apoptosis. 
Representative of two independent experiments.
vec / ctrl siRNA vec / CE siRNA





















Figure 5.3: CE depletion induces upregulation of CDK 
inhibitors in the presence of C-MYC overexpression. (A) 
IMEC/vec and IMEC/C-MYC were transfected with CE siRNA or a 
non-targeting control siRNA (-). Protein was extracted from cells 
after 72 hours and analysed by Western blotting. (B) Densitometry 
was performed using ImageJ software to quantify p21 and p27 
Western blot signal (normalised to actin) following transfection of 
siRNA as above. Similar results were obtained from IMECs 
cultured with and without FBS, therefore results from cells cultured 
in both conditions are pooled in this panel. Error bars represent 






















































cell cycle transit in IMECs. To confirm that CE depletion causes a cell cycle 
defect, DNA content and cell cycle phase should be analysed following CE 
knockdown by fluorescence-activated cell sorting (FACS). 
5.2.3 CE is required for C-MYC-induced transformation 
 In IMECs, overexpressed C-MYC induces anchorage-independent cell 
growth (Cowling et al., 2007). Non-transformed cells undergo anoikis (cell death 
resulting from extracellular matrix detachment) when not adhered to a solid 
surface, which is a strategy to eliminate misplaced cells and prevent metastasis. 
Conversely, transformed cells are often able to evade anoikis and proliferate 
without attachment, which can cause metastases in vivo. Therefore, the ability 
of cells to undergo anchorage-independent cell growth in vitro is indicative of 
their aggressiveness and metastatic potential in vivo (Mori et al., 2009). It was 
thus investigated whether CE inhibition affected C-MYC-driven anchorage-
independent growth. As alluded to above, IMECs maintained in FBS-
supplemented medium were used for this assay. IMEC/vec and IMEC/C-MYC 
were transfected with CE siRNA prior to being plated in media containing agar. 
This sets semi-solid and thus suspends cells in medium, allowing the ability of 
cells to form anchorage-independent colonies to be investigated. Similar to 
previous studies (Cowling and Cole, 2007a; Cowling et al., 2007), 50% of 
IMEC/C-MYC formed anchorage-independent colonies after 9-15 days (Figure 
5.4 A). CE depletion reduced the number of IMEC/C-MYC anchorage-
independent colonies by 30% (Figure 5.4 A), and the number of larger colonies 
over 50µm in diameter by 60% (Figure 5.4 B). Note that the variation in data for 
larger colonies lies mainly in the incidence of colony formation rather than 
































































Figure 5.4: CE is required for C-MYC-driven transformation in 
IMECs. (A) IMEC/vec and IMEC/C-MYC maintained with 5% FBS 
were transfected with CE siRNA or a non-targeting control (ctrl). 
After 72 hours cells were seeded in suspension. Colonies were 
scored using a graticule after 9-15 days. The percentage of cells 
that had formed colonies >20µm are reported. Error bars represent 
standard error of the mean, n=3. (B) As in (A) except the percentage 
of cells that formed colonies >50µm are reported. Error bars 
represent standard error of the mean, n=3. (C) as in (B) except each 
IMEC/C-MYC biological replicate shown. Significance calculated by 
Student’s t-test, ***p≤0.001; *p≤0.05. Figure continued overleaf.
CE siRNA
CE siRNA
CE siRNA: - +
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Figure 5.4 continued: IMECs with deregulated C-MYC require 
CE for cell transformation. (D) Bright-field images of IMEC/vec and 
IMEC/C-MYC transfected with CE siRNA or non-targeting control 
(ctrl) and suspended in soft agar. Micrographs were taken one month 
after cells were seeded in suspension. Scale bar represents 200µm. 
(E) as in (D) except scale bar represents 100µm.
vec / ctrl siRNA vec / CE siRNA
C-MYC / ctrl siRNA C-MYC / CE siRNA
D





colonies being counted different lengths of time after plating, cell passage 
number or slight difference in medium agar density. Representative 
micrographs were taken after one month (Figure 5.4 D and E). In summary, CE 
is important for C-MYC-driven anchorage-independent cell growth and thus C-
MYC-dependent cell transformation. 
5.2.4 High CE expression predicts poor breast cancer patient 
outcome 
 Since CE expression influenced C-MYC-induced transformation in 
IMECs, it was investigated if CE transcript levels correlated with breast cancer 
patient prognosis. The online ‘Kaplan Meier’ plotter was used which utilises 
microarray from patient tumour samples together with patient survival 
information (Gyorffy et al., 2010). For high/low gene expression cut-off 
selection, the programme tested each percentile of expression between the 
lower and upper quartiles, and the best performing threshold was selected 
(indicated on figures). Relapse-free survival (the time after successful treatment 
until relapse) and post-progression survival (survival time after a tumour 
spreads or worsens) were analysed (Figure 5.5 A). Expression of 
topoisomerase 2A (TOP2A), an established breast cancer prognostic marker, 
was investigated using the same search parameters as a positive control. There 
was little correlation between C-MYC expression and patient outcome. This is 
not necessarily surprising considering that C-MYC does not have to be 
transcriptionally upregulated to be oncogenic; changes in C-MYC protein levels 
and activity can be sufficient (Murphy et al., 2008; Wang et al., 2011). CE 
expression in breast tumours was inversely correlated with relapse-free survival 
(most so in those with the basal-like tumour subtype) and with post-progression 
survival (Figure 5.5 A). CE levels were analysed by the same means in ovarian,  
174
Figure 5.5: CE expression correlates with poor breast cancer 
patient outcome. (A) The online survival analysis tool ‘Kaplan Meier 
Plotter’ (www.kmplot.com) was used to determine how high (red) and 
low (black) expression of TOP2A, C-MYC and CE mRNA in tumours 
correlated with relapse-free or post-progression survival of patients 
with breast cancer in general or those with the basal sub-type of 
breast cancer. Sample sizes and cut-off values are indicated on 
graphs. Error bars represent the hazard ratio (95% confidence 






























































































































Figure 5.5 continued: CE expression correlates with poor breast 
cancer patient outcome. (B) as in (A) except high and low CE
mRNA levels in tumours is plotted against the relapse-free survival of 
patients with specific subtypes of triple-negative breast cancer. 
Sample sizes and cut-off values are indicated on graphs. Error bars 
represent the hazard ratio (95% confidence interval). Significance (p) 
was calculated using the log-rank test.


























































































































Figure 5.5 continued: CE expression correlates with poor breast 
cancer patient outcome. (C) Enriched GO terms for specific TNBC 
subtypes. Only the subtypes in which high CE expression predicts a 
poor outcome in are listed. Data from Lehmann et al. (2011). BL1, 
basal-like 1; BL2, basal-like 2; M, mesenchymal. See list of 




Enriched GO terms/canonical pathways
BL1
Cell cycle, DNA replication interactome, G2 pathway, 
RNA polymerase, ATR/BRCA pathway, G1 to S cell 
cycle.
BL2
EGF pathway, NGF pathway, MET pathway, WNT β-
catenin pathway, IGF1R pathway, 
Glycolysis/gluconeogenesis.
M
IGF/mTOR pathway, ECM pathway, Regulation of 
actin by RHO, WNT pathway, ALK pathway, TGFβ 
pathway.
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Figure 5.5 continued: CE expression correlates with poor breast 
cancer patient outcome. (D) as in (A) and (B) except analysis 
extended to include C-MYC co-factors and target genes. Figure 
depicts how high expression of these genes in tumours predicts breast 
cancer patient relapse-free survival or post-progression survival (PPS). 
A correlation between high expression of a gene and poor prognosis is 
illustrated by a p value of 0-0.1 (red/pink). A correlation between high 
expression of a gene and favourable prognosis is illustrated by a 
transformed p value of 0-(-0.1) (green). Relapse-free survival data is 
included for breast cancer patients (all), those with basal-like breast 
cancers, and those with specific subtypes of TNBC. Note that the C-
MYC co-factors listed are also transcriptionally regulated by C-MYC, 
and CCND1 can be induced or repressed by C-MYC in a system-
dependent manner. ACTB (beta-actin) was included in analyses as a 
randomly selected gene. Significance (p) was calculated using the log-
















Type C-MYC CE CDK7 TIP49 CDK9 NME1 FBL NCL ODC CCND1 p27 p21 ACTB TOP2A
All 0.003 0.000 0.000 0.000 0.100 0.000 0.001 0.000 0.140 -0.013 0.000 -0.031 0.000 0.000
Basal 0.260 0.008 0.000 0.000 0.016 0.002 0.003 0.210 0.000 0.070 0.360 -0.002 0.000 0.310
BL1 0.049 0.036 0.000 0.007 0.032 0.001 0.067 -0.017 0.380 0.010 0.048 -0.058 -0.097 0.068
BL2 -0.059 0.001 0.001 0.002 -0.018 0.058 0.098 0.032 -0.014 -0.074 0.360 0.120 0.000 -0.094
M -0.046 0.005 0.001 0.002 0.310 0.087 0.004 0.430 -0.001 0.210 0.260 0.300 -0.007 0.110
All 
(PPS)




lung and gastric cancers, but a correlation with survival was absent or less 
apparent (data not shown). The basal-like breast cancer tumour subtype  
(characterised by high expression of markers such as cytokeratins 5, 6 and 17) 
comprises 15-20% of all breast cancers and is biologically and clinically 
aggressive (Alluri and Newman, 2014). 80% of basal-like breast cancers are 
also classed as ‘triple-negative’, meaning they lack expression of oestrogen 
receptor (ER), progesterone receptor (PR) and human epidermal growth factor 
receptor 2 (HER2) thus rendering them resistant to available targeted therapies 
(Bertucci et al., 2012). Further analysis was conducted to analyse how CE 
expression correlated with survival in patients with different subtypes of triple-
negative breast cancer (TNBC) (ontology defined by gene expression profiling) 
(Lehmann et al., 2011). The ‘basal-like 1’, ‘basal-like 2’, and 
‘immunomodulatory’ TNBC subtypes are classified as basal-like. Intriguingly, 
CE expression was particularly anti-correlative with survival in patients with 
basal-like 1/2 and mesenchymal subtypes (Figure 5.5 B-C). Of interest, basal-
like 1 tumours exhibit overexpression of proliferation-associated genes including 
C-MYC (Lehmann et al., 2011). Furthermore, basal-like 2 tumours display gene 
expression signatures associated with growth factor signalling, and (as 
previously discussed) C-MYC is commonly activated by such signalling 
pathways. Mesenchymal tumour subtypes are enriched for gene expression 
signatures related to mTOR (mammalian target of rapamycin) which activates 
cap-dependent translation. This tumour subtype is also characterised by 
epithelial to mesenchymal transition (EMT) markers. EMT is associated with 
tumour invasiveness and metastasis, and is promoted by C-MYC in mammary 
epithelial cells (Cho et al., 2010; Cowling and Cole, 2007a). Consistent with C-




co-factors including CDK7 and TIP49, and C-MYC induced genes including 
NME1 and FBL, also correlated with poor patient prognosis (Figure 5.5D). 
Notably, the trend between patient survival and C-MYC co-factor expression 
was highly similar to that observed with CE expression (Figure 5.5D). A panel of 
breast cancer cell lines with defined molecular ontologies could be tested to 
determine whether these particular subtypes are responsive to CE inhibition. 
Moreover, it would be of interest to determine if CE expression correlates with 
survival in patients with high-C-MYC expressing tumours, and in cancers known 
to driven by MYC family members such as Burkitt’s lymphoma and 
neuroblastoma. 
Of note, breast cancers in general to not exhibit elevated CE expression 
(Shaul et al., 2016); perhaps breast cancer cells that inadvertently have 
elevated CE have a survival advantage. On the other hand, some B cell 
lymphoma cancer cell lines (including Burkitt’s lymphomas) which are known to 
be driven by C-MYC (Bahram et al., 2000; Bhatia et al., 1993; Cai et al., 2015; 
Li et al., 2003b; Nguyen et al., 2017), and lymphoma primary tumours, have 
exhibited heightened CE expression (Shaul et al., 2016). This suggests that 
elevated CE activity may be important for C-MYC’s oncogenicity in B cells, and 
this warrants further investigation. 
5.2.5 Examining cellular effects of CE knockdown in HeLa cells 
  In the previous chapter it was shown that C-MYC target genes were 
sensitive to CE depletion in HeLa cells with overexpressed C-MYC, but 
suppression of C-MYC desensitised target genes to CE inhibition. To determine 




(as in IMECs), HeLa cells were transfected with combinations of C-MYC siRNA 
and CE siRNA as before and cells were counted after 72 hours. Unexpectedly, 
C-MYC knockdown, CE knockdown and C-MYC/CE double knockdown had no 
effect on HeLa cell number (Figure 5.6 A) suggesting that this did not impact 
cell proliferation under these conditions. This is contradictory to prior studies 
which showed that C-MYC siRNA reduced proliferation of HeLa cells after 72 
hours (Cappellen et al., 2007) and CE siRNA induced HeLa cell apoptosis after 
48 hours (Chu and Shatkin, 2008). Potential causes of this discrepancy include 
the use of different cell passages or different knockdown efficiencies. Perhaps 
C-MYC-dependent cells are particularly dependent on CE, and those not 
dependent on C-MYC are less so. Alternatively, C-MYC may promote HeLa cell 
proliferation without causing net changes in cell number, since overexpressed 
C-MYC in some systems has paradoxical roles in promoting both cell growth 
and apoptosis (Murphy et al., 2008; Tansey, 2014). In favour of this, cleaved 
PARP was detected in control transfected cells more so than in other conditions 
(Figure 5.6 B). Additionally, less floating cells were observed in petri dishes 
after transfection of CE siRNA or C-MYC siRNA compared to control 
transfected cells (data not shown), suggesting that HeLa cells may be more 
primed for apoptosis in the presence of high C-MYC or CE levels. To test this 
hypothesis, additional markers of apoptosis should be analysed. For example, 
Annexin V staining could be performed to analyse cells undergoing apoptosis, 
and the nucleic acid stain SYTOX green could be used which only permeates 
dead cells. 
Interestingly, the colour of culture medium was noticeably less 
yellow/orange upon CE and C-MYC knockdown compared to control cells (data 
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Figure 5.6: Investigating how CE and C-MYC depletion affects 
HeLa cells. (A) HeLa cells were transfected with combinations of 
CE siRNA, C-MYC siRNA and non-targeting control siRNA (-) 
before being counted after 72 hours. Error bars represent standard 
error of the mean, n=5. (B) Cells were transfected with siRNA as in 
(A) and analysed by Western blotting. Representative of three 
independent experiments. Figure continued overleaf.
A
CE siRNA: - + - +
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Figure 5.6 continued: Investigating how CE and C-MYC 
depletion affects HeLa cells. (C) Bright-field images of HeLa cells 
transfected with CE siRNA or a non-targeting control siRNA (ctrl), 
taken at the indicated magnifications. Micrographs were taken 72 


























Figure 5.6 continued: Investigating how CE and C-MYC 
depletion affects HeLa cells. (D) As in (C) except taken at 400X 
magnification. White arrow=cell protrusion; white asterix=large, flat 
cell; black arrow=refractile cell; black asterix=multi-nucleic cell. Scale 
bar represents 50µm. Figure continued overleaf.
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Figure 5.6 continued: Investigating how CE and C-MYC depletion 
affects HeLa cells. (E) Bright-field images of HeLa cells transfected 
with C-MYC siRNA or a non-targeting control siRNA (ctrl) taken at the 
indicated magnifications. Micrographs were taken 60 hours post-




























Figure 5.6 continued: Investigating how CE and C-MYC depletion 
affects HeLa cells. (F) As in (E) except taken at 400X magnification. 
White arrow=cell protrusion; white asterix=large, flat cell; black 




 not shown) despite no alteration in cell number, indicating that control cells 
were more metabolically active. C-MYC is known to alter cell metabolism in 
many ways, including enhancing cell glycolysis which helps cancer cells cope 
with increased energy demands (Miller et al., 2012). Therefore, for example, it 
would be interesting to determine how CE depletion influenced HeLa cell 
glycolysis rates. 
Notably, CE depletion in HeLa cells caused morphological changes 
(Figure 5.6 C and D). Cells primarily became elongated and refractile, with a 
smaller population of cells becoming hypertrophic, flat and multinucleated. Both 
of these phenotypes are hallmarks of senescence. It would therefore be 
interesting to determine if CE depletion causes reduced cell proliferation over a 
longer time-course, and to investigate senescence markers such as β-
galactosidase activity. C-MYC knockdown also caused morphological changes 
associated with senescence, although there was a greater proportion of flat 
hypertrophic cells (Figure 5.6 E and F). This phenotype has also been observed 
in other cell types upon C-MYC depletion (Florea et al., 2013; Zhuang et al., 
2008) and tumour regression via C-MYC inhibition is dependent on senescence 
in certain mouse models (Wu et al., 2007). Additionally, CE and C-MYC 
knockdowns caused an apparent decrease in the formation of cell protrusions 
(Figure 5.6 C-F). Therefore, it could be investigated if CE knockdown reduced 
cell migration or invasion of HeLa cells. There are C-MYC target genes involved 
in senescence and cell motility (Gartel et al., 2001a; Staller et al., 2001b; Wang 
et al., 2013b; Yan et al., 2009), thus it would be of interest to determine if CE 
knockdown alters the expression of these genes. Indeed, in this chapter it was 




and p27 (Figures 5.3 A and B), which are each involved in distinct senescence 
pathways (Flores et al., 2014). 
5.2.6 Comparing CE depletion and CDK7 inhibition  
 THZ1 is a specific inhibitor of CDK7, the kinase responsible for 
phosphorylating RNA pol II CTD at position 5. THZ1 covalently binds to a 
cysteine residue outside of the kinase domain, allosterically causing irreversible 
deactivation (Kwiatkowski et al., 2014). In vitro, this compound greatly perturbs 
co-transcriptional mRNA capping and causes RNA pol II pausing defects 
(Nilson et al., 2015). Furthermore, THZ1 treatment induces apoptosis in many 
cancer cell lines and in mouse models of triple negative breast cancer, 
neuroblastoma and small cell lung cancer driven by MYC family members 
(Chipumuro et al., 2014; Christensen et al., 2014; Kwiatkowski et al., 2014; 
Nilson et al., 2015). Taking into account observations in this thesis, it is possible 
that mRNA capping inhibition contributes to THZ1 efficacy. It was investigated 
whether THZ1 treatment caused a similar cellular effect to CE inhibition. A 
fluorometric assay was used which measures the metabolic activity of cells, 
which be used as an approximation of cell viability. Since the cell lines used 
here proliferate at different rates, conditions were optimised (Figure 5.7). In 
previous experiments, cells were counted 72 hours post-CE siRNA transfection. 
However, a reduction in CE protein levels is not observed until 36-48 hours 
post-transfection. This means that cells were counted 24-36 hours after CE was 
depleted. THZ1 abolishes cellular S5p RNA pol II rapidly; after ~2 hours 
(Kwiatkowski et al., 2014), therefore fluorescence was measured 24 hours post-
THZ1 treatment to compare CDK7 inhibition with CE depletion. HeLa cells, 
which were not sensitive to CE depletion, were somewhat sensitive to THZ1  
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Figure 5.7: Optimising 96 well viability assays. IMEC/vec,
IMEC/C-MYC and HeLa cells were seeded in 96 well plates with the 
indicated numbers of cells in each well. CellTiter Blue dye (containing 
resazurin) was added 0-4 days after plating. Metabolically active cells 
catalyse resazurin to resorufin which emits fluorescence at 590nm, 



































































































(Figure 5.8 A) with an IC50 of ~390nM, similar to HeLa cells treated with THZ1 
for 72 hours in a previous study (IC50 357nM) (Kwiatkowski et al., 2014). It 
should be noted that HeLa cells only ranked 671-most sensitive to THZ1 out of 
1153 cell lines tested. In contrast, both IMEC/vec and IMEC/C-MYC were 
relatively insensitive to THZ1 when cultured with or without FBS, with the 
highest concentrations only causing a 40-50% decrease in cell viability (Figures 
5.8 A and B). Therefore, C-MYC sensitises IMECs to CE depletion but not to 
CDK7 inhibition. Perhaps more drastic changes in IMEC viability would be 
observed after a longer treatment with THZ1. To determine if C-MYC 
knockdown desensitised HeLa cells to CDK7 inhibition, cells were transfected 
with C-MYC siRNA and treated with THZ1 after 72 hours. Preliminary results 
indicate that C-MYC knockdown does not drastically alter HeLa cell sensitivity 
to CDK7 inhibition (Figure 5.8 C). Therefore, HeLa cells are not sensitive to CE 
or C-MYC inhibition, but are sensitive to CDK7 inhibition in a C-MYC-
independent manner. 
 IMECs were sensitive to CE depletion - but not CDK7 inhibition – in a C-
MYC-dependent manner. Therefore, it was investigated if CE knockdown and 
THZ1 differentially affected expression of C-MYC and the C-MYC target gene 
NCL. S5p RNA pol II, S2p RNA pol II and endogenous C-MYC levels were 
reduced by THZ1 treatment in a dose-dependent manner (Figure 5.9), 
consistent with previous studies (Christensen et al., 2014; Kwiatkowski et al., 
2014). NCL expression was elevated in IMEC/C-MYC cells, but was not 
depleted by THZ1 treatment (Figure 5.9). Reproducibly, the expression of 
exogenous C-MYC in IMEC/C-MYC was diminished with 75nM THZ1 but not 
with 375nM THZ1 (Figure 5.9). One potential explanation of the latter is that  
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Figure 5.8: Modulating C-MYC in IMECs and HeLa cells has no 
effect on sensitivity to THZ1. (A) IMEC/vec, IMEC/C-MYC and 
HeLa cells were treated with the indicated concentrations of THZ1 or 
DMSO for 24 hours before cell viability was measured using Cell Titer
Blue. 9000 cells seeded per well. Error bars represent standard error 
of the mean, n=3. (B) IMEC/vec and IMEC/C-MYC maintained in FBS 
were treated with the indicated concentrations of THZ1 or DMSO for 
24 hours before cell viability was measured as above. 6000 cells 
seeded per well. Average of two independent experiments. (C) HeLa 
cells were transfected with 25nM C-MYC siRNA or non targeting 
control (ctrl). 5300 cells seeded per well. After 72 hours, cells were 
treated with the indicated concentrations of THZ1 or DMSO for 24 
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Figure 5.9: Investigating IMEC response to THZ1. IMEC/vec and 
IMEC/C-MYC were treated with DMSO (-) or the indicated 
concentrations of THZ1 for 24 hours before protein was extracted 
and analysed by Western blotting. 3x105 cells were seeded per 
6cm plate. # IMECs treated with 10μM MG132 for 24 hours as a 







RNA pol II is titrated away from endogenous promoters when global 
transcription is inhibited at higher THZ1 concentrations, resulting in more RNA 
pol II availability. Additionally, THZ1 treatment did not induce PARP cleavage 
(Figure 5.9), suggesting that IMECs were not undergoing apoptosis. Taken 
together, CDK7 inhibition and CE inhibition have distinct effects in IMECs since 






 In this chapter it was shown that C-MYC-driven cells were sensitive to 
CE depletion, but not normal cells with basal C-MYC levels nor cells which are 
not driven by C-MYC. IMECs with deregulated C-MYC expression – and not 
normal IMECs – exhibited upregulation of negative regulators of the cell cycle 
p21 and p27 in response to CE depletion, consistent with CE being required for 
C-MYC-driven cell cycle progression. Importantly, CE depletion caused a 
significant reduction in anchorage-independent cell growth (a characteristic of 
malignant transformation) in IMECs with deregulated C-MYC, and breast cancer 
patients whose tumours express higher levels of CE have an unfavourable 
prognosis. Additionally, CE inhibition had distinct cellular effects to CDK7 
inhibition, and could have more specificity towards the C-MYC response. 
Collectively, these data strongly suggest that targeting mRNA capping should 
be investigated as a potential strategy to selectively intervene with C-MYC-
driven cancers. 
5.3.2 C-MYC deregulation sensitises cells to CE inhibition 
The finding that deregulated C-MYC induced CE dependency in IMECs 
is consistent with the differential dependency of C-MYC target genes on CE. 
Proliferation and anchorage-independent cell growth are indicative of cell fitness 
and the transforming capability of cells, which are controlled by a plethora of 
genes not necessarily regulated by C-MYC. Therefore, since there was a 
correlation between C-MYC target gene expression and IMEC transformation 




the effect of CE depletion in HeLa cells was not as drastic, changes in C-MYC 
target gene expression may confer the observed changes in cell morphology. 
Since C-MYC is deregulated in HeLa cells but C-MYC inhibition had no effect 
on HeLa cell number, it is possible that C-MYC was important for initial tumour 
development, but with the occurrence of further mutations was no longer 
required. In which case, perhaps sensitivity to CE inhibition is selective for C-
MYC-dependent cancer cells. Alternatively, as previously suggested, 
proliferation changes may be masked by concomitant C-MYC-induced 
proliferation and apoptosis. 
It is highly likely that cellular CE dependency varies depending on 
biological context. Ideally, CE knockdown should be performed in a panel of 
cancer cell lines with differential dependencies on C-MYC to comprehensively 
investigate if there is a correlation between C-MYC and CE dependency. 
Moreover, the dogma is that an oncogene and tumour-suppressor gene both be 
deregulated in order for oncogenesis to occur. Therefore, it would be interesting 
to determine if deactivation of a tumour suppressor gene (e.g. an anti-apoptotic 
gene) augments the sensitivity of IMECs to CE inhibition. 
It is worth noting that soft agar transformation assays ascertain the ability 
of cells to form anchorage-independent colonies when CE is already depleted. 
Therefore, in this experimental arrangement, the importance of CE in early 
malignant transformation is tested. To test whether CE could be a valid 
molecular target for cancer therapies, ideally CE should be withdrawn after 
colony formation to mimic treating a tumour. It is unlikely that siRNA would be 
able to transfect colonies suspended in soft agar, therefore perhaps using cells 




colony formation could determine whether CE inhibition causes colony 
regression.  
5.3.3 Potential involvement of CE in specific breast cancers 
CE transcript levels in basal-like breast cancer/TNBC tumours inversely 
correlated with patient survival. If high CE expression has a role in sustaining 
basal-like/TNBC tumours, this is of particular interest since these cancers tend 
to be unresponsive to available therapies, demonstrating an unmet need for 
new molecular targets. Curiously, C-MYC is also often deregulated in basal-
like/TNBCs, and a C-MYC target gene signature is apparent in basal/TNBC 
subtypes but not others (Alles et al., 2009; Chandriani et al., 2009; Gatza et al., 
2010; Horiuchi et al., 2012). Spliceosome inhibition in C-MYC-dependent pre-
clinical models of TNBC was shown to diminish tumourigenesis and metastasis 
(Hsu et al., 2015), highlighting that these cancers are particularly dependent on 
mRNA processing. Basal-like breast cancers/TNBCs are often associated with 
perturbation of the breast cancer 1 (BRCA1) tumour suppressor pathway 
involved in DNA repair, transcription, cell cycle regulation and apoptosis (Deng, 
2006; Lakhani et al., 2002). Not surprisingly, there are reports of BRCA1 and C-
MYC co-deregulation in these contexts (Adem et al., 2004; Grushko et al., 
2004). In fact, their protein products physically associate with each other and 
BRCA1 negatively modulates C-MYC transcriptional activity (Li et al., 2002; 
Wang et al., 1998). Furthermore, BRCA1 perturbs CDK7 activity and thus 
downmodulates RNA pol II CTD S5 phosphorylation (Moisan et al., 2004), 
therefore BRCA1 has the potential to control CE recruitment. It would therefore 
be interesting to determine if disruption of the BRCA1 pathway increases the 




Moreover, the effect of CE depletion could be compared in cancer cell lines with 
mutant or WT BRCA1. 
Additionally, CE transcript levels in mesenchymal breast tumours was 
anti-correlative with patient survival. C-MYC is known to promote EMT in 
mammary epithelial cells (Cho et al., 2010; Cowling and Cole, 2007a) and p21 
elevation has been shown to reverse C-MYC-induced EMT (Liu et al., 2009). It 
would thus be interesting to analyse if CE knockdown (via p21 elevation or 
otherwise) represses C-MYC-mediated EMT. 
It should be noted that overexpressing CE in the cells analysed here had 
no effect on proliferation (data not shown) suggesting that it is not a classical 
oncoprotein. However, cells may develop a dependency on CE upon 
transformation, which could provide a survival advantage to tumour cells which 
happen to have elevated levels of CE. This phenomenon is termed ‘non-
oncogene addiction’ (Nagel et al., 2016). 
5.3.4 CE inhibition and CDK7 inhibition elicit different cellular 
responses 
IMECs exhibited a C-MYC-dependent response to CE depletion, but not 
THZ1-mediated CDK7 inhibition. Although THZ1 was shown to decrease mRNA 
capping in vitro (Nilson et al., 2015), the distinct cellular response to CE 
depletion indicates that this is not THZ1’s primary mode of action in these cells. 
There are additional effects of THZ1 treatment in cells such as S5p and S2p 
RNA pol II depletion (not consistently observed in IMECs upon CE knockdown), 




2014; Nilson et al., 2015). This likely results in additional transcriptional events 
being perturbed and causing a different cellular response than CE knockdown. 
Deregulation of MYC family members was thought to confer sensitivity of 
neuroblastoma, small cell lung cancer and triple-negative breast cancer cells 
and mouse models to CDK7 inhibition in previous studies, which is somewhat 
contrary to cell lines used in this study. However, this was proposed to be due 
to MYC genes being regulated by super-enhancers: cis-acting genomic regions 
with hubs of transcription machinery to promote expression of particular genes, 
rendering MYC and other super-enhancer associated oncogenes particularly 
sensitive to CDK7 inhibition. Since these genes acquire super-enhancer 
regulation during malignant transformation, cellular ‘addiction’ to super-
enhancer-driven transcription may also require additional oncogenic events 
such as deregulation of other transcription factors or chromosomal 
rearrangements. Additionally, it should be noted that exogenous C-MYC in 
IMEC/C-MYC is not expressed from its endogenous location in genome and 
therefore is not regulated by its endogenous regulatory regions. This might 
explain why deregulated C-MYC expression in IMEC/C-MYC is less robustly 
perturbed by THZ1 compared to endogenous C-MYC in IMEC/vec. 
Nonetheless, these results are consistent with CE depletion and THZ1 acting 
via distinct mechanisms. For proper comparison of CE depletion and CDK7 
inhibition efficacy in C-MYC-driven transformation, C-MYC-dependent cell lines 






Chapter 6 : Final discussion and future work 
6.1 Summary 
C-MYC is a transcription factor and a driver of diverse cancer types. 
Amongst its many functions, C-MYC upregulates formation of the mRNA cap, 
which is important for transcript stability, processing and translation. mRNA 
capping is catalysed by two enzymes: CE which catalyses addition of the 5’ 
inverted guanosine moiety; and RNMT-RAM which methylates the guanosine 
group. Previous studies have focussed on the role of RNMT-RAM in mRNA 
capping regulation by C-MYC. Therefore, in this thesis the involvement of CE – 
the enzyme which initiates cap synthesis – was investigated. It was confirmed 
that CE interacted with the RNA pol II CTD phosphorylated at S5 residues and 
that C-MYC increased this phosphorylation event in cells. C-MYC regulated CE 
recruitment to S5p RNA pol II and SPT5 complexes; likely in a CDK7-
dependent manner. Moreover, on chromatin, C-MYC mediated CE recruitment 
to its target genes. The expression of C-MYC target genes, and also C-MYC 
itself, were highly dependent on CE. However, upon CE depletion, the change 
in C-MYC target genes exceeded the change in C-MYC expression, suggesting 
these two modules were partially uncoupled. This highlights a potential feed-
forward loop (Figure 6.1). A role for CE in the regulation of RNA pol II 
transcription was also identified, although whether this impacts C-MYC function 
is not yet clear. Surprisingly, in cells with basal C-MYC levels or cells insensitive 
to C-MYC, the vast majority of cellular CE was superfluous for cell viability. 
However, CE was required for in vitro neoplastic growth driven by deregulated 
C-MYC. CE depletion upregulated negative regulators of the cell cycle 










Figure 6.1: The interplay between C-MYC and CE. A bidirectional 
relationship exists between C-MYC and CE, in which C-MYC 
regulates CE recruitment and CE regulates C-MYC expression. 
Together, CE and C-MYC regulate C-MYC target genes and C-MYC-
driven transformation. It is also possible that CE regulates C-MYC 




required for C-MYC-driven cell cycle transit. Upon comparison with CDK7 
inhibition (which inhibits both transcription and mRNA capping), CE depletion 
presented a distinct cellular response and exhibited more specificity towards 
cells with deregulated C-MYC. Finally, in specific subtypes of breast cancer 
which commonly carry deregulated C-MYC, CE expression correlated with poor 
prognosis. Taken together, a direct mechanism by which C-MYC mediates 
mRNA cap formation was discovered, illustrating that C-MYC upregulates 
mRNA capping by synchronising multiple activities. Moreover, CE was identified 
as a potential therapeutic target to selectively intervene with C-MYC-driven 














6.2.1 CE regulation in C-MYC-dependent gene expression 
Studies in this thesis have revealed that C-MYC regulates CE, 
demonstrating that C-MYC synergises both mRNA guanylylation and cap 
guanosine methylation to drive mRNA capping via several mechanisms (Figure 
6.2). In summary, C-MYC increases the expression of CAK module components 
within TFIIH (including CDK7) and increases its recruitment to transcription start 
sites (Cowling and Cole, 2007b; Posternak et al., 2017). This promotes RNA pol 
II CTD S5 phosphorylation, which directly recruits CE and (through an 
uncharacterised mechanism) also recruits RNMT-RAM (Aregger and Cowling, 
2013; Cowling and Cole, 2007b; Ho et al., 1998; Lombardi et al., 2016; 
Posternak et al., 2017). Binding of S5p RNA pol II to CE stimulates CE activity, 
and C-MYC indirectly promotes RNMT-RAM activity via regulating SAHH 
expression (Fernandez-Sanchez et al., 2009; Ho and Shuman, 1999; Lombardi 
et al., 2016; Moteki and Price, 2002). From a wider perspective, this contributes 
to the multiple mechanisms by which C-MYC promotes gene expression. C-
MYC increases the transcription of thousands of genes (Dang, 2014; Littlewood 
et al., 2012), and simultaneous upregulation of transcript capping will stabilise 
transcripts during transcription; increasing the likelihood that they will be 
processed properly, exported into the cytoplasm and translated. Concurrently, 
C-MYC transcriptionally upregulates components of the eIF4F complex 
(including the cap-binding protein eIF4E) (Lin et al., 2008; Lin et al., 2012a) 
thereby enhancing translation via recruiting capped mRNA molecules to the 
ribosome (Figure 6.2). C-MYC also enhances translation via increasing tRNA 





Figure 6.2: C-MYC co-ordinates several aspects of cap-
dependent translation. C-MYC promotes the expression and 
recruitment of TFIIH subunits, which via the CDK7 kinase module 
regulates the recruitment of CE and RNMT to transcription start sites 
(Cowling and Cole, 2007b; Posternak et al., 2017). CDK7-dependent 
phosphorylation of the RNA pol II CTD also stimulates CE activity 
(Ho and Shuman, 1999; Moteki and Price, 2002). C-MYC 
upregulates SAHH, which promotes RNMT activity (Fernandez-
Sanchez et al., 2009). Additionally, C-MYC induces expression of
eIF4F complex components including eIF4E, enhancing cap-
dependent translation (Lin et al., 2008; Lin et al., 2012a). C-MYC 
also promotes translation in general by modulating tRNA production 
and ribosome biogenesis (not shown, van Riggelen et al., 2010b). 


















(Gomez-Roman et al., 2006; Ji et al., 2011; van Riggelen et al., 2010b). The 
model emerges that C-MYC promotes concomitant transcription, mRNA 
capping and translation of target genes to encourage rapid transduction of 
genetic information and protein synthesis. The relative importance of each node 
in C-MYC function is not clear, but this could vary in a cell- and context- 
dependant manner to govern differential gene expression. 
6.2.2 CE specificity 
The global specificity of CE in human cells has not yet been investigated. 
Based on studies in this thesis, it can be hypothesised that CE inhibition has a 
biased effect on C-MYC-induced genes and thus reverses the effect of C-MYC 
deregulation without causing adverse cellular effects. Observations alluding to 
this include the negative correlation between the effect of C-MYC 
overexpression and CE depletion on C-MYC target genes. Of note, C-MYC-
repressed genes are either unaffected or upregulated in response to CE 
depletion, arguing against CE activity being non-specific. Moreover, CE 
depletion reverses indicators of cell transformation in the presence of C-MYC 
deregulation to levels comparable to that in cells without C-MYC deregulation. It 
is worth noting that E2F1 – and probably other transcription factors – enhance 
CDK7 activity (Aregger and Cowling, 2012). Therefore, other transcription 
factors might depend on CE to drive their transcriptional programmes. In 
previous studies, partial inhibition of CDK7 did not impact gene expression 
globally but inhibited capping and expression of specific transcripts (Kanin et al., 
2007; Kwiatkowski et al., 2014; Viladevall et al., 2009), illustrating that CDK7-
dependent capping has the potential to be regulated in a gene-specific manner. 




MYC driving CDK7-dependent CE recruitment. During basal conditions, these 
transcripts may not be capped; instead undergoing internal ribosome entry site 
(IRES)-dependent/cap-independent translation (Komar and Hatzoglou, 2011).  
Alternatively, the differential dependency of certain genes on CE may be 
mediated indirectly by heightened transcriptional or translational burden, such 
as that upon C-MYC deregulation (discussed below). Global gene expression 
analyses are required to better understand CE specificity. 
6.2.3 Selective tolerance to CE depletion 
As determined by genetic knockout, yeast capping enzymes are 
essential for viability (Mao et al., 1995; Schwer and Shuman, 1994; Shibagaki et 
al., 1992; Shuman et al., 1994; Tsukamoto et al., 1997; Wang and Shuman, 
1997). Genome-wide knockout screens using the CRISPR system in seven 
human cell lines (including HeLa cells) across two different studies have also 
identified CE and RNMT as essential genes (Hart et al., 2015; Wang et al., 
2014). The observation in this thesis that CE is somewhat dispensable in 
certain cells was therefore unexpected. There are many possible explanations 
for this observation. One likely interpretation, due to CE being an essential 
gene, is that CE is in excess and therefore not limiting in these cells. For 
example, in conditions with low basal levels of transcription, perhaps a small 
fraction of cellular CE suffices to maintain mRNA capping. In cells with 
deregulated C-MYC, it is likely that CE is required in abundance but is highly 
used and therefore limiting; posing a burden upon the cell. Since mRNA 
capping is important for splicing (Inoue et al., 1989; Lewis and Izaurflde, 1997), 
another factor contributing to tolerance of CE inhibition could be mRNA 




depletion, thereby preventing synthesis of potentially toxic proteins (Egecioglu 
and Chanfreau, 2011; Kawashima et al., 2009). Global elevation of transcription 
could saturate these mechanisms. Consistently, in another study spliceosome 
inhibition is well tolerated in normal cells with basal levels of transcription, 
whereas it is not tolerated in the same cells upon C-MYC activation (Hsu et al., 
2015). There are many other cellular stresses emerging from C-MYC 
deregulation which could indirectly heighten cell sensitivity to CE depletion 
(Nagel et al., 2016). 
 Alternatively, perhaps cells can compensate in ways which we do not 
yet understand. For example, IRES-dependent translation might compensate 
for lack of cap-dependent translation in certain situations, and this could require 
factors which are limiting in cells with deregulated C-MYC. Indeed, previous 
studies have reported a switch from cap-dependent to cap-independent 
translation in conditions of cellular stress (Braunstein et al., 2007; Komar and 
Hatzoglou, 2005). Interestingly, C-MYC overexpression in mouse B 
lymphocytes increases global cap-dependent translation while preventing the 
switch to cap-independent translation in mitosis, which is crucial for translation 
of specific IRES-containing mRNAs important in mitotic progression (Barna et 
al., 2008). This would be consistent with C-MYC-overexpressing cells being 
deficient in IRES-dependent translation and therefore more dependent on 
mRNA capping and cap-dependent translation. Further investigation is required 





6.2.4 CE as a potential therapeutic target  
A therapeutic agent must display a sufficiently large therapeutic window. 
Identification of synthetic lethal genetic interactions with oncogenes provides a 
rational route to identify such therapies (Cermelli et al., 2014; Nijman, 2011). 
Synthetic lethality occurs when perturbation of two genes causes loss of cell 
fitness, whereas one perturbation is tolerated by the cell. These studies indicate 
that CE inhibition is synthetic lethal (or synthetic sick) with deregulated C-MYC 
(Figure 6.3). These observations are complementary to the finding that 
inhibition of cap methylation is synthetic lethal with C-MYC deregulation 
(Fernandez-Sanchez et al., 2009). Moreover, spliceosome inhibition was 
previously shown to be synthetic lethal with C-MYC activation (Hsu et al., 2015). 
It thus emerges that several steps of co-transcriptional mRNA processing are 
specifically important for C-MYC-dependent transformation, which is consistent 
with C-MYC widely increasing cellular transcriptional and translational load. 
Interestingly, in another study CE inhibition was shown to be synthetic lethal 
with tuberous sclerosis 1 (TSC1) or TSC2 deletion (Housden et al., 2015). 
Defective TSC1/2 regulation is associated with various cancers (Mieulet and 
Lamb, 2010). TSC1/2 are upstream negative regulators of mTOR complex 1 
(mTORC1) which activates eIF4E and thus cap-dependent translation (Showkat 
et al., 2014). There are reports of C-MYC functionally antagonising and 
transcriptionally downregulating TSC2 (Li et al., 2003b; Ravitz et al., 2007; 
Rosner et al., 2003; Tapon et al., 2001), suggesting that C-MYC and TSC1/2 
exist within the same pathway. Since C-MYC and TSC1/2 both regulate eIF4E 
(positively and negatively, respectively), perhaps aberrant control of the eIF4E – 
cap-dependent translation axis sensitises cells to CE inhibition (Figure 6.3). 


















Figure 6.3: Development of CE dependence. Known and 
potential mechanisms by which cells develop CE dependence are 
shown (denoted by solid and dashed arrows, respectively). In this 
thesis, C-MYC deregulation was shown to confer cellular 
dependence on CE. In another study, TSC1 or TSC2 deletion 
induced CE dependency (Housden et al., 2015). Potential factors 
contributing to CE dependence include global elevation of 
transcription (e.g. by C-MYC or other transcription factors; TFx), 
global elevation of translation (e.g. via C-MYC upregulating eIF4E 
and ribosome biogenesis), or activation of other stress pathways 









lethal with C-MYC dysregulation (Lin et al., 2012a). In such a scenario, cells 
may be addicted to eIF4E cap-dependent translation and inhibition of CE could 
thus curb eIF4E-dependent protein synthesis. 
The emergence of personalised medicine in cancer treatment, in which a 
therapy is chosen based on the tumour genome/transcriptome, has had some 
positive impact but tumour relapse is a problem (Ashley, 2016). Cancer is a 
heterogeneous cellular disease, therefore targeting a specific gene to attain 
complete and sustained tumour submission is challenging. Increased 
transcription and translation are common features of cancer cells (Bhagwat and 
Vakoc, 2015; Bhat et al., 2015; Bywater et al., 2013). Targeting a process like 
mRNA capping – which has the potential to interfere with both of these 
processes – could thus exploit the transcriptional/translational burden on cancer 
cells irrespective of their oncogenic aberrations (Figure 6.3). Oncogene 
transcripts tend to be intrinsically unstable compared to the average human 
mRNA, which has a half-life of 10 hours (Wilusz et al., 2001; Yang et al., 2003). 
For example, transcripts of C-MYC, C-FOS and C-JUN oncogenes all have half-
lives of 10-30 minutes (Bertani et al., 1989; Dani et al., 1984; Shyu et al., 1989). 
Therefore, uncapped oncogenic mRNAs might be more susceptible to 
degradation upon CE inhibition. Furthermore, a mechanism by which 
oncogenes (including C-MYC) can become deregulated is via stabilisation of 
their transcripts (Khabar, 2017; Weidensdorfer et al., 2009), which has the 
potential to be counteracted by CE inhibition. Another issue arising from the use 
of targeted cancer therapies is that cells can adapt in response to drug 
treatments via mutation of the target protein (Zahreddine and Borden, 2013). 




tumour cells (Forbes et al., 2017) is a favourable strategy. Globally defining the 
responsiveness of the transcriptome to CE inhibition in transformed and normal 
cells would help elucidate the mechanisms of CE dependency and indicate 
whether targeting CE/mRNA capping is a viable anti-cancer strategy. 
Prior to these studies, CE regulation has received minimal attention. On 
the other hand, there have been some investigations of RNMT-RAM in the 
context of cancer cells, and these studies provide further rationale for targeting 
mRNA capping as a therapeutic strategy. As previously discussed, RNMT-RAM 
is regulated by C-MYC and E2F1 oncogenic transcription factors (Cole and 
Cowling, 2009b; Dunn and Cowling, 2015). Furthermore, ectopic RNMT 
overexpression induces cell transformation; on its own but also in collaboration 
with C-MYC and RAS oncogenes (Cowling, 2009). RNMT-RAM also regulates 
the expression of CCND1 and C-MYC oncogenes (Cowling, 2009; Dunn et al., 
2016). Although the global impact of RNMT-RAM on cancer cell gene 
expression is not yet known, analyses in ESCs highlighted that RAM influences 
adhesion-associated genes (Grasso et al., 2016). If the same is true in cancer 
cells, this might implicate RNMT-RAM in the control of cancer cell invasion. 
Moreover, since RAM is required for stem cell pluripotency (Grasso et al., 
2016), it may be also be important in cancer stem cells (Kreso and Dick, 2014). 
More comprehensive studies are required to identify the best molecular target 





6.3 Future work 
 In this thesis, CE was identified as a novel mediator of C-MYC-
dependent transformation. However, this research raises many questions which 
require exploration. 
6.3.1 How does CE influence mRNA metabolism? 
 There is evidence for the mRNA cap promoting transcription, mRNA 
stability, splicing, 3’ end processing, nuclear export and translation (Lewis and 
Izaurflde, 1997; Ramanathan et al., 2016). However, the relative contribution of 
CE to these processes in human cells is not clear. In this thesis it was shown 
that CE influences transcript levels of C-MYC and C-MYC target genes, 
consistent with a role for CE in transcription, mRNA stability or transcript 
processing. Conversely, other studies show that RNMT-RAM influences C-MYC 
target gene transcript polysome loading and protein synthesis rather than 
altering mRNA levels, which is indicative of translational regulation (Cowling, 
2009; Cowling and Cole, 2007b; Posternak et al., 2017). In light of findings that 
both CE and RNMT-RAM are key for oncogenic C-MYC function, it will be 
important to fully characterise and compare their functions in mRNA 
metabolism. This should be tested in isogenic non-transformed cells and cells 
carrying deregulated C-MYC by knocking down CE and RNMT-RAM in parallel. 
They could also be inhibited in combination to determine whether this has a 
synergistic effect, and this would shed light on whether they differentially 
regulate gene expression. Extended RNA pol II ChIP-seq and GRO-seq 
(nascent pre-mRNA labelling with bromouridine) would highlight whether CE or 




transcription inhibitor and tracking mRNA decay over a time-course would 
indicate whether the capping enzymes impact transcript stability. Moreover, the 
relative levels of nascent and mature transcripts, and prevalence of poly(A)-
tailed transcripts, could be measured to detect any processing impairments. 
Polysome profiling – in which the relative abundance of transcripts with actively 
translating ribosomes is measured – could be performed to determine how CE 
alters translation relative to RNMT-RAM. Alternatively, ribosome profiling (Ribo-
seq) could be performed to globally analyse ribosome-protected fragments on 
mRNA molecules and thus determine the relative contribution of CE and RNMT-
RAM to translation regulation. These experiments would not only yield a greater 
understanding of CE and RNMT-RAM function, but would also provide insight 
into the mechanisms and consequences of C-MYC-mediated mRNA capping. 
Furthermore, studies here and elsewhere have highlighted a potential role of 
CE in RNA pol II pause release, independent of its capping activity. Therefore, 
the guanylyltransferase-dead mutant of CE (K294A) could be expressed in cells 
upon knockdown of endogenous CE before analysing C-MYC target gene 
expression. This would clarify the relative contribution of CE recruitment and 
mRNA capping to C-MYC-driven RNA pol II transcription. 
6.3.2 Does CE exhibit transcript specificity?  
In this thesis it was shown that C-MYC induces CE recruitment to 
transcription complexes. Moreover, C-MYC target gene transcripts are 
particularly sensitive to CE knockdown in conditions when C-MYC is 
deregulated. This is consistent with C-MYC recruiting CE to drive expression of 
its target genes. To determine if CE is truly used as a co-factor in C-MYC-driven 




alone is insufficient for C-MYC function) to CE, and the ability of the C-MYC 
DBD-CE fusion protein to activate transcription tested. However, how CE 
regulates the rest of the genome is not known. Performing RNA sequencing 
(RNA-seq) and proteomics would help determine if C-MYC target genes or 
indeed other sets of genes are particularly responsive to CE knockdown. 
Moreover, CE ChIP-seq could be performed to help differentiate which genes 
are directly regulated by CE from secondary effects. This could be performed in 
parallel with C-MYC ChIP and RNA pol II ChIP to determine if CE is 
preferentially recruited to C-MYC target genes or highly transcribed genes. 
There are likely additional features which influence the sensitivity of transcripts 
to CE inhibition, such as mRNA instability elements and 5’ UTR structures, 
which should also be interrogated. 
6.3.3 What are the mechanisms of CE dependency? 
Studies here determined that C-MYC-driven cells are particularly dependent 
on CE, whereas elsewhere it was shown that cells carrying deletion of the 
tumour suppressor complex TSC1/TSC2 within the mTOR pathway also exhibit 
heightened dependency on CE (Housden et al., 2015). The mechanisms 
governing these vulnerabilities are not known. A common consequence of C-
MYC and mTORC1 pathway deregulation is heightened cap-dependent 
translation, converging on eIF4F (Lin et al., 2008; Pourdehnad et al., 2013; 
Showkat et al., 2014). Therefore, the oncogenic, cap-binding eIF4E subunit of 
eIF4F could be overexpressed in cells to determine if this induces CE 
dependency. Moreover, a panel of cell lines with different basal protein 
synthesis rates could be tested to determine if sensitivity to CE inhibition 




MYC deregulation and TSC1/TSC2 depletion synergise in conferring CE 
dependency to determine whether they act via the same mechanism.  
It was shown that high expression of CE in basal-like breast cancer/TNBC 
predicts an unfavourable patient outcome. Since perturbation of the BRCA1 
tumour suppressor pathway is a common feature of these tumours, the effect of 
BRCA1 depletion on CE dependency could be tested. C-MYC and BRCA1 both 
influence RNA pol II transcription (positively and negatively, respectively) 
(Dang, 2014; Mullan et al., 2006), therefore perhaps elevated mRNA synthesis 
is a governing factor of CE dependency. This could be tested by correlating 
nascent transcription rates in a cell line panel with cellular sensitivity to CE 
inhibition. Additionally, it could be tested whether a sub-lethal dose of a 
transcription inhibitor (for example the CDK7 inhibitor THZ1) desensitises cells 
to CE inhibition, to investigate whether basal transcription activity is a 
determining factor of CE dependency. 
Consistent with CE being an essential gene, it is likely that CE dependency 
is determined by whether it is limiting under certain conditions. To confirm this, 
gel filtration could be performed to determine the relative abundance of cellular 
monomeric CE and CE in transcription complexes. Moreover, it could be tested 
whether capping still occurs in cells upon CE knockdown using a N7-
methylguanosine antibody or recombinant eIF4E to capture capped transcripts, 
and whether the absence of the cap correlates with CE dependency. Finally, 
although CE knockout was described as lethal in seven human cell lines 
including HeLa cells (Hart et al., 2015; Wang et al., 2014), it would be 
interesting to attempt CRISPR-mediated knockout of CE in IMECs since CE 




6.3.4 Is targeting mRNA capping a viable therapeutic strategy? 
In this thesis it was shown that CE knockdown specifically interferes with 
functions of deregulated C-MYC, and leaves untransformed (or C-MYC-
independent) cells largely unaffected. This presents strong rationale to consider 
CE as a potential therapeutic target in C-MYC-driven cancers, although a 
number of experiments would substantiate this hypothesis. 
Firstly, the efficacy of CE knockdown should be tested over a larger range of 
non-transformed and cancer cell lines. Of particular interest would be those 
exhibiting and lacking C-MYC deregulation for comparison. TSC1/TSC2 mutant 
cancer cell lines and basal-like/TNBC cell lines could also be included in 
analyses. If CE knockdown proves to perturb cancer cell growth, following CE 
depletion cells could be injected into nude mice to determine their ability to form 
tumours in vivo. Since RNMT and SAHH also mediate C-MYC-driven 
transformation, it might be favourable to analyse RNMT and SAHH depletion in 
parallel to CE depletion in order to determine the best molecular target for 
mRNA capping inhibition.  
Studies here show that CE inhibition is well-tolerated by non-transformed 
cells, and thus may display a therapeutic window in vivo. However, since CE is 
an essential gene, it would be favourable to determine whether sustained or 
enhanced CE knockdown has a cytotoxic effect on non-transformed cells, and 
to what extent CE inhibition can be tolerated. Human cell lines and mouse 
models conditionally expressing CE short hairpin RNA (shRNA) could be made 




latter could be crossed to mouse models of C-MYC-driven Burkitt’s lymphoma 
or TNBC to determine if CE is required for the oncogenic potency of C-MYC. 
A specific inhibitor of CE would be more therapeutically relevant than 
genetic inhibition. The immunosuppressive agent mizoribine monophosphate 
(MZP) has been identified to inhibit human CE via an allosteric mechanism 
which perturbs RNA 5’ guanylylation (Picard-Jean et al., 2013). However, MZP 
is also a potent inhibitor of inosine-5′-monophosphate dehydrogenase (IMPDH), 
which mediates guanine nucleotide biosynthesis. Moreover, MZP is not 
particularly effective at inhibiting CE in vitro (IC50  80µM). Studies presented in 
this thesis warrant the development of a potent, specific CE inhibitor to truly 
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